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I. Context of the study 
Plants and cereals are subject to numerous fungal contaminations occurring either in 
fields or during storage processes. Many species of fungi exist and are able to grow on various 
types of cereals (maize, wheat, barley, soybean, rice, rye…) or on food commodities (seeds, 
peanuts, fruits, spices, forages…) (Figure 1) (AFSSA 2009).  
 
 
Figure 1 – Major mycotoxins produced by fungi and naturally found in several food products 
These fungi are able to produce several toxic molecules, called mycotoxins (from 
Greek μύκης (mykes, mukos) ‘fungus’ and Latin (toxicum) ‘poison’) (Aiko and Mehta 2015). 
Mycotoxins are secondary metabolites; and unlike primary metabolites, they are not essential 
to the development and survival of the fungus but could constitute an advantage during the 
colonization of ecological niche when in competition with other microorganism. These 
molecules also discourage predators from eating the fungus (Keller et al. 2005). 
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Mycotoxins can be divided into polyketoacids, terpenes, cyclopepetides and nitrogen 
metabolites, depending on their origins and their structures (AFSSA 2009). They can also be 
classified according to their toxic effects. Mycotoxins considered important in terms of food 
safety are aflatoxins (AF), ochratoxins (OT) (in particular ochratoxin A (OTA)), patulin 
(PAT), fumonisins (FB), zearalenone (ZEA) and trichothecenes (TCT), especially 
deoxynivalenol (DON) (Figure 2) (Bennet and Klich 2003). Several factors control fungal 
growth and mycotoxin production, such as weather conditions, agricultural practices or 
storage conditions (Hesseltine 1976). 
 
Figure 2 – Structural diversity of major mycotoxins 
The toxic effects of moulds and fungi were already known in ancient times. 
Historically, many illnesses linked to mycotoxicoses have been reported (AFSSA 2009). The 
most famous case, which occurred in the Middle Ages, is known under the name of ignis 
sacer (sacred fire) or St Anthony's fire. It was caused by toxins of Claviceps purpurea, the 
ergot alkaloids of rye (Figure 3). Ergotism reached epidemic proportions, mutilating and 
killing thousands of people in Europe. Victims of ergotism suffered from delirium, 
prostration, acute pain, abscess and gangrene of the extremities, leading to serious and 
incurable infirmity. Epidemics occurred from the 8
th
 to the 15
th
 century due to the bad quality 
of food and contamination with fungal sclerotia. Similarly, fusariotoxins (toxin T2 and ZEA), 
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seem to have been involved in the decline of the Etruscan civilization 5 centuries B.-C 
(Richard 2003). “Yellow rice disease” or shoshin-kakke disease in Japan was also a 
mycotoxicosis caused by unhygienic conditions and practices, which is induced by the 
Citreoviridin, a metabolite produced by Penicillium citreonigrum.  This fungus used to grow 
readily on rice during its storage (after harvest), especially in the colder regions of Japan. New 
hygiene measures applied, more rigorous than before, made it disappear (Udagawa and 
Tatsuno 2004). In 1960, the turkey X disease has been an important episode of mycotoxicosis 
on animals. It killed thousands of turkey, ducklings and other domestic animals in England. 
This allowed the discovery of aflatoxins, main mycotoxin produced by Aspergillus flavus, 
and present in a high quantity in groundnut flour designed for poultry’s food (Blount 1961). 
                               
Figure 3 – “Saint Antoine tentation” painted between 1512 – 1516 by Grünewald (on the left). Ears of 
rye contaminated with ergot (on the right). 
Most mycotoxins have an acute toxicity, but nowadays it’s exceptional to be exposed 
to such high doses in Europe (Européenne C. 2003). In this part of the world chronic 
contamination is the most threatening, due to the persistence of these mycotoxins in food and 
the repeated ingestion by animals for example. In 2004, a worldwide survey showed that 72% 
of more than 19000 samples analyzed contained detectable amounts of AF, FB, DON, ZEA or 
OTA (Figure 4). Among them, 38% represented a co-contamination by 2 or more mycotoxins 
(Schatzmayr and Streit 2013). Several toxic effects can be induced, depending of the 
mycotoxin and the organ targeting. At high doses, mycotoxins exposure can leads to general 
cytotoxicity, biochemical lesions and impact on early cellular functions in the cascade of 
events (Bryden 2012; Maresca and Fantini 2010). At low doses, various functions of tissues 
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and organs can be impaired. And some mycotoxins are also genotoxic, carcinogenic and 
teratogenic (Maresca and Fantini 2010). 
 
Figure 4 - Global mycotoxin prevalence in surveyed regions (adapted from Schatzmayr and Streit 
2013). Aflatoxins (AF), zearalenone (ZEA), deoxynivalenol (DON), fumonisins (FB), ochratoxin A 
(OTA). 
II. Problem of DON contamination 
A. Occurrence 
DON is produced by Fusarium fungi, one of the most common mycotoxin in the world. It 
and can be found in many cereals and raw materials, like wheat, barley, oat, rye, maize and 
sometimes on rice, sorghum and triticale. A worldwide survey to assess the contamination by 
mycotoxins in feed and feed raw materials, done on 19,000 samples, shows that DON was 
present in 56% of the tested samples (Schatzmayr and Streit 2013). 
Fungal infection and DON production are difficult to predict and regulate; because largely 
dependent on the weather, high humidity and low temperature, and so vary greatly from year 
to year and between areas (Rotter et al. 1996). In developed countries, where storage 
conditions are well managed and controlled, DON contamination is especially a pre-harvest 
problem. While, in developing countries, DON can also be produced during the storage stage. 
So, DON can be commonly detected at low levels (< 1 ppm) and sporadically at higher levels 
(5 to 20 ppm) on cereals intended to be given to animals or humans (Abouzied et al. 1991). It 
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can also be present in end products, such as the cereal-based food for adults and infants or 
even at low levels in beer (Lombaert et al. 2003; Scott 1996). 
Economic losses due to DON contamination are difficult to evaluate. Nevertheless a 
computer simulations evaluated that the annual costs for DON in the USA were $637 million 
in crop losses (mainly wheat and corn), $18 million in feed losses and $2 million in livestock 
losses (EFSA 2013). 
 
B. Toxicity 
The toxicity of DON is well known and numerous studies bring information on its toxic 
effects at high and chronic doses (Maresca 2013; Pestka 2010; Wang et al. 2014). A high 
concentration of DON causes effects and symptoms that are similar to those observed during 
an exposure to ionizing radiation, such as abdominal distress, salivation, discomfort, diarrhea, 
vomiting, leukocytosis and gastrointestinal bleeding. It also has high emetic and anorexic 
effects, that are equal or even higher to those of observed with the most toxic trichothecene B 
(Pestka and Smolinski 2005). Actually, the first name of DON was “vomitoxin” due to its 
emetic effects seen in pigs (Vesonder et al. 1973). 
A chronic exposure can impact growth (by anorexia and disregulation of nutrients 
efficacy), immunity (increased or decreased) and reproduction in animals. At acute doses it 
can induces emesis, abdominal distress, malaise, diarrhea and increases the salivation (Pestka 
2010). At low dose it impairs the growth and the immune function in human and interferes 
with nutritional efficiency on pigs (Rotter et al. 1996). At higher doses it causes diarrhea, 
emesis, leukocytosis, hemorrage, endotexemia and ultimately shock-like death (Ueno 1983). 
 
C. Detoxification methods for DON 
The effectiveness of detoxification methods of mycotoxins depends on several 
parameters, the nature of the food/feed, the environmental conditions such as moisture 
content, temperature, as well as the type of mycotoxin, its concentration and the extent of 
binding between mycotoxin and constituents (Grenier and Oswald 2011). 
DON resist to most of the industrial processes; it is stable at high temperature, due to 
its high chemical stability and can be found in numerous final processed products (Hazel and 
Patel 2004). Actually DON is completely stable at 120°C, quite stable at 180°C and partially 
stable at 210°C (OMS 2001). At concentrations below 1mg/kg, DON is mainly found on the 
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seed surface but at higher concentrations, it can be found in the entire grain (Charmley and 
Prelusky 1994). To reduce the occurrence and the impact of mycotoxins and especially DON, 
several detoxifying strategies were established in the feed chain, including the prevention of 
fungal growth and the production of mycotoxin, strategies to reduce or eliminate mycotoxins 
from contaminated raw or finished materials or even in diverting contaminated product to low 
risk uses including animal feeds (Bryden 2012). However, the amount of information related 
to mycotoxins detoxifying methods is still limited. From the described detoxifying strategies 
there are three principal categories used: the physical, the chemical and the biological 
methods. 
 
1. Physical methods 
Some processes used to detoxify mycotoxins (such as milling, irradiation, ethanol 
fermentation or extrusion) were initially developed for other purposes, and some were 
specifically developed for the detoxification itself (such as sorting, cleaning or washing). 
These practices, are linked to the FAO guidelines, namely fulfilled: cheap and simple, no 
production of toxic metabolites, and no change in the nutritional value or properties of raw 
materials. However, all these approaches present some inconvenient. The standard processes, 
like milling and baking, do not allow the elimination of DON with efficacy (Abbas et al. 
1985; Hart and Braselton 1983). Dry milling, permit an elimination that is up to 40% of DON 
present in the flour; sieving or cleaning can reduce the concentration in DON by over 60% 
(Pestka and Smolinski 2005). The problem of the milling and grain separation process, 
commonly used for human’s food, is that it concentrates all the mycotoxins in bran and Germ, 
fractions will be used later for animal feed. However, in the sieving and cleaning procedures, 
an important loss of grains is reported. In their study, Trenholm et al. (1991) did observe a 
73% reduction of DON, but they have also observed that up to 69% of the total weights of the 
corns was removed as well. And after flotation and washing, the cost of drying grains is high. 
 
 
2. Chemical methods 
Several chemical processes, using molecules like ammonia, calcium hydroxide, 
chlorine, hydrochloric acid, ozone, sodium bisulphate and sodium hydroxide are able to 
degrade DON.  In fact ammoniation has been proved to reduce the aflatoxin levels but this 
process is not accepted in all countries and is quite expensive (Norred et al. 1991; Park and 
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Price 2001). With alkalization, DON can be transformed into different products, with various 
toxicity (Bretz et al. 2005; Bretz et al. 2006; Young et al. 1986). 
In majority, the chemical methods can reduce mycotoxins’ levels, but they can also 
severely damage the nutrient quality of the grains and can be health hazards on their own. Not 
only that, they can result in the formation of degraded products that might be constituted of 
new and unknown biologically active mycotoxins (Humpf and Voss 2004). 
 
3. Biological methods 
Two strategies are possible to manage DON, once present in plants and cereals. The 
first strategy consist on preventing the production of DON in infected crop by controlling the 
plant pathogens (Fusarium spp.). Equipping crops with DON detoxification activities can 
reduce the concentration of mycotoxin in grain and also increase the resistance against 
infection (Karlovsky 2011). It was shown that DON plays a role in the infection; host plants 
inoculated with fungal strain not able to produce TCT can’t be able to infect the plant (Maier 
et al. 2006; Proctor et al. 1995). Another study shows that a major QTL responsible for the 
resistance of wheat to FHB co-segregated with the ability to detoxify DON by glycosylation 
(Lemmens et al. 2005); It has been proved that by selecting a plant naturally resistant to 
Fusarium, its capacity to glycosylate DON into D3G can be increased by 2.7 times more 
(Sasanya et al. 2008). 
Some companies also tried to build transgenic plants, by transferring the 3-O-
acetyltransferase gene issued from F. sporotrichioides to the plant in order to reduce the 
pathogenicity of Fusarium (Karlovsky 2011). 
The second strategy consists in detoxifying DON that has been produced, by physical 
and chemical methods as we saw but more innovative by biological methods. The bio-
detoxification of mycotoxins, by isolating microorganisms and/or enzymes that will degrade 
or metabolize the mycotoxins, is currently an innovative and promising strategy aiming to 
control mycotoxicoses in animals (Schatzmayr et al. 2006). (Cheng et al. 2010) obtained two 
Bacillus strains able to detoxify DON in wheat and maize. In another study, Bacillus sp. 
LS100, which transforms deoxynivalenol (DON) to a less toxic chemical de-epoxy DON 
(DOM-1) has been assessed. This intestinal bacteria, Genus novus species novus of family 
Coriobacteriaceae BBSH 797, isolated from digestive tracts, is able to de-epoxydize DON to 
DOM-1 (Fuchs et al. 2002). There is also the bacterial strain Devosia mutans 17-2-E-8, 
isolated from an alfalfa soil enriched with F. graminearum-infested corn that is able to highly 
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reduce DON level, in producing an epimer, the 3-epi-DON (He et al. 2015b; Zhou and He 
2009, 2010).  
Bringing the enzymatic kit to animals, by the use of bacteria, will allow them detoxify 
mycotoxins, and easily and effectively protect them against the toxic effects of mycotoxins. 
Definitely, since decontaminated or detoxified crops are cheaper (since they are considered as 
products of lower quality), they are mainly used for feed production and animal feeding 
(Grenier and Oswald 2011), in which explains why animals are very exposed. The need of 
feed additives preventing the absorption of mycotoxins and by that occurrence of their toxic 
effects in farm animals has increased significantly. Indeed, the adsorption is not a viable 
option regarding trichothecenes, zearalenone and ochratoxins, that’s why the mycotoxin 
inactivation by biotransformation is a very promising strategy to detoxify these mycotoxins. 
However, all the additives and bacterial products have to be tested before coming into the 
market to assure their efficiency and safety. In vitro and in vivo tests are mostly important to 
check and follow their scientific development and improvement. Sensitive parameters such as 
biochemistry, gross pathology, histopathology, immune parameters and animal performances 
have to be measured to evaluate their toxicity. This is why the aim of this thesis was to 
evaluate the toxicity of the products issued from biological detoxification and to assess the 
efficiency of this process in order to protect animals or humans from the toxic effects of 
DON. 
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III. Literature review 
 
The literature review consists on three reviews covering different aspects studied 
during this thesis. The first two reviews deal with the different effects caused by mycotoxins 
and the intestine or the immunity of pigs. The third review focuses on new forms of 
mycotoxins derived from these mycotoxins, the "masked" and "modified" mycotoxins.  
To date, contamination by mycotoxins cannot be avoided. Mycotoxins can be present 
in several types of cereals (maize, wheat, barley, oats, rice ...) and end up in high 
concentrations due to cultural practices or storage. These mycotoxins can be found in co-
contamination in pig feed. All these mycotoxins have toxic effects on pig that is particularly 
sensitive because of its simple digestive system and its high cereal rich diet. The first two 
reviews have a look on the two most affected parameters after a contamination by one or 
more mycotoxin, on the gut and the immune system of the pig. Mycotoxins contaminations, 
mainly by ingestion, cause many toxic effects on the digestive system and small intestine. 
The first review presents the different mycotoxins that are found in pig’s feed and their effects 
and consequences on the intestine and the general health of the pig. Mycotoxins have been 
also described as responsible of modifying important functions of the intestine (barrier 
function, mucus production, nutrient absorption…). 
The second review reports the effect of mycotoxins on the immune system of pigs. Certainly, 
many mycotoxins have an immune-modulatory effect on the immune response and may affect 
the vaccine response as well as induce an increased susceptibility to infections or chronic 
infectious diseases. 
Finally, the last review presents advances in terms of new analytical methods allowing 
the identification of new forms of mycotoxins, the mycotoxins called maskedand modified. It 
is important to study these new forms of mycotoxins to evaluate their impact on pig health 
and to assess whether they can represent an additional threat that will have to be taken into 
account in the overall management of the risk of mycotoxins. 
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A. Feed mycotoxins: impact on pig intestinal health 
 
Nowadays, many mycotoxins can contaminate cereals and feeding stuffs designated to the 
pig consumption. These mycotoxins have several toxic effects on pigs, which are greatly 
impacted, due to their high sensibility and their cereals rich diet. 
Due to the way of exposure, by ingestion, intestine is the major organ targeted by 
mycotoxins. This review summarizes the major effects induced by these mycotoxins on the 
intestine, on its integrity, its biological function and on its immune response. It also highlights 
the consequences of this contamination, which increases the translocation of bacteria and 
enhances the susceptibility to other diseases and thus impairs the global health of pigs. 
This review is currently submitted to Porcine Health Management. 
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Abstract 12 
Mycotoxins are secondary metabolites of fungi that grow on a variety of substrates. Due to their high 13 
consumption of cereals and their sensitivity, pigs are highly impacted by the presence of mycotoxins. 14 
Pigs can be exposed to different mycotoxins such as aflatoxins, ochratoxins, fumonisins, zearalenone, 15 
and trichothecenes especially deoxynivalenol. At the European level, regulations and 16 
recommendations exist for these mycotoxins in pig feed. The intestine is the first barrier to food 17 
contaminants and can be exposed to high concentrations of mycotoxins upon ingestion of 18 
contaminated feed. Mycotoxins target this organ, they alter the intestinal barrier, impair the immune 19 
response, reduce feed intake and weight gain. Among them, deoxynivalenol and fumonisin have been 20 
studied especially for their toxicity in the intestine. Their presence in feed increases the translocation 21 
of bacteria; mycotoxins can also impair the immune response and enhance the susceptibility to 22 
infectious diseases. In conclusion, because of their effect on the intestine, mycotoxins are a major 23 
threat to pig health, welfare and performance. 24 
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Introduction  29 
Food safety is a major issue throughout the world. In this respect, much attention 30 
needs to be paid to the possible contamination of food and feed by fungi and the risk of 31 
mycotoxin production. Mycotoxins are secondary metabolites produced by filamentous fungi, 32 
mainly by species from the genus Aspergillus, Fusarium and Penicillium. They are produced 33 
on a wide variety of substrates before, during and after harvest. Mycotoxins are very resistant 34 
to technological treatments and difficult to eliminate, and therefore they can be present in 35 
human food and animal feed. The ingestion of mycotoxin-contaminated feed can induce acute 36 
diseases, and the ingestion of low doses of fungal toxins also causes damage in case of 37 
repeated exposure. 38 
Monogastric livestock, pig and poultry, are particularly vulnerable to mycotoxins 39 
because of the high percentage of cereals in their diet and because they lack a rumen with a 40 
microbiota able to degrade mycotoxins before their intestinal absorption. From a pig health 41 
perspective, the most notorious mycotoxins (Fig.1) are aflatoxins (AF), ochratoxin A (OTA), 42 
fumonisins B (FB), zearalenone (ZEN), and trichothecenes, especially deoxynivalenol (DON) 43 
(CAST 2003). 44 
This review will summarize the effect of mycotoxins on the intestine and analyze the 45 
consequences in terms of pig health. 46 
 47 
I- Toxicity of the main mycotoxins in pig feed  48 
The toxicity of mycotoxins varies according to several parameters such as the dose, the duration of 49 
exposure, the age and the sex of the animal, as well as nutritional factors (Andretta et al. 2012; Bryden 50 
2007; Wild 2007). For example, the effects of AF, FB or DON on performance are greater in males 51 
and young pigs (Andretta et al. 2012; Marin et al. 2006). In the European Union, only AFs are 52 
regulated in animal feed; recommendations exist for OTA, DON, T2 and HT-2 toxins, FB1, FB2 and 53 
ZEN (Tab. 1). 54 
 55 
 56 
 57 
 58 
 59 
 60 
 61 
 62 
 63 
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 64 
Fig. 1. Chemical structure of the main mycotoxins present in pig feed. 65 
 66 
 The AFs are rapidly absorbed and metabolized in the liver (Haschek et al. 2002); they 67 
are hepatotoxic, and  have some impacts on growth and on the immune response of the pig 68 
(Meissonnier et al. 2006). OTA is nephrotoxic and hepatotoxic and its oxydative metabolites 69 
are genotoxic (Aish et al. 2004; Pfohl-Leszkowicz and Manderville 2007). Among 70 
mycotoxins, pigs are very sensitive to DON, the most common mycotoxin of the type B 71 
trichothecene. Short exposure to high doses of DON induces vomiting and lower doses cause 72 
feed refusal (Haschek et al. 2002); chronic exposure is associated with weight loss, anorexia, 73 
immunomodulation and alteration of intestinal barrier functions (Haschek et al. 2002; Pestka 74 
2010; Pinton and Oswald 2014). Type A trichothecene T2 and HT2 toxins have similar but 75 
more pronounced effects than DON. They also induce irritation of the intestine and the skin 76 
and increase the sensibility of pigs to diseases (Bryden 2012).  77 
 78 
 79 
 80 
 81 
 82 
 83 
 84 
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Table 1. Regulation and recommendations for the main mycotoxins present in pigs feed and feedstuffs. 85 
 (EC Directive 2002/32/EC, and EC Recommendations 2006/576/EC and 2013/165/EU)  86 
 87 
Mycotoxins Pig feeds 
Max. content mg/Kg 
(ppm) 
AFB1+ B2 Cereals 60 
Complete and complimentary 
feeding stuffs for pigs, horse, 
rabbit and pets 
0.5 
OTA Complete and complimentary 
feeding stuffs for pigs 
0.05 
DON Cereals 
 (without maize by-products) 
8 
 (12) 
Complete and complimentary 
feedstuffs for pigs 
0.9 
ZEN Cereals 
 (without maize by-products) 
2 
 (3) 
Complete and complimentary 
feeding stuffs: 
-for piglets and gilts 
-for sows and fattening pigs 
 
 
0.1 
0.25 
FB1+FB2 Cereals 60 
Complete and complimentary 
feeding stuffs for pigs, horse and 
rabbit 
5 
T2+HT2 Complete and complimentary 
feeding stuffs for animals 
-Oat milling products (husks) 
-Other cereals products 
-Compound feed, with the 
exception of feed for cats 
 
 
1 
0.5 
0.25 
 88 
FB1 is the most prevalent toxin of the fumonisin family. It has a carcinogenic effect in 89 
humans and induces multiple toxic effects in different animal species. In pigs, this toxin 90 
induces pulmonary oedema (Haschek et al. 2002) and alters the immune response with a 91 
dysregulation of the T helper lymphocytes TH1/TH2 balance (Marin et al. 2006; Taranu et al. 92 
2005). The last mycotoxin with a recommendation for pig feed is ZEN. This toxin has an 93 
impact on pig fertility and reproduction. ZEN and its principal derivatives, α-zearalenol (α-94 
ZEL) and β-zearalenol (β-ZEL) (more toxic than the other two), are non-steroidal oestrogens 95 
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inducing an oestrogenic response in animals (Fink-Gremmels and Malekinejad 2007). In pigs, 96 
especially young sows, ZEN induces red patching and tumefaction of the vulva, a prolapse of 97 
the vulva and sometimes of the rectum (Gaumy et al. 2001). 98 
In terms of intestinal toxicity, the effects of DON and FB have been studied in detail in pigs; 99 
by contrast only few papers are concerned with the effect of OTA or AF on this organ. 100 
  101 
II- Effects of mycotoxins on the pig intestine  102 
 The intestinal tract is the first target for mycotoxins following ingestion of 103 
contaminated feed. The intestinal epithelium is a single layer of cells lining the gut lumen that 104 
acts as a selective filter, allowing the translocation of dietary nutrients, essential electrolytes, 105 
and water from the intestinal lumen into the blood circulation. It also constitutes the largest 106 
and most important barrier to prevent the passage of harmful intraluminal substances from the 107 
external environment into the organism, including foreign antigens, microorganisms, and their 108 
toxins. Following the ingestion of mycotoxin-contaminated feed, intestinal epithelial cells 109 
may be exposed to high concentrations of toxins, potentially affecting intestinal functions 110 
(Alassane-Kpembi and Oswald 2015; Ghareeb et al. 2015; Grenier and Applegate 2013). 111 
  112 
A. Effect on intestinal histomorphology 113 
Consumption of mycotoxin-contaminated feed induces histological damage on 114 
intestinal tissue. Epithelial lesions in the intestine of pigs fed with a diet naturally 115 
contaminated with DON were observed (Bracarense et al. 2012; Eriksen and Pettersson 116 
2004). Jejunal lesions, including shortened and coalesced villi, lysis of enterocytes, and 117 
edema, were also observed in an ex-vivo model of intestinal tissues after exposure to DON 118 
(Lucioli et al. 2013; Pinton and Oswald 2014). Exposure to FB also induces changes in 119 
intestinal villi morphology such as reduced villi height and villi fusion and atrophy 120 
(Bracarense et al. 2012). 121 
A study on pigs showed that low doses of ZEN do not impair the morphology and 122 
ultrastructure of the small intestine (Obremski et al. 2005), in contrast to what has been 123 
observed in rats (Liu et al. 2014). 124 
As far as AFB1 is concerned, no data on the effect of this toxin on the histomorphology of the 125 
pig intestine are available. Nevertheless, exposure of broiler chicken to AFB1 induced a 126 
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decreased jejunal villus height, villus height/crypt ratio, and shedding of epithelial cells on the 127 
tip of jejunal villi (Zhang et al. 2014). 128 
 129 
B. Effect on intestinal digestion and nutrient absorption 130 
 The regressive intestinal lesions observed upon exposure to mycotoxins may explain, 131 
at least in part, the reduced absorption of nutrients and the impaired digestion observed after 132 
ingestion of mycotoxins. Pigs consuming corn culture extracts containing FB showed a 133 
markedly lowered activity of aminopeptidase N (Lessard et al. 2009). Likewise, exposure to 134 
1.5mg/kg b.w. FB1 has been shown to induce sphingolipid depletion in pig intestinal 135 
epithelium, which can result in a deficiency of folate uptake (Grenier and Applegate 2013; 136 
Loiseau et al. 2007). The sodium-glucose dependent transporter (SGLT-1) activity is 137 
particularly sensitive to DON inhibition. SGLT-1 is the main apical transporter for active 138 
glucose uptake in the small intestine. Inhibition of SGLT-1 has nutritional consequences and 139 
could explain diarrhea associated with DON ingestion, since this transporter is responsible for 140 
daily absorption of water in the gut (Maresca 2013). Conversely, sodium-dependent glucose 141 
absorption might be up-regulated in pigs after acute or long term exposure to the mycotoxin 142 
FB1 (Lessard et al. 2009). 143 
 144 
C. Effect on barrier function 145 
Several mycotoxins are able to alter intestinal barrier functions (Ghareeb et al. 2015; 146 
Grenier and Applegate 2013). They affect the intestinal epithelium permeability through 147 
modulation of the tight junction complexes. A defective expression of occludin and E-148 
cadherin has been observed in the ileum of piglets fed low doses of FB1 (Lucioli et al. 2013). 149 
The FB-induced alteration of the sphingolipid biosynthesis pathway and the associated lipid 150 
rafts could also contribute to impairing the establishment and maintenance of tight junctions. 151 
Likewise, the activation of MAP kinases by DON affects the expression and cellular 152 
localization of proteins forming or being associated with tight junctions such as claudins and 153 
ZO-1, which results in increased intestinal paracellular permeability (Pinton and Oswald 154 
2014). Similarly to DON, T2-toxin, FB1 and ZEN have been shown, in vitro and in vivo, to 155 
impair the pig intestinal barrier function and to promote oral absorption of antibiotics such as 156 
doxycycline, chlortetracycline and paromomycin (Goossens et al. 2012; Goossens et al. 157 
2013).  158 
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D.  Intestinal immune system 159 
 Some mycotoxins impact the systemic and/or the local immune response. At the 160 
intestinal level, they decrease the immunity leading to enhanced intestinal infections. They 161 
also have a direct or indirect proinflammatory effect (Cano et al. 2013; Maresca 2013). 162 
Indeed, the intestine is a major source of cytokines and chemokines, molecules involved in 163 
the regulation of the immune system.  Among cytokines, IL-8, which is a chemoattractant 164 
cytokine, is of particular interest because it is involved in the recruitment of 165 
polymorphonuclear neutrophils at the site of infection, mediating a non-specific acute 166 
inflammatory response.  167 
Ingestion of FB1 specifically decreases expression of IL-8 mRNA in the ileum of 168 
exposed piglets while expression of other inflammatory cytokines is not affected. This 169 
decrease of IL-8 caused by FB1 may lead to reduced recruitment of inflammatory cells in the 170 
intestine during infection, and may contribute to the observed increased susceptibility of FB1-171 
treated piglets to intestinal infections (Bouhet and Oswald 2007). 172 
 DON modulates intestinal innate immunity both directly (through activation of signal 173 
pathways) and indirectly (through crossing of luminal bacterial antigens, which was observed 174 
together with bacterial translocation following mucus layer alteration and tight junction 175 
opening) (Maresca et al. 2008). DON affects expression of proteins involved in epithelial 176 
innate immunity, including inflammatory cytokines, COX-2 and β-defensins (Cano et al. 177 
2013; Lessard et al. 2015). Numerous studies have demonstrated that DON stimulates 178 
expression and secretion of IL-8 and thus potentially participates indirectly in the central 179 
effects of DON in terms of feed refusal and emesis. As described for immune cells (Pestka 180 
2010), DON has a biphasic effect on the secretion of IL-8 by intestinal epithelial cells: Low 181 
doses of toxin cause a massive increase in secretion of IL-8, whereas higher doses inhibit it. 182 
Such a biphasic effect explains why DON acts: (i) as a proinflammatory toxin leading to 183 
intestinal inflammation at low doses; and (ii) as an inhibitor of intestinal immunity leading to 184 
higher susceptibility of animals to intestinal infections at higher doses (Maresca 2013). 185 
The ability of ZEN to interact with the pig immune system has been poorly investigated. 186 
However, it is known that exposure to high concentrations of ZEN (5-250mg/Kg feed or 200-187 
1000 µg/Kg b.w./day) induces chronic inflammation of the genital tract in females pigs 188 
(EFSA 2011; JECFA 2011). In vitro analyses also show that ZEN and its metabolites have 189 
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differential effects on synthesis of the inflammatory cytokines IL-8 and IL-10 in swine 190 
intestinal epithelial cells (Marin et al. 2015).  191 
There is no report of OTA- induced impairment of local immunity. However, this 192 
mycotoxin decreases the level of inflammatory cytokines (TNF-alpha and IL-10) in the 193 
plasma of exposed pig (Bernardini et al. 2014). 194 
 195 
E. Intestinal microbiota 196 
 The gut hosts an important microflora. Surprisingly, the impact of mycotoxins on the 197 
intestinal microflora has been poorly investigated. As far as pigs are concerned, only two 198 
studies have investigated the impact of mycotoxins on the intestinal microflora (Burel et al. 199 
2013; Wache et al. 2009). The first study indicates that consumption of feed naturally 200 
contaminated with DON (2.8 mg/kg) for four weeks had a moderate effect on cultivable 201 
bacteria in the pig intestine, but changed the microflora (Wache et al. 2009). In the second 202 
study, pigs received feed contaminated with 12 mg FB/kg feed for 63 days. This diet 203 
transiently affected the balance of the digestive microbiota during the first four weeks of 204 
exposure; a co-infection with Salmonella typhimurium amplified this phenomenon (Burel et 205 
al. 2013). 206 
 Two recent studies performed on rats have also demonstrated an effect of OTA and 207 
AF on the intestinal microbiota (Guo et al. 2014; Wang et al. 2016). The effects of 208 
mycotoxins on the intestinal microbiota are not surprising; indeed other secondary metabolites 209 
produced by the same fungi, antibiotics, are well known for their effect on the gut flora. 210 
Recent advances in next-generation sequencing technologies and metagenomics should give 211 
us a comprehensive analysis of the effect of mycotoxins on the structure and function of gut 212 
microbial ecosystem in the near future.  213 
 214 
III- Consequences of intestinal toxicity of mycotoxins for pig health  215 
A. Impairment of zootechnical performance 216 
All damage induced by mycotoxins on the intestine level and on the different 217 
functions lead to different symptoms expressed by the pig. Such symptoms are either directly 218 
associated with local toxicity in the intestine, or indirectly with a systemic effect, and with 219 
visible impact on the overall health of the pig. 220 
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The colloquial name of DON, vomitoxin, refers to its emetic effect observed both in 221 
field reports and in experimental intoxications where high doses of the toxin were given orally 222 
or intravenously to pigs. Complete feed refusal was observed at levels of 12 and vomiting at 223 
20 mg DON/kg feed. Pig feeding trials with naturally or artificially contaminated diets have 224 
shown decreased feed consumption and weight gain at doses from 0.6 to 3mg DON/kg feed 225 
(Bracarense et al. 2012). A meta-analysis showed that deoxynivalenol reduced feed intake and 226 
weight gain by 26%; the same analysis also demonstrated a 16% reduction of feed intake in 227 
response to AFB1(Andretta et al. 2012).  228 
Consumption of pure FB1 or FB1-contaminated feed also induces a slight reduction of 229 
body weight in piglets. Although FB are poorly absorbed and metabolized in the intestine, 230 
they induce intestinal disturbances (abdominal pain or diarrhea) and cause extra-intestinal 231 
organ pathologies (pulmonary edema in pigs, leukoencephalomalacia in horses, or neural tube 232 
defects in rodents). 233 
Ingestion of ZEN and OTA doesn’t alter zootechnical performance (Bernardini et al. 234 
2014; Schoevers et al. 2012). However ZEN can induce a decrease in reproductive 235 
performance with a reduction of healthy follicles leading to premature oocyte depletion in 236 
adulthood and so leading to abortion (Schoevers et al. 2012).  237 
 238 
B. Bacterial translocation 239 
The intestinal disturbance induced by mycotoxins may lead to increased bacterial 240 
translocation across the intestine and increased susceptibility to enteric infections. The loss of 241 
tight junction integrity and resulting increased paracellular permeability can lead to entry of 242 
bacteria that are normally restricted to the gut lumen. Such an increase in bacterial passage 243 
through intestinal epithelial cells after mycotoxin exposure has major implications for pig 244 
health in terms of sepsis, inflammation and enteric infection. 245 
 Porcine ileal loops were used to reproduce Salmonella typhimurium induced intestinal 246 
inflammation. Co-exposure to bacteria and DON dramatically enhances the inflammatory 247 
response to S. typhimurium in the ileal loops, with a clear potentiation of expression of IL-1β, 248 
IL-8 or IL-6 (Vandenbroucke et al. 2011). It has been suggested that this potentiation 249 
coincided with significantly enhanced Salmonella invasion in and translocation over intestinal 250 
epithelial cells.  251 
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 A higher susceptibility of the gastrointestinal tract to other bacteria was reported in 252 
pigs exposed to FB1. Two separate studies analyzed the effect of low to moderate doses of 253 
FB1 on intestinal colonization and mucosal response to pathogenic strains of Escherichia coli 254 
(Devriendt et al. 2009; Oswald et al. 2003). Besides, translocation of bacteria to the 255 
mesenteric lymph nodes and dissemination to the lungs, and to a lesser extent to liver and 256 
spleen, were observed in FB1-treated pigs in comparison to untreated animals (Oswald et al. 257 
2003). 258 
A study on human enterocytes exposed to low doses of DON or OTA showed an 259 
increase of translocation of commensal bacteria across the epithelium even without alteration 260 
of the intestinal permeability (Maresca et al. 2008). The mechanism involved in this increase 261 
is not elucidated, but this phenomenon could be due to an energetic modification of the cell 262 
status with a reduction of ATP levels (Grenier and Applegate 2013). 263 
 264 
Conclusion 265 
 The intestine is a target for mycotoxins and as illustrated in this paper this may have 266 
some consequences in terms of pig health (fig.2). Regulations and recommendations exist for 267 
six mycotoxins (AF, FB, OTA, ZEN, T2/HT2 and DON) present in pig feed. Among them, 268 
DON and FB have been studied especially for their toxicity in the intestine. They are not only 269 
locally toxic for this organ, but also dysregulate many intestinal functions and impair the 270 
immune response. This results in systemic toxicity leading to many symptoms and 271 
impairment of zootechnical parameters. Feed contamination with mycotoxins also increases 272 
translocation of bacteria across the intestine and thus intestinal and systemic infections, and so 273 
aggravates pigs’ condition. For AF, ZEN and OTA, little is known about their intestinal 274 
toxicity on pigs. 275 
 The increased performance of analytical methods reveals new toxins, especially 276 
emerging ones, as well as "masked" or "modified" forms. Occurrence and toxicity of these 277 
new mycotoxins are poorly documented (Broekaert et al. 2015; Pierron et al. 2015), and thus 278 
it still needs to be determined if they represent a new risk in pig production.  279 
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 280 
Fig.2: Summary of the intestinal toxicity of the main mycotoxins present in feed pig. 281 
 282 
 Global surveys indicate that animals are generally exposed to more than one 283 
mycotoxin (Streit et al. 2012). Indeed fungi are able to produce several mycotoxins 284 
simultaneously; and it is common practice to use multiple grains in animal diets. 285 
Unfortunately, the toxicity of mycotoxin mixtures cannot be predicted based on their 286 
individual toxicities. Interactions between concomitantly occurring mycotoxins can be 287 
antagonistic, additive, or synergistic (Alassane-Kpembi et al. 2015). The data on combined 288 
toxicity of mycotoxins are limited and therefore, the health risk from exposure to a 289 
combination of mycotoxins is incompletely understood (Alassane-Kpembi et al. 2016; 290 
Grenier and Oswald 2011) and deserves further investigation. 291 
 292 
 293 
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B. Impact of mycotoxin on immune response and consequences for 
pig health 
 
Many mycotoxins, alone or in co-exposure, can contaminate cereals and feeding stuffs for 
pig consumption. These mycotoxins induce different toxic effects on pigs and especially on 
the immune system. They are able to modulate or dysregulate the immune response. 
This review summarizes the major effects induced by these mycotoxins on the immune 
response. It also highlights the consequences of these contaminations, which increase the 
susceptibility to infectious diseases or to chronic infection and can also decrease the vaccine 
efficacy. Moreover these mycotoxins can be found in co-contamination, with, as a 
consequence, a potential increase of the effects observed and an impairment of the global 
health of the pig. 
This review was published this year in Animal Nutrition. 
 
 
60 
 61 
 
 62 
 
 63 
 
 64 
 
 65 
 
 66 
 67 
  
 68 
  
 
69 LITERATURE REVIEW 
C. Masked mycotoxins: a risk in pig production? 
 
Currently, many mycotoxins induce toxic effects on pigs and are regulated in pig feed. 
New analytical methods of detection allow highlighting new types of molecules that derivate 
from these mycotoxins. There are also present in cereals and feed and their toxicity is not very 
well-known. 
This review summarizes the knowledge on mycotoxins, their occurrence, their effects on 
pigs and their regulation in pig feed at the European level. It presents new forms of 
mycotoxins, the “masked” and the “modified” mycotoxins, which are derivated from these 
mycotoxins and which are recovered in co-occurrence with them in pig feed. It makes a 
statement on the way of production, the occurrence, the toxicity and the metabolization of 
these molecules in the pig. It summarizes the knowledge on these “masked” and “modified” 
mycotoxins, and talks about the necessity to take into account these molecules in the 
regulation of mycotoxins in pig feed. 
This review was published in the book of the 48
th
 days of the Journées de la Recherche 
Porcine (JRP), and as been presented as an oral synthesis at these same days of JRP in 
February 2016. 
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Les mycotoxines "masquées" : un nouveau risque en production porcine ? 
Les mycotoxines sont des métabolites secondaires de moisissures qui peuvent contaminer différentes céréales et par conséquent 
l’alimentation du porc. Au niveau européen, des réglementations et des recommandations pour l'alimentation animale ont été 
édictées pour six mycotoxines dont la toxicité est documentée. Les avancées dans les techniques de détection ont permis de 
mettre en évidence des dérivés de ces mycotoxines "natives", appelés mycotoxines "modifiées" ou plus spécifiquement 
mycotoxines "masquées" lorsqu'elles sont issues d'une métabolisation par la plante. 
Du fait de leur caractérisation récente, peu d’informations sont disponibles sur leur occurrence dans l'alimentation du porc et leur 
toxicité pour cette espèce. Les données préliminaires indiquent que ces toxines peuvent être présentes à de fortes concentrations 
dans les aliments. Le porc pourrait être une espèce cible également pour ces "nouvelles" mycotoxines, du fait de sa grande 
sensibilité à la présence de mycotoxines conventionnelles, et à son régime alimentaire composé en grande partie de céréales. Ces 
mycotoxines "modifiées" peuvent augmenter la somme de mycotoxines auquel le porc est exposé, si elles sont hydrolysées dans 
l’organisme de l’animal. 
Cette revue recense les connaissances actuelles sur la toxicité des formes "modifiées" du déoxynivalénol, des toxines T2 et HT2, de 
la zéaralenone, de la fumonisine et de l'ochratoxine A pouvant se retrouver dans l’alimentation du porc. Nous nous attacherons à 
comparer le métabolisme et la toxicité  des formes "modifiées" à celle de leurs précurseurs et à analyser la possible reconversion 
de ces formes "modifiées" par la flore intestinale ou les voies de métabolisation du porc.  
Masked mycotoxins: a new risk in pig production? 
Mycotoxins are secondary metabolites originating from mold, which contaminate many cereals and their by-products and so can 
be found in the pig’s diet. Some recommendations and regulations for animal feed have been decreed in the EU for six mycotoxins 
for which the toxicity is well known. Recent detection methods have revealed new mycotoxins and new molecules that are 
derivates of these mycotoxins. They were originally called “Masked” mycotoxins because they are not detected by conventional 
analytical methods. Then, they are more generally called “Modified”, and “masked” when they are metabolized by the plant. 
So because of the difficulty in detecting them, there is little information about the toxicity of these molecules and they are not 
included in the current regulation on mycotoxin contamination in pig feed. Moreover, a high proportion of these modified 
mycotoxins can be found in co-contamination with the mycotoxins. Pigs are really sensitive to mycotoxins, and their high cereal-
rich diet means that they are highly susceptible to mycotoxins and to these modified mycotoxins. These modified mycotoxins can 
potentially increase the amount of mycotoxins to which pigs are exposed if they are hydrolyzed in the animal. 
This review summarizes recent knowledge about the toxicity of the modified mycotoxins of deoxynivalenol, T2 and HT2 toxins, 
zearalenone, fumonisin and ochratoxin A, and presents recent studies about the metabolization and toxic effects on the animals of 
these modified mycotoxins, and their potential impact on their health. 
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INTRODUCTION  
 
Nowadays, contamination by fungi cannot be avoided. Ecological conditions allowing 
the development of fungi (bad weather, humidity, high heat, plant sensitivity…), makes the 
management of the contamination of raw materials difficult. During a fungi contamination, 
mycotoxins, which are secondary metabolites, are produced and found into the seeds. These 
toxins are present in numerous cereals and by-products. A survey realized on 1100 different 
samples of animals’ feed show that about 70% of the samples are contaminated (Streit et al. 
2013). 
The presence of these mycotoxins is considered as a serious threat to the health 
(Bryden, 2007; Wild and Gong 2010). The syndromes caused by the ingestion of high or 
medium doses of mycotoxins are well characterized and can go from acute mortality to 
reduced growth or problems in reproduction (Bryden, 2012). Consuming smaller amounts of 
toxins can lead to an alteration in the immune response and decrease the resistance to 
infectious diseases (Oswald, 2007). Some mycotoxins have an acute toxicity (a single 
exposure at a high dose) that is very strong, but it is exceptional in Europe being exposed to 
toxic doses in a single ingestion of contaminated food. Chronic effects (repeated exposure to 
low or very low doses) are the most feared due to the repetitive diet of the animals and 
because of the persistence of these toxins that are often resistant to high temperatures and 
technological processes used in the animal feed industry. 
Recent advances in analytical methods have revealed new forms of mycotoxins and 
“masked” mycotoxins, not detected by conventional analytical methods. Currently, only 
"native" mycotoxins are regulated and taken into account in the calculation of the total 
exposure in raw or processed food. Actually, only few data are available on these new 
molecules where the risk to underestimate the toxicity induced by these molecules is not 
included in the regulation. Therefore, it becomes important to better know the risk that these 
"masked" mycotoxins can pose to humans and animals. 
After the presentation of the conventional mycotoxins usually detected, this review 
provides a summary of current knowledge on “masked” mycotoxins, their identity, their 
occurrence, their metabolism and toxicity. It concludes on the potential danger that these 
“masked” toxins can represent on the health of the pig. 
 
 
83 LITERATURE REVIEW 
1. THE MYCOTOXINS REGULATED IN PIG’S FEED  
 
In animal feed, only aflatoxins (AF) are regulated in Europe. There are some 
recommendations (Table 1) for five other toxins, which occur regularly and which are known 
to be toxic to swine. There are the ochratoxin A (OTA), the deoxynivalenol (DON), the toxins 
T2 and HT2, the fumonisins (FB1, FB2) and the zearalenone (ZEN) (Bennett et Klich, 2003).  
Table 1 – Reglementation and recommendation of mycotoxins in pig feed: different type of feed and maximum 
levels 
(EC Directive 2002/32/EC, et EC Recommandations 2006/576/EC et 2013/165/EU) (adapted from Stoev, 2014). 
Mycotoxins
1
 Feed 
Maximum 
levels, 
mg/kg of 
feed 
AFB1+ B2 Cereals for animal 60 
Complete food for pig, horse, 
rabbit and pets 
0,5 
OTA Complete food and dietary 
supplement for pig 
0,05 
DON Cereals for animals 
(excepted by-product of maize) 
8 
 
(12) 
Complete food and dietary 
supplement for pig 
0,9 
ZEN Cereals for animals 
(excepted by-product of maize) 
2 
 
(3) 
Complete food and dietary 
supplement : 
-for piglet and young saw 
-for saw and feeder pig 
 
 
0,1 
0,25 
FB1+FB2 Cereals for animal 60 
Complete food and dietary 
supplement for pig, horse and 
rabbit 
5 
T2+HT2 Complete food and dietary 
supplement for animals : 
-product oat milling 
-other grain products 
-complete feed excepted for cat 
 
 
1 
0,5 
0,25 
1Abbreviations : Aflatoxin B1 (AFB1), Aflatoxin B2 (AFB2), Ochratoxin A (OTA), Deoxynivalenol (DON), Zearalenone (ZEN), Fumonisin 
B1 (FB1), Fumonisin B2 (FB2), Toxin T2 (T2) and toxin HT2 (HT2). 
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These molecules belongs to different families of mycotoxins, with various chemical 
structures, and so various toxic effects on pig. The dose, time of exposure, the specie, the age 
and the status of the animal (Bryden, 2007; Wild, 2007). 
The Table 2 lists the major known effects of these mycotoxins on pig health. 
AF are quickly absorbed and metabolized in the liver by the microsomal system which 
actives or modifies the metabolites (Riley, 1998; Haschek et al., 2002). AF alters the global 
immune response (innate and cellular) in pigs (Meissonnier et al., 2006). 
OTA is mainly toxic to the liver and kidneys and causes kidney diseases in pigs. OTA 
affects the renal proximal tubule (Krogh, 1987; Marquardt and Frohlich, 1992). Moreover 
OTA acquires a genotoxic effect after its metabolization in the body (Ash et al., 2004; Pfohl-
Leszkowicz and Manderville, 2007; Steyn et al., 2009). DON is the most common 
trichothecenes B. Pig is very sensitive to this mycotoxin, which can induce at low 
concentration feed refusal, and in higher concentrations vomiting (Haschek et al., 2002). 
Chronicle doses of DON (low concentrations on the long term), induce in pigs weight loss, 
anorexia, immunomodulation and a modification of the intestinal barrier function (Trenholm 
et al, 1984;. And Rotter al., 1996; Haschek et al., 2002; Pinton, Oswald, 2014). Toxins T2 and 
HT2 that belong to the family of trichothecenes A have similar effects but more pronounced 
than Trichothecenes B. They induce irritation to the gastrointestinal tract and skin, and they 
increase the sensitivity of the animal disease (Bryden, 2012). 
Fumonisins are constituted of 12 compounds including fumonisin B1 (FB1), which is 
the most toxic and most studied. Fumonisins induce multiple toxic effects on animals with a 
known carcinogenic effect. In pigs, the FB1 affects the specific and the humoral responses by 
altering the balance of helper T cells, TH1 / TH2 (Taranu et al., 2005; Marin et al., 2006) 
 FB1 induced pulmonary edema in pigs (Haschek et al., 2002). Zearalenone (ZEN) has 
a significant effect on reproduction and fertility especially in swine. The α-zearalenol (α-ZEL) 
and β-zearalenol (β-ZEL), from the reduction of ketones by ZEN-reductase of the host, are 
non-steroidal estrogens that induce estrogenic activity in the animal (Fink-Gremmels and 
Malekinejad, 2007). ZEN and its derivatives cause redness and swelling of the vulva, vaginal 
prolapse and sometimes rectal prolapse in sows. In young sows, they can induce a significant 
swelling of the vulva (Gaumy et al., 2001). 
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Table 2- Associated effects to mycotoxins’ presence in pig feed 
 Mycotoxins
1
 
Effects
2
 AFB1 
AFB2 
OTA DON T2 
HT2 
FB1 
FB2 
ZEN 
Anorexia + + +++ +++ +  
Growth +++ + +++ ++ +  
Hepatotoxicity +++ +   ++  
Nephrotoxicity  +++   +  
Abortion     + ++ 
Infertility      +++ 
Vulvovaginite      +++ 
Pulmonary oedema     +++  
Immuno-modulation +++  ++ ++ +++ + 
1Abbreviations : Aflatoxin B1 (AFB1), Aflatoxin B2 (AFB2), Ochratoxine A (OTA), Deoxynivalenol (DON), Zearalenone (ZEN), Fumonisin B1 
(FB1), Fumonisin B2 (FB2), Toxin T2 (T2) and toxin HT2 (HT2). 
2+, ++, +++ : low effect, middle, and high of mycotoxin (s) on the parameter studied 
 
2. « MODIFIED» MYCOTOXINS IN PIG FEED  
2.1. Presentation  
New analytical methods allowed putting in evidence new secondary metabolites and 
some molecules derivate from these mycotoxins. The term of “masked” mycotoxins” was 
introduced in 1990 by Gareis to describe a glucoside zearalenone not detected during routine 
analysis, but hydrolyzed during digestion (Gareis et al., 1990). 
Figure 1 - Systematic definition of “modified mycotoxins” (Rychlik et al. 2014)
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Indeed, different changes can occur in the structure of mycotoxin, which make them 
undetectable by conventional analytical techniques (Table 3). There are biological changes 
(did by a plant, fungus or animal body) or chemical ones such as the ones caused during 
thermal food processing methods. 
The name of "masked mycotoxin" has often been an ambiguous use, and recently some 
authors have proposed a more precise terminology for the various forms of mycotoxins 
(Berthiller et al, 2013;. Rychlik et al, 2014). 
 
These authors have redefined the terminology of "masked mycotoxin" strictly and introduced 
the concept of "modified mycotoxins." Figure 1 shows for example, all the forms described 
for DON. 
Mycotoxins called "native or free" correspond to the basic structures of mycotoxins formed 
by molds. Most likely to be found in the pig supply is DON, ZEN, fumonisin, aflatoxin and 
OTA. 
Matrix-associated mycotoxins correspond to the "native" mycotoxins bound to a matrix, i.e. 
physically dissolved and / or trapped and / or forming a covalent bond with the matrix. Thus, 
Fumonisins are able to bind to polysaccharides or proteins by their two tricarballyliques acids 
chains, thus forming the hidden fumonisins (hidden F) or linked with starch (F related to 
starch) (Seefelder et al., 2003). 
Excepted these binding phenomena in a matrix, "native" mycotoxins can undergo biological 
or purely chemical transformations. The term "modified mycotoxin" was proposed to 
describe any biological or chemical modification of the chemical structure of a "native" 
mycotoxin (Rychlik et al., 2014). 
"Biologically modified" mycotoxins indicate compounds derived from biotransformation in 
an animal body, plant or a mold. Biotransformation are divided into two main types: Phase I 
reactions (oxidation, reduction or hydrolysis) and phase II reactions (conjugation). 
Generally, biotransformation allows detoxification of toxics, for example in facilitating their 
excretion. However in some cases, it can lead to a more toxic molecule than the parent 
compound. This is for example the case of aflatoxin B1-epoxy which is derived from the 
oxidation of AFB1 by cytochromes P450 during the biotransformation reactions of stage I in 
animals. Glucuronide forms (DON3-GlcA, ZEN14-GlcA, T2-GlcA, HT2-3 / 4-GlcA) come 
from the Phase II biotransformation of the "native" mycotoxins corresponding by the animal, 
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and represent examples of mycotoxins called "biologically modified - conjugated". They 
correspond to the excretion of the native mycotoxins in animal body. 
DON-3-β-D-glucopyranoside (D3G) and zearalenone-14-β-D-glucopyranoside (ZEN14G) are 
issued from DON or ZEN respectively after the phase II biotransformation of metabolization 
by plant. By convention, the terminology of "masked mycotoxin" was reserved only for the 
"biologically modified" mycotoxins from the conjugation reaction in a plant (Berthiller et al., 
2013). 
At present, the four major "hidden" mycotoxins in the strict sense are the ZEN14G, the D3G, 
T2 toxin-glucoside (T2-Glc) and HT2 toxin-glucoside (HT2-Glc) (Lattanzio et al. 2012). It is 
interesting to note the case of the acetylated derivative of 3ADON, an acetylated derivative of 
DON. This compound can be produced both by the fungus, in this case it is a "native" 
mycotoxin, and by transgenic varieties of rice, wheat and barley expressing the gene of the 3-
O-acetyltransferase, and therefore considered as a "hidden"mycotoxin. Gene transfer of the 3-
O-acetyltransferase to plants is a promising strategy to reduce the pathogenicity of Fusarium 
that affect some plant species. Indeed, it’s established that the conversion of DON into 
3ADON by the plant can limit the aggressiveness of Fusarium (Karlovsky, 2011). 
Table 3- Major « modified » mycotoxins (adapted from Broaekart et al., 2015) 
"Native"mycotoxin "Modified" mycotoxin   
Deoxynivalenol 15-acétyl-DON (15ADON) 
3-acétyl-DON (3ADON) 
DON-3-O-glucoside (DON3O-Glc) 
DON-3/8/15-glucuronide (DON3/8/15-GlcA) 
3-acetyl-DON-glucuronide (3ADON-GlcA) 
DON-3-β-D-glucopyranoside (D3G) 
DON-oligosaccharides 
Deepoxy-DON (DOM-1) 
3-epi-DON 
9-hydroxylmethyl DON lactone 
Nor-DON A-F 
DON-sulfonate (DON-S) 
Zearalenone ZEN-14-glucuronide (ZEN14-GlcA) 
ZEN-14-β-D-glucopyranoside (ZEN14G) 
ZEN-14-sulfate (ZEN14S) 
α-zearalenol (α-ZEL) 
β-zearalenol (β-ZEL) 
α-zearalenol-14-α-D-glucopyranoside (α-
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ZEL14G) 
β-zearalenol-14-β-D-glucopyranoside (β-
ZEL14G) 
T2 T2-glucuronide (T2-GlcA) 
T2-glucoside (T2-Glc) 
HT2 HT2-3/4-glucuronide (HT2-3/4-GlcA) 
HT2-glucoside (HT2-Glc) 
Fumonisin F N-(carboxymethyl) 
FB1 N-(1-deoxy-D-fructos-1-µl) 
HFBx 
F-N-acetyl 
F-O-acetyl 
F cachées 
F liées à l’amidon 
Aflatoxin AFB1-epoxide 
Ochratoxin OTA-oligossacharides 
14-(R)-OTA 
14-decarboxy-OTA 
In bold: Masked mycotoxins in the strict sense 
 
Other mycotoxins may be "biologically modified" by the action of a microorganism, and are 
grouped under the term of “mycotoxins differently modified”. The Deepoxy-DON (DOM-1) 
and 3-epi-DON, resulting from the transformation of DON by bacteria extracted from human 
microbiota or animal, belong to this group (Eriksen et al., 2002; Karlovsky, 2011; Gratz et al., 
2013). 
"Chemically modified" mycotoxins are the last group. The chemical modifications may or 
may not depend from the heat. "Chemically modified- thermally formed" mycotoxins 
appear during food processes such as baking, roasting, freezing or extrusion. These thermo-
dependent changes are known for many mycotoxins, in particular fumonisins capable of 
entering into a Maillard reaction, due to the reduction of sugars with the production for 
example of fumonisin B1 N- (1-deoxy D-Fructos-1-yl) and fumonisin N- (carboxymethyl) 
(Hmph and Voss, 2004). 
We can also mention the derivatives of DON (Nordon A-F and 9-hydroxymethyl DON 
lactone) as thermal degradation products; some of which can be found in commercial food 
samples (Bretz et al., 2005). "chemically modified – non-thermally formed" mycotoxins are 
formed by different processes,  including hydrolysis carried out with fumonisins (HFBx), 
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sulfation of DON leading to DON-sulfonate or the degradation products of ochratoxins by UV 
rays (Beyer et al, 2010;. Heydt-Schmidt et al, 2012.). 
 
2.2. Occurrence of “natives” and “modified” mycotoxins 
Some "modified" mycotoxins, particularly the "hidden" forms but also the “matrix-
associated” forms and some chemically modified forms can be found in pig feed. Table 4 
shows data of occurrence of major mycotoxins and their "modified" forms in cereal samples 
(wheat, barley, corn, oats and rice) over the period from 2010 till 2014. 
The "native" mycotoxins represent the major part in food contamination. However, other 
forms are also concomitantly found in foods. It is currently possible to detect many 
"modified" mycotoxins, but few quantitative data are available, particularly because of a lack 
of analytical standards and reference materials. 
Table 5 provides more information on the proportion of certain "modified» mycotoxins for 
which few data are available, compared to their "native" form. For some mycotoxins, such as 
T2-HT2-Glc and Glc, the occurrence data are from only one study. Their presence was 
reported for the first time in 2012 in wheat and oats naturally contaminated (Lattanzio et al, 
2012). 
For the D3G, discovered earlier, more data are available on its occurrence and its ratio to 
DON. The proportion of this "masked" mycotoxin is stable in food and corresponds, to 
almost, 20% of the DON present (Berthiller et al, 2009). However, the ratios vary depending 
on the cereal, genotype concerned, the country and the year of harvest and can increase up to 
46%. (Berthiller et al, 2009; De Boevre et al, 2012). Also the increasing use of Fusarium 
resistant plants, able to glucosylate DON in D3G, could increase the ratio D3G / DON. Some 
studies of these resistant plants have even found up to 2.7 times more D3G present in the 
plant than DON (Sasanya et al, 2008). 
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Table 4 - Occurrence of trichothecenes and ZEN and occurrence of their “modified” forms in cereals (samples 
of wheat, barley, oat, maize and rice from different countries) (adapted from (Broekaert et al. 2015) 
Mycotoxins
1
 
 
Number of 
samples
2
 
Incidence, 
% 
Mean, µg/kg of 
feed 
DON 5743 84 458 
3ADON 2227 22 14,7 
15ADON 686 31 36,6 
D3G 529 55 85 
NIV 3062 32 17,8 
ZEN 2158 12 39,6 
ZEN14G 36 25 37 
ZEN14S 12 25 6 
T2 321 45 16,7 
HT2 321 54 61 
T2-Glc 15 73 2,4 
HT2-Glc 15 80 5,1 
1 
Abbreviations: Nivalenol (NIV), see also Tables 1 and 3. The "native" mycotoxins are in italics and "modified" 
mycotoxins in bold. 
2
Country of different grains analyzed: Austria, Belgium, China, Denmark, Finland, Italy, Nigeria, Norway, 
Czech Republic and Sweden. 
In terms of matrix- associated fumonisins (physically entrapped), their proportions compared 
to the ones of free fumonisins are more variable. Their presence has been shown after a 
hydrolysis step of raw materials (Dall'Asta et al., 2009). The proportion of physically trapped 
forms change according to the genotype of corn and according to the culture conditions 
(Dall'Asta et al., 2012). 
In conclusion, more occurring data on different crops and in different countries are needed to 
properly assess the risk associated with the presence of these new mycotoxins. 
 
2.3. Metabolization and toxicity of “modified” mycotoxins on pig 
The occurrence of "modified" mycotoxins in feed and animal exposure to these new toxins 
raise a number of questions and the need to investigate the metabolism and toxicity of these 
compounds (EFSA, 2014). It is important to study the intrinsic toxicity of these toxins, but 
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also to know their metabolism and in particular to determine if "modified" mycotoxins are 
converted into their "native" forms. 
Some recent studies were interested in the effects of these "modified" mycotoxins on the pig, 
on in vitro or in vivo models. Most of these studies focus on the metabolism of these 
molecules and few about their toxicity. 
Table 5 - "Modified" mycotoxin proportion compared to their "native" mycotoxins in raw materials naturally 
contaminated 
Raw 
materials 
"Modified" mycotoxins
1
  Number of 
samples 
Mycotoxins proportion 
"modified"/ "native", % 
References 
Wheat, 
Maize 
D3G 77 20% 
up to 46% 
(Berthiller et al. 2009) 
Cereals D3G 21 6-29% (Desmarchelier and Seefelder 2011) 
Maize, 
Wheat, Oat 
D3G 11 up to 30% De Boevre et al. (2012) 
Maize ZEN14S 41 up to 30% (Streit et al. 2013) 
Wheat ZEN14G 10 up to 30% (Scheneweis et al. 2002) 
Wheat T2-Glc, HT2-Glc 9 up to 12% (Lattanzio et al. 2012) 
Oat T2-Glc, HT2-Glc 9 2% (Lattanzio et al. 2012) 
Maize Fumonisins associated to matrix 
Fumonisins associated to matrix 
Fumonisins associated to matrix 
31 
97 
120 
up to 100% 
up to 60% 
j up to 60% 
(Dall'Asta et al. 2010) 
(Dall'Asta et al. 2010) 
(Dall'Asta et al. 2012) 
1Abbreviations: see tables 1 et 3. 
 
2.3.1. Inherent toxicity of "modified" mycotoxins for pigs 
Studies on the toxicity of "modified" mycotoxins mainly concern the "modified" forms 
of DON and ZEN. The majority of these studies were conducted in vitro on human cells and 
only a few are interested in vivo toxicity in animals, including mice and pigs. 
The toxicity of DON were compared to those of its acetylated derivatives (3ADON and 
15ADON) taking into account the cell proliferation, activation of MAPKs (mitogen-activated 
protein kinase) and expression of tight junction proteins as well that the expression of 
cytokines in pigs (Pinton et al., 2012). Percentages of cell viability of the pig intestinal cells 
(IPEC-1) incubated for 24 hours in the presence of DON, 3ADON and 15ADON were 
decreased to 60%, 13% and 69%. The expression of the junction proteins by these porcine 
intestinal cells is decreased by 40% in the presence of 15ADON, and is equivalent to the 
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DON and 3ADON. The 15ADON also showed more toxicity than DON and 3ADON on the 
activation of MAPKs, in vitro on IPEC-1 cells, ex vivo on explant cultures of porcine jejunum 
or in vivo in the tissue jejunal piglets (Pinton et al., 2012). 
One of the known derivatives of DON is the DOM-1 coming from a bacterial transformation 
reducing the 12,13-epoxy group, which is essential in the toxicity of DON and trichothecenes 
in general (Schatzmayr et al., 2006; Zhou et al. 2008). Thus the DOM-1 is considered as a 
non-toxic metabolite of DON. An in vitro study showed that the DOM-1 was 54 times less 
toxic than DON level of DNA synthesis in mouse fibroblasts (Eriksen and Pettersson, 2004). 
The toxicity of DOM-1 on production parameters was evaluated in vivo in pigs. Animals 
receiving the contaminated food with DON 5mg / kg feed and the bacterial strain capable of 
deepoxydise DON, showed no decrease in food intake or weight gain (He et al., 1993; Li et 
al., 2011). However the in vivo evaluation of the pure DOM-1 toxicity on intestine and on the 
pig organism has not been evaluated. 
Compared to DON, the D3G was nontoxic on pig jejunum ex vivo study with an inability to 
induce a D3G ribotoxic stress and to activate the MAPK pathway central, in the 
implementation of the observed pro-inflammatory response with DON (Pierron et al., 2016). 
This inability of D3G to induce a pro-inflammatory response, on the contrary to DON, is 
confirmed in the rat with an absence of an over-expression of cytokines and chemokines (Wu 
et al., 2014A). Moreover, the power of the emetic D3G seems much lower than that of DON 
(Wu et al., 2014b). 
Several studies have compared estrogenic powers of the ZEN and its two derivatives α- ZEL 
and β-ZEL. Estrogenicity of these molecules thus ranks as follows: β-ZEL <ZEN <α-ZEL 
(Mukherjee et al, 2014.). At the cellular level, higher cytotoxicity and genotoxicity of β-ZEN 
compared to the α-ZEN were shown on endometrial pig cells (Tiemann et al., 2003; Othmen 
et al, 2008), while the α- ZEL was more toxic than the β-ZEL on pig oocytes (Alm et al., 
2002). In summary, the hierarchy in the toxicity of these two "modified" mycotoxins, α-β-
ZEL and ZEL, is not clearly established and it depends on the cell type considered. Overall, 
their toxicity is lower than ZEN. 
Generally, glycosylated and sulfated forms of ZEN, as ZEN14G and ZEN14S, seem unable to 
bind to estrogen receptors and induce in vitro toxicity (Poppenberger et al., 2006; Berthiller et 
al., 2009). However, Plasencia and Mishra (1991) found in our study that ZEN4S was able to 
induce the same estrogenic activity than ZEN in the rat uterus enlargement bioassay. 
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Overall, the compounds from the detoxification pathways of plants, "masked" forms sensu 
stricto are less toxic or inactivated with respect to the "native" molecule. The metabolic 
pathways of the plant which are similar to those of animals (e.g. conjugation reactions to 
different molecules sulfate, glutathione or glucuronic acid), increase the polarity of these 
molecules, thereby facilitating their excretion and decreasing their toxicity (Yiannikouris and 
Jouany 2002; Homolya et al, 2003). 
 
2.3.2. Metabolization of “modified” mycotoxins in pig 
Questions about the conversion of "modified" mycotoxins into "native" mycotoxins 
are as old as the discovery of the first "modified" mycotoxin. 
Very early, it has been shown that exposing orally a piglet for 2 weeks to the ZEN14G, it was 
possible to find in his urine and feces varying amounts of ZEN and its estrogenic metabolite 
α-ZEL (Gareis and al., 1990). This study highlights the fact that a significant part of the pig 
exposure to mycotoxin could come from the conversion of "modified" mycotoxins. Such 
conversion may be due to the activity of digestive enzymes and metabolism of the animal. It 
may also result from the enzymatic activity of the digestive flora followed by reabsorption of 
the "native" mycotoxin and / or its metabolites. Table 6 summarizes the features of some 
“modified” mycotoxin along the digestive tract and their hydrolyzed to “native” form. 
Pig is physiologically very close to man, particularly in terms of gastrointestinal tract. In an in 
vitro system mimicking human in successive stages, the action of salivary juice, gastric juice, 
intestinal juice and bile, D3G, ZEN14G and ZEN14S are retained respectively to 99.5%, 
97.3% and 98.6% (De Nijs et al, 2012;. Dall'Erta et al, 2013.). However, D3G that is not 
converted by the enzymes present in saliva and mammalian stomach, may be hydrolyzed by 
lactic acid produced by certain bacterial species such as Enterococcus mundtii and 
Lactobacillus plantarum present in the gastrointestinal tract (Berthiller et al., 2011). 
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Table 6 – Becoming of some “modified” mycotoxins along the digestive tract 
(adapted from De Boevre et al., 2015)
2 
 Mycotoxins
1
 
Compartment D3G
3
 3 ADON & 
15ADON
3
 
ZEA14G
3
 ZEA14S
4
 Hidden 
Fumonisins
4
 
Bound 
Fumonisins
4
 
Saliva 
 
 
Stomach 
 
 
Small intestine 
 
 
Colon 
Stable 
 
 
Stable 
 
 
Max. 5% D3G detected 
 
 
Max. 2% D3G detected 
Feces : DON+DOM-1 
Stable 
 
 
11%DON (3ADON) 
13% DON (15ADON) 
 
0% 3ADON 
0% 15ADON 
 
Deacetylation + 
glucuronidation 
Stable 
 
 
Max.19% ZEN 
 
 
Traces  of 
ZEN14G detected 
 
Feces : 40% ZEN 
Feces : 60% 
catabolites 
Stable 
 
 
Stable 
 
 
Stable 
 
 
Feces : 40% 
ZEN 
Feces : 60% 
catabolites 
Stable 
 
 
Stable 
 
 
Stable 
 
 
Max.99% 
fumonisins 
Stable 
 
 
Stable 
 
 
Stable 
 
 
Stable 
1Abbreviations: see tables 1 and 3 
2In italic:% of “modified” mycotoxin found after oral ingestion in different parts of the diigestive tract. In normal character: % of 
“modified” mycotoxin found in his ‘native” form in the different parts of the digestive tract. “Traces” if the molecule is slightly transformed 
and “stable” if the molecule is not transformed in its“native” form in the compartment. 
3Based on in vitro and in vivo experiments 
4 Based on in vivo experiments 
As for DON, “modified” forms of ZEN can be deconjugated after fermentation in presence of 
human feces, and so the “native” forms can be released (Dall’Erta et al, 2013). An increase of 
30-50% of detectable fumonisins is observed, after food matrix digestion (Dall’Asta et al, 
2010). This suggests that the gastrointestinal enzymes are capable of destroying the 
interactions between the matrix and fumonisin, salting-out forms of "native" mycotoxins. For 
the DOM-1, from a bacterial transformation, there is no in vivo study with pure DOM-1. 
The epimerization forming the 3-epi-DON, is an irreversible reaction (Karlovsky, 2011). But 
currently there is no data available on its toxicity. In terms of acetylated forms of DON, they 
are quickly deacetylated in DON within the organism of animal (Wu et al., 2010). 
These in vitro results therefore show that some "modified" mycotoxins can be transformed 
back into their "native" mycotoxins in variable proportions. This suggest that this 
transformation would be mainly due to intestinal microbiota. 
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One study looked at the becoming of DON or D3G orally and intravenously administered to 
piglets (Nagl et al., 2014). DON is excreted largely in the urine, mainly in the first eight post-
exposure hours by mainly "native" form and to a minor form of DON-3-glucuronide (DON3-
GlcA) and DON-15-glucuronide (DON15-GlcA). Urinary excretion of D3G administered 
orally, although a majority, appearing between the 8th and the 24th hour post-exposure. Only 
a tiny fraction of D3G was found unprocessed in the urine, most of which is converted into 
DON, and as well in DON3 GlcA-and-DON15 GlcA. In the case of D3G parenteral 
administered, most of the administered dose was recovered unchanged in the urine within the 
first eight hours. This study demonstrates that (i) the contaminant D3G pig feed can be 
converted to DON in the digestive tract, (ii) due to the delayed urinary excretion, this 
conversion takes place probably in the lower portion of the digestive tube, and (iii) the DON 
from the D3G of microbial hydrolysis may well be absorbed and contribute significantly to 
the total exposure of pig to DON. 
 
3. ASSESSMENT OF THE EXPOSURE AND CHARACTERIZATION OF THE RISK 
FOR THE “MODIFIED” MYCOTOXINS IN PIG 
In 2014, EFSA performed a work of assessing exposure of pig to certain "modified" 
mycotoxins and on the characterization of the risk associated to these molecules (EFSA, 
2014). Mycotoxins concerned are ZEN, nivalenol (NIV) (a mycotoxin of the family of 
trichothecenes such as DON), T2 toxin and HT2 and fumonisins. 
Exposure calculation traduces in cumulative exposure the increase of exposure of one 
mycotoxin due to the conversion of “modified” forms into “native” mycotoxin. 
As in human, the increase was estimated at 100% for ZEN, 30% for NIV, 10% for T2 and 
HT2, and 60% for fumonisins. 
Table 7 presents the calculation of estimated exposure to these “modified” and 
“natives” mycotoxins. 
Based on NOEL (No Observed effect Level) of ZEN fixed at 10µg/Kg BW per day for these 
estrogenic effects, EFSA has estimated that the increase exposure, linked to the “modified” 
forms, was not enough to overcome the regulation of ZEN in pig feed. 
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The LOAEL (Lowest Observed Adverse Effect Level) established for NIV in pigs is 100 
µg/Kg BW/day (EFSA, 2013). The calculation of estimated exposure in NIV and NIV from 
the “modified” forms retransformed will represent 2-3% of the LOAEL (Table 7). So, EFSA 
estimated that the addition of “modified” forms of NIV, was not likely to jeopardize the safety 
of pig feed. 
 
Table 7 - Pigs exposure estimation for certain mycotoxins ("native" accumulated forms and "modified") in two 
hypotheses (h) high and low (adapted from (EFSA 2014)1 
Age 
Weig
ht, kg 
Feed daily 
intake 
(Kg/day) 
Level of exposure, µg/kg feed daily intake/day 
ZEN 
"native" 
&"modified" 
NIV 
"native" 
&"modified" 
Toxins T2 + HT2 
"native" 
&"modified" 
Fumonisins 
"native" 
&"modified" 
h low h high h low h high h low h high h low h high 
Piglet 20 1 0,7 1 0,53 2,07 0,3 1,43 3,7 10,3 
Feeder Pig 100 3 0,6 0,9 0,31 1,21 0,31 0,96 7,4 11,1 
Saw 200 6 2,2 2,5 0,32 1,26 0,33 0,92 4,6 11,9 
1Abbreviations: see tables 1, 3 and 4. 
 
Starting from the most pessimistic hypothesis, the cumulative exposure in T2 and 
HT2, and their "modified" forms correspond to 9% of the LOAEL group established at 29 
µg/kg BW/day for these trichothecenes of group A (EFSA, 2011). On this basis, the EFSA 
considered that the inclusion of "modified" forms of T2 and HT2 also was not likely to 
jeopardize the level of food safety for pigs for these mycotoxins. In the highest hypothesis, 
cumulative exposure to "native" fumonisin and their "modified" forms represent 25% of the 
LOAEL established by EFSA in 2005 at 200 µg/kg BW/day. For these mycotoxins the safety 
of food for pigs does not appear compromised. 
To sum up, the EFSA issued an opinion on four mycotoxins or groups of mycotoxins 
(ZEN, NIV, T2/HT2 and fumonisins) for which no new concern seem to emerge following 
the consideration of exposure to "modified" forms. One advice for DON and its "modified" 
forms is being written. Such advices of reference are not yet available for aflatoxins and 
ochratoxin, which are two families of mycotoxins respectively subject to regulation and 
recommendation in pig feed. 
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CONCLUSION 
New methods in toxicology and in analysis allow to increase the knowledge on the 
hazards present in food and to put in evidence new types of mycotoxins. However, effects of 
these “modified” and “masked” mycotoxins on the health is not well known. Actually, only 
few studies in vivo and in vitro are available on the metabolization of these molecules into the 
animal. More studies are necessary to better understand their impact on the health of pigs and 
humans. 
The percentage of “modified” mycotoxins are generally lower than the one of “native” 
mycotoxins which means that the observed toxic effects are mainly due to “native 
mycotoxins”. However, the feasible hydrolyze of “modified” mycotoxins in the intestine, 
could increase the total amount of mycotoxins to which pigs are exposed, and so minimize the 
real risk of exposure for the animal. 
Many “modified” mycotoxins are retransformed into their “native” mycotoxins. For this 
reason, it’s important to take into account both “modified” and “natives” mycotoxins in the 
risk assessment of exposure. Actually, only “natives” mycotoxins are regulated, but 
“modified” forms can be found in important proportion in cereals. Indeed, for example, 
glucosylated forms, as D3G can reach in proportion 30% of the “native” mycotoxins. 
The EFSA recent works tend to consider the amount of “natives” and “modified” mycotoxins 
in order to calculate the risk linked to the exposure to mycotoxins. 
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Aims of the thesis 
 
The Fusarium mycotoxin deoxynivalenol (DON) is one of the most frequently 
widespread mycotoxin worldwide, in cereals and feed raw materials. DON is known for its 
toxic effects on animals, and causing big economic losses. Due to its high structural stability 
of the DON makes its elimination difficult, once present in cereals or feed materials. Several 
strategies were then developed to manage mycotoxins and DON contamination, like physical 
(cleaning, sieving), chemical (ammoniation) and biological (binding agents, feed additives) 
treatments.  
Thereby, in the context of use of new strategies of detoxification, some metabolites are 
formed during the biological transformation of DON. In this context my work deals with the 
toxicity of biological degradation product of mycotoxins the deepoxy-deoxynivalenol (DOM-
1) and the 3-epi-deoxynivalenol (3-epi-DON) from bacterial degradation and the 
deoxynivalenol-3-β-D-glucopyranoside (D3G) transformed into the plant.  
The general objective of this thesis was to assess the toxicity of three derivatives of 
DON: D3G, DOM-1 and 3-epi-DON. 
Indeed, one of the major questions associated with these metabolites of DON is related 
to their toxicity: are they toxic by themselves? Indeed, little is known about the toxicity, of 
these masked and modified forms of DON, compared to the extensively investigated DON. 
As part of this thesis, I assessed the toxicity of these DON derivatives with a special emphasis 
on DOM-1 with an in vivo experiment. 
Intestine is the first exposed organs to xenobiotics or mycotoxins, present in food, and so 
constitutes the first barrier upon exposure of toxins and could be exposed to high level of 
mycotoxins (Rotter et al. 1996). Intestinal viability cells could be directly damage or it is  the 
barrier function that can be impaired, and so promote the entry of contaminant in the blood 
and in all the organism. Thus, analysis focused on intestinal tissue. 
Moreover, DON is well known for its immunomodulatory effects and for its great impact on 
the intestine, the first organ targeted following the ingestion of mycotoxins. DOM-1, 3-epi-
DON and D3G derivatives of DON may also have an impact on these two functions. 
Therefore, it becomes important to know whether these transformations of DON will lead to 
less toxic molecules for animal or whether they will induce other effect on the animal. 
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The specific aims of this research were: 
 to assess the toxicity of the masked form of DON, D3G, and to determine its 
molecular mode of action using in vitro, ex vivo and in silico approaches (Chapter 
I, Part 1). 
 to assess the toxicity of two microbial derivatives of DON, DOM-1 and 3-epi-
DON and to determine their mode of action using in vitro, ex vivo and in silico 
models. In the case of DOM-1, in vivo experiment was also performed to assess its 
toxicity and anorectic effect in piglets (Chapter I, Part 2 & Chapter II). 
 as DON was always included as a positive control, the experiments allowed us to 
get more insight on intestinal toxicity of DON, especially at the transcriptional 
level (Chapter I). 
 
The aim of this thesis was to assess the toxicity of several DON derivatives, formed either 
in the plant (D3G) or after microbial transformation (DOM-1 and 3epiDON).  D3G is formed 
by a natural way of defense in plant, aiming to manage xenobiotics and their excretion. 
Microbial transformation, is the use of isolated and stabilized microorganism able to 
transform mycotoxin. 
The use of in silico, in vitro, and ex vivo models, allow the comparison of the intestinal 
and immune toxicity of D3G, DOM-1 and 3-epi-DON to the one of DON. In silico analysis 
allowed to draw molecules in three dimensions, to determine the interaction of the molecules 
and the ribosome and to understand the molecular mechanism of toxicity. In vitro model using 
cell line is a powerful enabling tool for the exploration of fundamental questions regarding 
cell and the study of drug delivery dynamics and kinetics. 
To study the toxicity of DON and its derivatives on intestinal epithelial cells, the choice 
was to use the human intestinal cell line Caco-2. It has advantages to express characteristics 
markers of adults’ intestinal cells and to be a reference line in toxicology studies, and to be 
largely used to study intestinal absorption (Sambruy et al. 2001). The explant model was also 
chose to enable directly testing the toxicity of molecules on intestinal living tissue keeping its 
polarity and extracellular integrity (Gonzalez-Vallina et al. 1996). Moreover, in the context of 
3R, it limits the use of animals, and to test many conditions with limited number of animals. 
In vivo pig model allowed studying more deeply the comparative toxicity of DON and DOM-
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1, on the intestine and on the immune response. Therefore in the context of risk assessment, in 
vivo experiment allows to investigate the metabolism of modified mycotoxin into the animal. 
Experimental animal phases were conducted on pigs at the ToxAlim laboratory. From an 
agronomic point of view, breeding a monogastric animal such a pig is particularly vulnerable 
to mycotoxins due to the importance of share of cereals in its diet. In addition, pig is very 
sensitive to mycotoxins, due to the absence of ruminal tank, known to contain 
microorganisms capable of degrading toxins before their intestinal absorption. Finally, 
considering the similarity in the immune and digestive systems of pigs and humans, the use of 
pig model permit also to extrapolate data to man. For the choice of doses and time of 
exposure, this work fits in the current dynamic of a toxicological study, for chronical 
exposure going from low doses to moderate ones, not inducing major clinical manifestations. 
Finally, performing microarray analysis on all the genome of the pig allowed identifying 
genes and biological pathways impacted by DON as well as demonstrating the absence of 
toxicity of the DON derivatives. 
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Abstract (250 words) 35 
The contamination of cereals with deoxynivalenol (DON), the most prevalent mycotoxin in 36 
the world, cannot be avoided however biotransformation can be used to reduce its toxicity. 37 
Bacteria are able to de-epoxidize or epimerize DON to deepoxy-deoxynivalenol (deepoxy-38 
DON or DOM-1) or 3-epi-deoxynivalenol (3-epi-DON), respectively. Using in silico, in vitro 39 
and ex vivo approaches, the intestinal toxicity of DON, deepoxy-DON and 3-epi-DON was 40 
compared and the molecular basis for the reduced toxicity investigated. In human intestinal 41 
epithelial cells, deepoxy-DON and 3-epi-DON were not cytotoxic, did not change the oxygen 42 
consumption or impair the barrier function. In intestinal explants, exposure for 4 hours to 43 
10µM DON induced intestinal lesions not seen in explants treated with deepoxy-DON and 3-44 
epi-DON. A pan-genomic transcriptomic analysis was also performed on intestinal explants 45 
treated with DON and its biotransformation metabolites. 747 probes, representing 323 genes, 46 
involved in immune and inflammatory responses, oxidative stress, cell death, molecular 47 
transport and mitochondrial function, were differentially expressed, between DON-treated and 48 
control explants. By contrast, no differentially expressed genes were observed between 49 
control, deepoxy-DON and 3-epi-DON treated explants. Both DON and its biotransformation 50 
products were able to fit into the pockets of the A site of the ribosome peptidyl transferase 51 
center. In this position DON forms three hydrogen bonds with the A site and activates 52 
MAPKinases (mitogen-activated protein kinases). By contrast deepoxy-DON and 3-epi-DON 53 
only form two hydrogen bonds and do not activate MAPKinases. Our data demonstrate that 54 
bacterial de-epoxidation or epimerization of deepoxy-DON modified their interaction with the 55 
ribosome, leading to an absence of MAPKinase activation and toxicity. 56 
 57 
58 
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Introduction 59 
Mycotoxins are toxic secondary metabolites produced by various molds, such as Aspergillus, 60 
Penicillium and Fusarium which may contaminate food and feed at all stages of the food/feed 61 
chain (Bennett and Klich 2003; Frisvad et al. 2006). Despite the improvement of agricultural 62 
and manufacturing practices, mycotoxin contamination cannot be avoided and still represents 63 
a permanent health risk for both humans and animals. It is thus important to develop 64 
decontamination strategies (Awad et al, 2010). Among mycotoxins, deoxynivalenol (DON) 65 
produced by Fusarium species, is commonly detected in cereal crops, including wheat, barley, 66 
and maize. It is the most abundant trichothecene in food with a frequent occurrence at 67 
toxicologically relevant concentrations worldwide (EFSA 2013, CAST 2003). 68 
DON causes acute and chronic disorders in humans and animals, with the gastrointestinal 69 
tract being an organ sensitive to its adverse effects (Pestka 2010a). DON affects the intestinal 70 
histomorphology, impairs barrier function and nutrient absorption (Maresca 2013 ; Pinton and 71 
Oswald 2014). DON also disrupts the local intestinal immune response; it triggers and 72 
potentiates intestinal inflammation (Cano et al. 2013; Vandenbroucke et al. 2011). At the 73 
cellular and subcellular level, DON binds to the ribosome, inhibits protein and nucleic acid 74 
synthesis and triggers ribotoxic stress (Shifrin and Anderson 1999; Pestka et al, 2004; Garreau 75 
de Loubresse et al. 2014) leading to the activation of kinases, MAPKs and their downstream 76 
signaling pathways (Pestka 2010b).  77 
Several strategies have been developed to limit DON toxicity (Zhou et al. 2008), among them, 78 
bacterial biotransformation which depends on the ability of microorganisms to generate DON 79 
metabolites with reduced toxicity. De-epoxidation is a reductive chemical reaction opening 80 
the 12,13-epoxy ring transforming DON into its de-epoxide metabolite de-epoxy-81 
deoxynivalenol (deepoxy-DON or DOM-1) (Fig.1) (Sundstol Eriksen et al. 2004). Several 82 
microbial strains are capable of DON de-epoxidation (Schatzmayr et al. 2006; Zhou et al. 83 
2008). Several in vitro studies demonstrated the reduced toxicity of deepoxy-DON. In vivo 84 
trials on farm animals receiving feed contaminated with DON have also shown a beneficial 85 
effect of the bacteria able to de-epoxidize DON, according to zootechnical parameters and 86 
immune response (Grenier et al. 2013). The hydroxyl on carbon 3 also seems to be significant 87 
for the toxic activity of DON and a detoxification strategy targeting this part of the C3-OH, 88 
leading to the formation of 3-epi-DON, was recently proposed (Karlovsky 2011). Four 89 
bacterial strains, all isolated from soil, have been described to epimerize DON into 3-epi-90 
DON (Karlovsky 2011; He et al. 2015a). Only one paper has investigated the effect of 3-epi-91 
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DON and demonstrated the lack of toxicity, both in vitro and in vivo, of this DON metabolite 92 
(He et al. 2015b). 93 
The aim of the current study was to assess the efficacy of microbial transformation through 94 
analysis of the intestinal toxicity of deepoxy-DON and 3-epi-DON. Using physiological, 95 
histological and transcriptomic analysis, we have observed reduced toxicity of deepoxy-DON 96 
and 3-epi-DON, both for human intestinal epithelial cells and pig intestinal explants. We have 97 
further demonstrated that these microbial metabolites of DON fit into the ribosome pocket but 98 
do not elicit ribotoxic stress or activate the MAPKinase pathway. Our paper provides the first 99 
molecular insight for the reduced toxicity of deepoxy-DON and 3-epi-DON. 100 
101 
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Experimental procedures 102 
Toxins 103 
Purified DON was purchased from Sigma-Aldrich (St Louis, MO, USA). DOM-1 was 104 
obtained by transformation of crystalline DON (Romer Labs, Tulln, Austria), dissolved in 105 
medium 10 (Caldwell and Bryant, 1966) at a concentration of 2 mg/ml, by inoculation with 106 
BBSH 797, Gen. nov. sp. nov. of family Coriobacteriaceae in sterile medium, at 37°C for six 107 
days. Biotransformation of DON to deepoxy-DON was confirmed by LC-MS/MS, and 108 
deepoxy-DON was purified by solid phase extraction and preparative HPLC (Schwartz-109 
Zimmermann et al., 2014). The purity of the deepoxy-DON preparation was 99%, based on 110 
chromatograms recorded at 220nm. 111 
3-epi-DON was produced by microbial transformation of DON (He et al. 2015a). Briefly, 112 
DON was co-incubated with the bacterial strain, Devosia mutans 17-2-E-8, in corn meal broth 113 
medium at 28 °C for 48 h. High-speed counter-current chromatography (HSCCC) and 114 
preparative high performance liquid chromatography (prep-LC) were applied to separate 3-115 
epi-DON. The obtained product was analyzed by liquid chromatography (LC) and identified 116 
by congruent retention time and UV/Vis spectrum and mass spectrometric (MS) data. Nuclear 117 
magnetic resonance (NMR) experiments such as correlation spectroscopy (COSY), 118 
heteronuclear single quantum coherence (HSQC) and nuclear overhauser effect (NOE) were 119 
conducted for structural characterization of 3-epi-DON. The 3-epi-DON used in the 120 
experiment had a purity of 96.8%. 121 
Toxins were dissolved in dimethyl sulfoxide (DMSO) (Sigma-Aldrich) and stored at -20°C 122 
until use. 123 
 124 
Caco-2 cell culture 125 
Caco-2 cells (passages 99 - 106) obtained from the TC7 were cultured in 75-cm
2
 culture 126 
flasks (Cellstar cell culture flasks, Sigma-Aldrich) in Dulbecco’s Modified Eagle Medium 127 
enriched with glutamine (Gibco, Cergy-Pontoise, France), supplemented with 10% of heat 128 
inactivated fetal bovine serum, 0.5% of gentamycine (Eurobio, Courtaboeuf, France) and 1% 129 
of non-essential amino acids (Sigma-Aldrich). Cells were maintained at 37° C in an 130 
atmosphere of 5% CO
2
 and 90%  relative humidity. The medium was changed every 2 days. 131 
Cells were passaged once a week. The partially confluent cell monolayers were trypsinized 132 
with Trypsin-EDTA (Eurobio). 133 
 134 
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Cell viability assay 135 
Cell viability assay was performed with the CellTiter-Glo Luminescent Cell Viability Assay 136 
(Promega, Madison, USA) according to manufacturer’s instruction. This test measures the 137 
quantity of ATP, proportional to the quantity of cells. Cells were seeded at the density of 138 
1.56x10
5
cells/cm
2
 in 96-well microtiter plates. Cells were grown for 24 hours and exposed to 139 
DON, deepoxy-DON or 3-epi-DON, or corresponding concentrations of DMSO, for 48 hours. 140 
Luminescence was measured with a spectrophotometer (TECAN Infinite M200, Männedorf, 141 
Switzerland). 142 
 143 
Trans-epithelial electrical resistant measurements  144 
To assess the integrity of individual monolayers, trans-epithelial electrical resistance (TEER) 145 
was measured as already described (Pinton et al. 2012). Cells (1.34 x 10
5
 cells/cm
2
) were 146 
grown until differentiation on polyethylene terephthalate membrane inserts (surface area 0.3 147 
cm
2
, pore size 0.4 µm) in 24-well format (Becton Dickinson, Pont de Claix, France). The 148 
medium was changed every two days. Differentiated cells were exposed to 10µM of diluent 149 
or toxins, DON, deepoxy-DON or 3-epi-DON. The culture medium in the apical side of 150 
differentiated cells in each well was replaced every two days with medium containing toxin. 151 
The TEER was measured for each well daily for 11 days using a Millicell-ERS Voltohmmeter 152 
(Millipore, Saint-Quentin-en-Yvelines, France). TEER values were expressed as % of initial 153 
values. 154 
 155 
Oxygen consumption measurements 156 
The acute effect of toxins on oxygen consumption of Caco-2 cells was assessed using an 157 
XF24 extracellular flux analyzer (Seahorse Bioscience, North Billerica, USA). The procedure 158 
was performed according to the manufacturer's instructions. Briefly, cells were cultured in 159 
XF24 cell culture microplates at 1.5x10
4
 cells per well and maintained as described above. 160 
Oxygen consumption rates (OCR) were measured in both differentiated and undifferentiated 161 
proliferated Caco-2 cells in non-buffered DMEM (Seahorse Bioscience) supplemented with 162 
10 mM glucose, 2 mM sodium pyruvate (Sigma-Aldrich) and 2mM glutamine (Eurobio) and 163 
adjusted to pH 7.4. OCR was monitored every 20 minutes before (basal level) and after 164 
injection of diluent or toxins (10µM). OCR values from each well were normalized against 165 
viable cell counts (calculated with a Malassez cell) and expressed as a percentage of the 166 
baseline value. 167 
 168 
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Intestinal jejunal explants 169 
Jejunal explants were obtained from 5 week old crossbred castrated male piglets as described 170 
previously (Lucioli et al. 2013). The experiment was conducted under the guidelines of the 171 
French Ministry of Agriculture for animal research. Two authors (I.P.O. and A.P.) have an 172 
official agreement with the French Veterinary Services permitting animal experimentation. 173 
Explants were treated for 4 hours at 39°C with 10µM of toxins (DON, deepoxy-DON or 3-174 
epi-DON) or diluent (DMSO) in complete medium. After incubation, treated explants were 175 
fixed in 10% formalin (Sigma-Aldrich) for histological analysis or stored at -80°C for RNA 176 
extraction. 177 
 178 
Histological assessment 179 
Explants fixed with 10% formalin for 24 hours were dehydrated and embedded in paraffin 180 
wax (Labonord, Templemars, France) according to standard histological procedures. Sections 181 
of 5 µm were stained with haematoxylin and eosin (Sigma-Aldrich) for histopathological 182 
assessment. Histological findings were scored based on histological changes and the severity 183 
of lesions as previously described (Lucioli et al. 2013). 184 
 185 
Gene expression analysis of explants by RT-qPCR 186 
For the gene expression analysis, total RNAs were extracted in lysing matrix D tubes (MP 187 
Biomedicals, Illkirch, France) containing guanidine thiocyanate-acid phenol (Eurobio). The 188 
quality of these RNA was assessed (Agilent RNA 6000 Nano Kit Quick, Agilent Bioanalyzer 189 
2100); the mean RNA Integrity Number (RIN) of these mRNA preparations was 6.32 ± 0.83.  190 
Reverse transcription and RT-qPCR steps were performed as already described (Gourbeyre et 191 
al. 2015; Halloy et al. 2005) with previously published primers (Pierron et al. 2015). 192 
Amplification efficiency and initial fluorescence were determined by the ΔCt method. 193 
Obtained values were normalized using two reference genes, ribosomal protein L32 (RPL32) 194 
and cyclophilin A (CycloA). Gene expression levels of treated explants were expressed 195 
relative to the mean of the control explants. 196 
 197 
Gene expression analysis by microarray 198 
The microarray GPL16524 (Agilent technology, 8 x 60K) used in this experiment consisted of 199 
43,603 spots derived from the 44K (V2:026440 design) Agilent porcine specific microarray. 200 
This was enhanced with 9,532 genes from adipose tissue, 3,776 genes from the immune 201 
system and 3,768 genes from skeletal muscle (Pierron et al. 2015). For each sample, Cyanine-202 
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3 (Cy3) labeled cRNA was prepared from 200 µg of total RNA using the One-Color Quick 203 
Amp Labeling kit (Agilent) according to the manufacturer's instructions, followed by 204 
Agencourt RNAClean XP (Agencourt Bioscience Corporation, Beverly, Massachusetts). 205 
About 600 ng of Cy3-labelled cRNA were hybridized on SurePrint G3 Porcine GE 206 
microarray (8X60K) following the manufacturer’s instructions. Slides were scanned 207 
immediately, after washing on an Agilent G2505C Microarray Scanner with Agilent Scan 208 
Control A.8.5.1 software. All experimental details are available in the Gene Expression 209 
Omnibus (GEO) database under accession GSE66918 210 
(http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?token=olixoosedvmdnqr&acc=GSE66918). 211 
The differentially expressed (DE) genes (adjusted p-value ≤ 0.05) were hierarchically 212 
clustered and visualized in heat maps. Functional analysis of DE genes was performed using 213 
the Ingenuity pathway Analysis tool (IPA, http://www.ingenuity.com) to identify pathways 214 
and processes affected by toxins. 215 
 216 
Immunoblotting 217 
Expression of the phosphorylated MAPK p38 and JNK (Jun amino-terminal kinases) was 218 
assessed on differentiated Caco-2 cells and jejunal explants by immunoblotting as previously 219 
described (Pinton et al. 2012). Cells differentiated on 24-well inserts or explants were treated 220 
with 10µM of diluent (DMSO) or toxins, DON, deepoxy-DON or 3-epi-DON for 1 hour. 221 
Proteins were extracted, quantified and a total of 15 µg of protein was separated by SDS-222 
PAGE. The membranes were probed with rabbit antibodies (Cell Signaling Technology, 223 
Danvers, USA) specific for: phospho-SPAK/JNK or phospho-p38 diluted at 1:500 or GAPDH 224 
diluted at 1:1000. After washing, the membranes were incubated with 1:10,000 CF
TM
770 goat 225 
anti-rabbit IgG (Biotium, Hayward, USA) for the detection. Antibody detection was 226 
performed using an Odyssey Infrared Imaging Scanner (Li-Cor Science Tec, les Ulis, France) 227 
with the 770nm channel. The expression of the proteins was estimated after normalization 228 
with GAPDH signal.  229 
 230 
Molecular modeling. 231 
All the compounds tested were modeled with NAMD under VMD1.9. The structures of 232 
deepoxy-DON and 3-epi-DON were built using molefacture from the DON structure included 233 
in PDB-file 4U53, after adding hydrogen chirality and atom verification for minimization. 234 
Docking of deepoxy-DON and 3-epi-DON was done in VMD based on the carbon backbone 235 
of DON. To relax structures and to evaluate the interaction of H-bonds between ribosome and 236 
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ligand, a semi-rigid energy minimization was calculated by NAMD using AMBER topology 237 
and parameter files with a fixed ribosome structure and a flexible structure for the ligand. 238 
 239 
Statistical analysis 240 
Data are expressed as a mean ± SEM of values. The results were analyzed using the Fisher 241 
test on equality of variances, one-way ANOVA and Bonferroni as a test post-hoc; p-values < 242 
0.05 were considered significant. 243 
Microarray data from Feature Extraction software was analyzed with R using Bioconductor 244 
packages and the limma lmFit function as previously described (Pierron et al. 2015). Probes 245 
with adjusted p-value ≤ 0.05 were considered differentially expressed between treated and 246 
control conditions. Hierarchical clustering was applied to the samples and the probes using 1-247 
Pearson correlation coefficient as distance and Ward’s criterion for agglomeration. 248 
249 
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Results  250 
Deepoxy-DON and 3-epi-DON do not impair proliferation of human intestinal cells  251 
Comparative effects of deepoxy-DON, 3-epi-DON and DON were first evaluated on 252 
proliferating human Caco-2 cells. The cell viability was assessed by the quantification of ATP 253 
using the luminescent cell viability assay. As shown in figure 2, 48 hours exposure to 254 
deepoxy-DON or 3-epi-DON at concentrations up to 30µM had no significant impact on cell 255 
viability. By contrast DON markedly decreased the viability of proliferating cells in a dose-256 
dependent manner; exposure to 10µM of DON for 48 hours reduced cell viability by 257 
approximately 70%. The IC50 was calculated at 1.30µM. 258 
 259 
Deepoxy-DON and 3-epi-DON do not impair cell viability and TEER of differentiated 260 
human intestinal cells 261 
V. The comparative toxicity of deepoxy-DON, 3-epi-DON and DON was also performed 262 
on differentiated Caco-2 cells through the measurement of TEER. As already described 263 
(Pierron et al. 2015), differentiated cells are more resistant to DON and at least 30µM are 264 
needed to induce a significant decrease in viability. At 10µM of DON, a significant decrease 265 
of TEER in differentiated Caco-2 cells at a non-cytotoxic dose was observed (Figure 3). The 266 
decrease was time-dependent and reached 25% after 2 days and about 90% at 10 days. By 267 
contrast, cells treated with 10µM deepoxy-DON or 3-epi-DON didn’t show any decrease in 268 
TEER. 269 
 270 
Deepoxy-DON and 3-epi-DON do not affect oxygen consumption in Caco-2 cells 271 
The impact of deepoxy-DON, 3-epi-DON and DON on bioenergetic function in Caco-2 cells 272 
was evaluated using extracellular flux analyses. As shown in figure 4, DON linearly 273 
decreased the rate of oxygen consumption in a time-dependent manner starting at the 40 274 
minute stage. Approximately 3 hours after DON exposure, oxygen consumption values were 275 
32% less than the base value. By contrast, deepoxy-DON and 3-epi-DON had no effect on the 276 
cellular oxygen consumption of proliferating Caco-2 cells and displayed bioenergetics 277 
profiles comparable to that of control cells. Similar data were obtained with differentiated 278 
Caco-2 cells (data not shown).  279 
 280 
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Deepoxy-DON and 3-epi-DON do not induce histological alterations of intestinal explants 281 
In order not to restrict the observations to an intestinal cell line, experiments were also 282 
performed on jejunal explants, a model developed to assess short-term effects of mycotoxins 283 
(Lucioli et al. 2013). The effects on intestines of deepoxy-DON, 3-epi-DON and DON were 284 
first compared with histology (Figure 5). Lymphatic vessel dilation was observed at different 285 
intensities in all groups. Control explants displayed normal villi lined with columnar 286 
enterocytes (Figure 5A). Explants exposed to deepoxy-DON (Figure 5C) and 3-epi-DON 287 
(Figure 5D) presented similar features but mild interstitial edema and cell debris on apical 288 
surface (arrow) were also observed. By contrast, multifocal to diffuse villi atrophy, multifocal 289 
villi fusion (arrows), necrosis of apical enterocytes and cellular debris (arrowhead, Figure 5B) 290 
were observed after 4 hours of explant incubation with 10µM of DON.  291 
 292 
Deepoxy-DON and 3-epi-DON do not induce intestinal inflammation  293 
To complete the analysis of the intestinal toxicity of deepoxy-DON and 3-epi-DON, their 294 
effects on the expression of inflammatory genes were analyzed by RT-qPCR. As already 295 
described (Cano et al. 2013), a strong intestinal inflammatory response was observed in 296 
jejunal explants in the presence of DON and a significant increase in expression of IL-1α, 297 
TNFα, IL-1β, IL-8, IL-12p40 Il-17A and IL-22 was also observed (Table 2). By contrast, no 298 
induction in the expression of these genes was observed in deepoxy-DON and 3-epi-DON 299 
treated explants, demonstrating that microbial transformation of DON to DEEPOXY-DON  or 300 
3-epi-DON led to decreased inflammatory response in intestinal explants (Table 2). 301 
 302 
DON but not deepoxy-DON and 3-epi-DON changes gene expression profile in intestinal 303 
explants 304 
The effects of DON, deepoxy-DON and 3-epi-DON were investigated beyond the 305 
inflammatory response, through a genome wide transcriptomic analysis. Exposure to DON 306 
resulted in differential expression of 747 probes; 681 and 66 probes corresponding to 303 and 307 
33 genes were up- and down-regulated respectively (Figure 6A). By contrast, no genes were 308 
differentially expressed in deepoxy-DON and 3-epi-DON treated explants when compared to 309 
control explants, indicating that microbial transformation of DON to deepoxy-DON or 3-epi-310 
DON abolishes the toxicity of the mycotoxin.  311 
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DON differentially expressed genes were then selected to perform principal component 312 
analysis (PCA) (Figure 6B) and cluster analysis (Figure 6C). Two clusters were distinguished, 313 
indicating up-regulated and down-regulated genes (supplementary table 3). The most 314 
significantly up-regulated genes in DON-treated explants, with a change of more than 2.4 fold 315 
compared to control, were immune genes such as CCL20, CXCL2, PRDM1, AREG, CSF2, 316 
FOSL1 (Table 3). As expected, the 6 pro-inflammatory cytokines already tested in RT-qPCR 317 
analysis were also up-regulated in the DNA array analysis; a strong correlation between the 318 
two methods of analysis was observed (coefficient R²=0.96). DON also increased the 319 
expression of the ER heat shock protein HSP70 gene (HSPA2), genes of ubiquitination 320 
pathway (HSPA2, BIRC2, NEDD4L, BIRC3) and genes of metallothioneins (MT1A, MT1M 321 
and MT2B). DON decreased expression of the CHAC1 gene, genes for molecular transport 322 
including ABCC2, SLC15A1, SLC9A2, the CCL24 gene which is thought to play a role in the 323 
immune response, the MLEC gene which is connected to protein misfolding under conditions 324 
of endoplasmic reticulum (ER) stress, and other genes (table 3).  325 
Pathway analysis of differentially expressed genes exposed to DON was performed using 326 
Ingenuity Pathway Analysis software (IPA). The top 10 scored pathways are listed in Table 4. 327 
DON disturbed pathways related to immunity/inflammation, such as cytokines regulations 328 
(IL-17 axis, IL-10 signaling), leukocytes functions (diapedesis), iNOS and NFkB signaling. 329 
DON affected other pathways associated with cell cycle regulation, apoptosis and ER stress 330 
response. Moreover, the results underlined the effects of DON on PXR/RXR, FXR/RXR 331 
signaling pathways and mitochondrial L-carnitine Shuttle Pathways.  332 
 333 
In silico analysis of the interaction of deepoxy-DON and 3-epi-DON with ribosomes and 334 
their inability to activate MAPKs 335 
The above data indicate that microbial transformation of DON into deepoxy-DON or 3-epi-336 
DON abrogates its toxicity. The last step of this study was to investigate the underlying 337 
mechanism and more specifically to determine the ability of DON, deepoxy-DON and 3-epi-338 
DON to bind to the A site of the ribosome peptidyl transferase center and to activate the 339 
MAPKs.  340 
As expected, after 1 hour of exposure to 10µM DON, MAPKs were activated in both 341 
differentiated monolayers Caco-2 cells and jejunal explants (Figure 7). In cells, DON 342 
significantly increased phosphorylated p38 (3.24 ± 0.75 vs. 1 ± 0.09) compared to the control 343 
(relative intensity in arbitrary unit (A.U.); p<0.05; n=3) and phosphorylated SapKjunk (7.28 ± 344 
0.64 vs. 1 ± 0.12 for control A.U.; p<0.05; n=3). By contrast, deepoxy-DON and 3-epi-DON 345 
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were not able to activate these MAPKs in Caco-2 cells (Figure 7 panel A). Similar trends 346 
were observed in jejunal explants (Figure 7 panel B). 347 
The last step was to investigate the ability of DON and its bacterial metabolites, deepoxy-348 
DON and 3-epi-DON, to bind to the 60S sub-unit inside the A-site of the peptidyl transferase 349 
center of the ribosome. The crystallographic data (4U53.pdb) obtained for DON and yeast 350 
ribosomes were used (Garreau de Loubresse et al. 2014). As shown in Figure 8, (panel A) 351 
DON is able to fit in the pocket of the A-site of the ribosome 60S subunit. Within the pocket, 352 
the 3-hydroxyl group of DON is associated with a magnesium atom and stabilized by other 353 
nucleotides. In this position, DON forms 3 hydrogen bonds with the A-site. The first one is 354 
between the oxygen of the DON epoxy group on C12 and one hydrogen of the sugar of the 355 
uracil U2873; the second one is between the oxygen of the C15 group CH2OH and one 356 
hydrogen of the guanine basis G2403; and the last one is between the hydrogen of the C3 357 
group and one oxygen of the uracil U2869. The in silico analysis revealed that both deepoxy-358 
DON and 3-epi-DON were also able to fit into the pocket of the peptidyl transferase center of 359 
the ribosome. However, because of the absence of the epoxy group or the isomeric change, 360 
these two metabolites were only able to form 2 hydrogen bonds with the A sites of the 361 
peptidyl transferase center. Deepoxy-DON and 3-epi-DON didn’t form the bond with U2873 362 
and U2869, respectively. 363 
364 
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Discussion 365 
 Despite good agricultural practices, contamination by mycotoxins cannot be avoided. 366 
Several strategies have been developed to reduce mycotoxin exposure. Among them, 367 
microbial transformation is of interest but requires demonstration of the absence of toxicity of 368 
the metabolites produced. The aims of the present study were (i) to analyze the intestinal 369 
toxicity of two bacterial metabolites of DON, deepoxy-DON and 3-epi-DON and (ii) to 370 
investigate the molecular basis for their reduced toxicity. 371 
 Through the action of bacteria, DON can be epimerized on the hydroxyl group of C3 372 
or de-epoxidized on the C12-C13 epoxide (Karlovsky 2011). Epimerization is an aerobic 373 
irreversible transformation that may require two enzymatic activities of partially overlapping 374 
substrate specificity which occur together in sequence: oxidation of DON to 3-keto-DON and 375 
then conversion to 3-epi-DON. To date only four bacterial strains have been described to 376 
epimerize DON to 3-epi-DON (Karlovsky 2011). A very recent paper shows that this 377 
bacterial metabolite is substantially less toxic than DON when tested in vitro on proliferating 378 
human Caco2 cells, as well as in vivo when given orally to mice for 14 days (He et al. 2015b). 379 
Deepoxy-DON is obtained after de-epoxidation of DON; several bacterial species and 380 
enzymes are able to catalyze this reaction (Karlovsky 2011). The lower toxicity of deepoxy-381 
DON, as compared to DON has been demonstrated in vitro on Swiss mouse 3T3 fibroblasts 382 
(Sundstol Eriksen 2004), lymphocytes (Schatzmayr et al. 2006) and brine shrimp (Swanson et 383 
al. 1987). In vivo supplementation of DON-contaminated feed, with bacteria and/or an 384 
enzyme able to de-epoxidize DON, induced a reduction of the toxicity as shown by 385 
measurement of zootechnical or immune parameters (Li et al. 2011; He et al. 1993; Grenier et 386 
al. 2013).  387 
In the present study, we observed reduced intestinal toxicity of 3-epi-DON and deepoxy-DON 388 
when compared to DON. The toxicity of DON and its bacterial metabolites, was first 389 
investigated on proliferating and differentiated Caco-2 cells. As already demonstrated, DON 390 
induced a significant decrease in Caco-2 cell proliferation, reduced their barrier function and 391 
altered their respiratory capacities (Alassane-Kempbi et al. 2013, Akbari et al. 2014; Bin-392 
Umer et al. 2014). This is the first investigation of the toxicity of deepoxy-DON on human 393 
intestinal epithelial cells, although the absence of toxicity of 3-epi-DON on Caco-2 cells has 394 
been recently demonstrated (He et al. 2015b). 395 
 The toxicity of DON and its bacterial metabolites on intestinal tissues was further 396 
evaluated. Because of the difficulties accessing human intestinal samples, the study was 397 
performed on porcine intestinal explants. Indeed pigs are very sensitive to DON and can be 398 
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considered good models for extrapolation to humans, with a digestive physiology very similar 399 
to that of humans (Nejdfors et al. 2000; Pinton and Oswald 2014). Histological assessment 400 
showed normal villi lined with columnar enterocytes, mild interstitial edema and cell debris 401 
on the apical surface for the control, 3-epi-DON and deepoxy-DON treated explants. This is 402 
in accordance with the absence of histopathological lesions observed in mice after a 14 day 403 
oral exposure to 25 or 100 mg 3-epi-DON /Kg bw (body weight) (He et al. 2015). Effects of 404 
purified deepoxy-DON on the intestine have never been tested, however nutritional strategies 405 
including bacteria/enzyme transforming DON to deepoxy-DON have reduced the occurrence 406 
and extent of intestinal lesions (Grenier et al. 2013) and showed the same zootechnical 407 
performance as in control animals (He et al. 1993; Li et al. 2011). By contrast, as already 408 
shown, treatment with 10µM of DON induces intestinal damage indicated by villi atrophy and 409 
villi fusion (Lucioli et al. 2013). To confirm that the two microbial transformation products of 410 
DON were not toxic, a pan-genomic analysis using a DNA array containing 62,976 probes 411 
was performed on jejunal explants. It revealed that no probes were differentially expressed 412 
between control explants and the ones treated with either deepoxy-DON or 3-epi-DON. To 413 
the best of our knowledge this is the first genome wide analysis performed for deepoxy-DON 414 
and 3-epi-DON. 415 
 The global transcriptomic analysis of the effect of DON on the intestine indicated that 416 
DON does not only interfere with genes involved in the immune response. As already 417 
described for human and murine thymus cells (Van Kol et al. 2011; Katika et al. 2012; Mishra 418 
2014), DON exposure also targets ER (endoplasmatic reticulum) stress, protein synthesis, 419 
oxidative stress, cell cycle regulation and apoptosis in intestinal tissues. The strong alteration 420 
of the gene MLEC implicated in misfolded glycoprotein quality control observed herein is 421 
likely due to the arrest of translation induced by ribotoxic stress. This leads to less protein 422 
entering the ER to temper the unfolded protein response and therefore protein synthesis 423 
(Katika et al. 2012). The increased gene expression of the ER heat shock protein HSP70 could 424 
also reduce the accumulation of unfolded protein in ER lumen. An increased expression of 425 
some genes involved in the ubiquitination pathway was observed in the presence of DON.  426 
This result could indicate that the presence of DON may induce the increase in proteins 427 
involved in protein degradation (Shen et al. 2007; Osman et al. 2010; Katika et al. 2012). Our 428 
data also underline the decrease of the unfolded protein response pro-apoptotic gene CHAC1. 429 
The CHAC1 protein seems to play a role in glutathione degradation (Kumar et al. 2012). ER 430 
stress could also induce leakage of calcium from the reticulum leading to activation of NFkB, 431 
NRF2-mediated oxidative stress response and apoptosis (Katika et al. 2012). The present 432 
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work emphasizes the effect of DON on metallothioneins MT1A, MT1M and MT2B. A 433 
relationship between metallothionein protein levels, used as a marker of oxidative stress, and 434 
mycotoxins in the liver of rats fed on naturally contaminated wheat has been reported 435 
(Vasatkova et al. 2009). Therefore, it could be assumed that MTs are associated with 436 
pathways protecting the intestine against DON toxicity. The present study underlines the 437 
effect of DON on the genes of intestinal transporters. DON decreases the expression of the 438 
solute carrier SLC15A1 and SLC9A2 involved in proton-coupled oligopeptides transporter 439 
PepT1 and a Na+/H+ exchanger, respectively (Bookstein et al. 1997; Smith et al. 2013). 440 
Similar effects on other mRNA expression transporters as sugars transporters were described 441 
in the jejunum and to a lesser extent in the liver of broilers exposed to DON (Dietrich et al. 442 
2012). Accordingly, it has been experimentally shown that DON decreases the intestinal 443 
uptake of various nutrients in human epithelial intestinal cell line HT-29-D4 (Maresca et al. 444 
2002). This effect is likely due to a specific modulation of intestinal transporters expression, 445 
rather than a consequence of cell damage. The transcriptomic analysis demonstrates that DON 446 
down-regulates the expression of ABCC2 gene that encodes for MRP2, a protein involved in 447 
efflux of DON and other mycotoxins and also in the transport of a wide range of organic 448 
anions including bile salt flow (Videmann et al. 2007). An action of DON on mitochondrial 449 
dysfunction, attested to by the down-regulation of CPT1A mRNA was also observed in this 450 
study. CPT1A encodes for a key regulatory enzyme of β-oxidation and is required for 451 
transport of long chain fatty acids into mitochondria (Nakamura et al. 2014). The modulation 452 
of β-oxidation in addition to the modulation of intestinal transporters could explain the energy 453 
failure reported after DON exposure (Maresca et al.2002). It is now necessary to investigate 454 
these changes at the protein level. 455 
 The use of bacteria is a promising approach to DON decontamination. In the present 456 
study we observed that deepoxy-DON and 3-epi-DON were devoid of intestinal toxicity. The 457 
underlying mechanism was further investigated. DON is known to develop its toxic potential 458 
by interacting with the peptidyl transferase at the 60S ribosomal subunit level, blocking the 459 
protein synthesis at the elongation step, inducing a ribotoxic stress and activating 460 
MAPKinases (Maresca 2013; Pestka et al. 2004; Garreau de Loubresse et al. 2014). In 461 
accordance with literature, we observed that DON induced phosphorylation of JNK and p38 462 
proteins (Sergent et al. 2006; Lucioli et al 2013). By contrast deepoxy-DON and 3-epi-DON 463 
did not active these signaling pathways, suggesting an absence of ribotoxic stress. To further 464 
the analysis, a modeling of deepoxy-DON and 3-epi-DON in the ribosome peptidyl 465 
transferase center was performed. DON and its bacterial metabolites fit into the A-site pocket, 466 
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however whereas DON binds to the peptidyl transferase center with three hydrogen bonds, 467 
only two hydrogen bonds were identified between deepoxy-DON or 3-epi-DON and the 468 
peptidyl transferase center. This suggests that the absence of the epoxy group or the isomeric 469 
transformation decreases the affinity of these latter metabolites for the active site pocket A of 470 
the ribosome and prevents the induction of ribotoxic stress. In silico modeling revealed that a 471 
third hydrogen bond (the one between the oxygen of the C15 group CH2OH and the hydrogen 472 
of the guanine base G2403) could be involved in the interaction of DON with the ribosome. It 473 
would be of interest to establish whether this H-bond is necessary for the toxicity of DON. 474 
Unfortunately we were not able to identify a proper DON metabolite or another fusariotoxin 475 
metabolite to confirm the involvement of this H-bound in the structure-toxicity relationship. 476 
 In conclusion, the present study confirms that the toxicity of DON is not only linked to 477 
the epoxy group but is also influenced by the C3 group (Sato and Ueno 1977; Sundstol 478 
Eriksen 2004, Karlovsky 2011). It demonstrates that microbial biotransformation of DON into 479 
deepoxy-DON or 3-epi-DON decreases the intestinal toxicity of this mycotoxin. The 480 
underlying metabolism causes decreased affinity of the metabolites to the ribosome and the 481 
lack of MAPKinases activation. These data significantly increase the current knowledge of 482 
intestinal toxicity of DON, deepoxy-DON and 3-epi-DON and contribute to the evaluation of 483 
the effectiveness of the microbial biotransformation strategies in the fight against mycotoxins. 484 
485 
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Table 1. Primer sequences used for RT-qPCR analysis (F: Forward; R: Reverse) 640 
 641 
 642 
  643 
Gene symbol Gene name Primer sequence References 
CycloA Cyclophilin A F: CCCACCGTCTTCTTCGACAT NM_214353 
    R: TCTGCTGTCTTTGGAACTTTGTCT Gourbeyre et al. 2015 
RPL32 Ribosomal Protein L32 F: AGTTCATCCGGCACCAGTCA NM_001001636 
    R: GAACCTTCTCCGCACCCTGT Gourbeyre et al. 2015 
IL1A Interleukin 1- alpha F: TCAGCCGCCCATCCA NM_214029,1 
    R: AGCCCCCGGTGCCATGT Cano et al. 2013 
IL1B Interleukin 1 - beta F: ATGCTGAAGGCTCTCCACCTC NM_214055 
    R: TTGTTGCTATCATCTCCTTGCAC Gourbeyre et al. 2015 
IL8 Interleukin - 8 F: GCTCTCTGTGAGGCTGCAGTTC NM_213867 
    R: AAGGTGTGGAATGCGTATTTATGC Grenier et al. 2011 
TNFA Tumor necrosis factor -alpha 
F: ACTGCACTTCGAGGTTATCGG NM_214022 
R: GGCGACGGGCTTATCTGA Gourbeyre et al. 2015 
IL12p40 Interleukin 12 - p 40 F: GGTTTCAGACCCGACGAACTCT NM_214013 
    R : CATATGGCCACAATGGGAGATG Cano et al., 2013 
IL17A Interleukin 17 - alpha F: CCAGACGGCCCTCAGATTAC AB102693 
    R: CACTTGGCCTCCCAGATCAC Cano et al. 2013 
IL22 Interleukin - 22 F: AAGCAGGTCCTGAACTTCAC AY937228 
    R: CACCCTTAATACGGCATTGG Cano et al. 2013 
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Table 2. DON but not deepoxy-DON & 3-epi-DON up regulated mRNA relative expression levels of pro-644 
inflammatory cytokines and chemokines in pig jejunal explants 645 
 646 
Cytokines 
Explant treatments 
Control DON Deepoxy-DON 3-epi-DON 
IL1B 1.00 ± 0.40
a
 17.4 ± 5.1
b
 0.7 ± 0.2
a
 0.8 ± 0.3
a
 
IL1A 1.00 ± 0.30
a
 3.9 ± 1.4
b
 0.9 ± 0.2
a
 0.9 ± 0.2
a
 
IL8 1.00 ± 0.20
a
 4.5 ± 1.2
b
 1 ± 0.1a 0.9 ± 0.2
a
 
IL12p40 1.00 ± 0.31
a
 2.3 ± 0.4
b
 1.2 ± 0.2
a
 0.9 ± 0.2
a
 
IL17A 1.00 ± 0.50
a
 15.8 ± 5.6
b
 0.8 ± 0.1
a
 1.3 ± 0.4
a
 
IL22 1.00 ± 0.30
a
 7.9 ± 1.3
b
 1.3 ± 0.5
a
 1.4 ± 0.5
a
 
TNFA 1.00 ± 0.30
a
 3.5 ± 0.5
b
 1.1 ± 0.4
a
 1.1 ± 0.3
a
 
 647 
Notes: results are expressed in arbitrary units relative to control group. Results are mean ±SEM of 6 animals. 648 
Means in a row without a common letter differ (Newman-Keuls test, P<0.05). 649 
 650 
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Table 3: Top scored differentially expressed genes in DON treated porcine jejunal explants  652 
 Gene symbol Gene name -log  
(p-value) 
Ratio 
a. Genes up-regulated 
IL1B interleukin 1 beta 4.428 1.29E-11 
CCL20 chemokine (C-C motif) ligand 20 3.481 1.79E-06 
IL1A interleukin 1. alpha 3.207 6.46E-09 
CXCL2 chemokine (C-X-C motif) ligand 2 3.129 1.87E-04 
IL22 interleukin 22 2.955 1.13E-07 
PRDM1 PR domain containing 1 with ZNF domain 2.793 4.76E-06 
AREG/AREGB amphiregulin 2.662 1.94E-11 
CSF2 
colony stimulating factor 2 (granulocyte-macrophage) 
2.593 1.86E-05 
IL8 interleukin 8 2.585 1.25E-06 
FOSL1 FOS-like antigen 1 2.447 4.22E-04 
IER3 immediate early response 3 2.446 1.95E-04 
CCR7 chemokine (C-C motif) receptor 7 2.325 1.79E-08 
CALCB calcitonin-related polypeptide beta 2.313 9.03E-11 
GADD45A growth arrest and DNA-damage-inducible alpha 2.270 5.61E-08 
TNFAIP3 tumor necrosis factor alpha-induced protein 3 2.260 1.36E-08 
RND1 Rho family GTPase 1 2.255 3.24E-06 
IER2 immediate early response 2 2.227 3.44E-06 
CD83 CD83 molecule 2.207 1.10E-05 
PLAUR plasminogen activator. urokinase receptor 2.085 9.86E-04 
BTG2 BTG family member 2 2.073 1.25E-06 
IFRD1 interferon-related developmental regulator 1 2.025 1.14E-08 
RGS1 regulator of G-protein signaling 1 2.020 3.24E-06 
GEM 
GTP binding protein overexpressed in skeletal muscle 
2.013 4.52E-05 
CCL4 chemokine (C-C motif) ligand 4 2.004 6.44E-04 
STX11 syntaxin 11 1.989 4.27E-05 
GADD45G growth arrest and DNA-damage-inducible gamma 1.881 2.26E-06 
GADD45B growth arrest and DNA-damage-inducible beta 1.873 9.01E-04 
NEDD9 
neural precursor cell expressed developmentally down-regulated 
9 
1.870 1.15E-10 
LAMA3 laminin. alpha 3 1.858 2.07E-05 
CD274 CD274 molecule 1.846 8.75E-11 
IL17A interleukin 17A 1.844 2.11E-11 
b. Genes down-regulated 
CHAC1 cation transport regulator homolog 1 (E. coli) -1.696 9.18E-04 
ABCC2 
ATP-binding cassette sub-family C (CFTR/MRP) member 2 
-1.015 2.45E-06 
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SLC15A1 
solute carrier family 15 (oligopeptide transporter) member 1 
-0.851 3.56E-05 
SLC9A2 
solute carrier family 9 subfamily A (NHE2 cation proton 
antiporter 2) member 2 
-0.804 9.09E-06 
CCL24 chemokine (C-C motif) ligand 24 -0.784 8.75E-04 
MTTP microsomal triglyceride transfer protein -0.755 3.26E-05 
DMBT1 deleted in malignant brain tumors 1 -0.666 2.67E-04 
MLEC Malectin -0.654 9.50E-04 
SSH1 slingshot protein phosphatase 1 -0.628 1.06E-03 
VPS26B vacuolar protein sorting 26 homolog B (S. pombe) -0.610 1.04E-03 
ACE2 angiotensin I converting enzyme 2 -0.607 7.35E-04 
SCGB2A1 secretoglobin. family 2A member 1 -0.594 2.74E-04 
MYEOV myeloma overexpressed -0.592 1.58E-04 
NPR3 natriuretic peptide receptor 3 -0.582 8.74E-04 
CBL Cbl proto-oncogene. E3 ubiquitin protein ligase -0.574 3.70E-04 
PLOD2 procollagen-lysine 2-oxoglutarate 5-dioxygenase 2 -0.547 3.98E-05 
C4BPA complement component 4 binding protein Alpha -0.525 1.04E-03 
ARHGEF37 Rho guanine nucleotide exchange factor (GEF) 37 -0.521 9.19E-04 
DESI2 desumoylating isopeptidase 2 -0.501 3.04E-04 
STOML3 stomatin (EPB72)-like 3 -0.487 8.33E-04 
UNC119B unc-119 homolog B (C elegans) -0.467 2.42E-04 
ZER1 zyg-11 related. cell cycle regulator -0.455 4.92E-04 
EGLN1 egl-9 family hypoxia-inducible factor 1 -0.443 2.26E-04 
TCAP titin-cap -0.441 8.90E-04 
PECAM1 platelet/endothelial cell adhesion molecule 1 -0.431 1.43E-04 
ZCCHC14 zinc finger CCHC domain containing 14 -0.430 5.16E-04 
GALNT4 polypeptide N-acetylgalactosaminyltransferase 4 -0.395 6.91E-04 
ANKRD13A ankyrin repeat domain 13A -0.388 8.85E-04 
UNC45A unc-45 homolog A (C. elegans) -0.377 7.64E-04 
TPP1 tripeptidyl peptidase I -0.375 5.37E-04 
OSBPL7 oxysterol binding protein-like 7 -0.349 1.05E-03 
 653 
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Table 4.  Ten top scored canonical pathways differentially regulated in 10µM DON treated porcine jejuna explants and list of genes in each pathway 655 
a. Up-regulated pathways 
Ingenuity Canonical Pathways  -log 
(p-value) 
Ratio 
Molecule
s 
Granulocyte Adhesion and Diapedesis 1.18E01 1.1E-01 
CCL3,IL1B,MMP12,EZR,CCL20,CLDN4,CCL3L1/CCL3L3,SELE,MMP13,
CXCL2,VCAM1,CXCL8, CXCR4, IL18, 
   IL1RN,TNF,CXCR2,ICCL4,XCL1    
Agranulocyte Adhesion and Diapedesis 1.13E01 1.04E-01 
CCL3,IL1B,MMP12,EZR,CCL20,CLDN4,CCL3L1/CCL3L3,SELE,MMP13,
CXCL2,VCAM1,CXCL8, 
   
CXCR4,IL18,IL1RN,TNF,CXCR2,IL1A,CCL
4,XCL1    
Glucocorticoid Receptor Signaling 1.11E01 7.69E-02 
HSPA2,NFKB1,CCL3,CSF2,JAK2,IL1B,PLAU,SELE,NFKBIE,NFATC1,NF
KBIA,VCAM1,CXCL8, 
   
FOS,IL1RN,DUSP1,SGK1,NR3C1,TNF,SMAD3,CDKN1A,IL10,F
OXO3  
Differential Regulation of Cytokine Production in 
Intestinal Epithelial Cells by IL-17A and IL-17F 1.07E01 3.91E-01 
CCL3,CSF2,IL1B,TNF,IL1A,IL17A,IL10,CC
L4,IL17F    
Communication between Innate and Adaptive Immune 
Cells 1.01E01 1.25E-01 
CCR7,CCL3,CSF2,IL1B,CCL3L1/CCL3L3,CD40,CXCL8,CD83,IL18,IL1RN
,TNF,IL1A,IL10,CCL4 
Differential Regulation of Cytokine Production in 
Macrophages and T Helper Cells by IL-17A and IL-17F 1.01E01 4.44E-01 
CCL3,CSF2,IL1B,TNF,IL17A,IL10,CCL4,IL
17F    
Hepatic Fibrosis / Hepatic Stellate Cell Activation 9.55E00 1.03E-01 
CCR7,NFKB1,IL1B,EDNRB,MMP13,CD40,VCAM1,CXCL8,IFNGR1,TNF,S
MAD3,IL1A,EDN1,IL4R, 
   IL10,TIMP       
IL-10 Signaling 9.48E00 1.54E-01 
FOS,IL18,NFKB1,IL1RN,IL1B,SOCS3,TNF,IL1A,IL4R,IL10,NFK
BIE,NFKBIA  
T Helper Cell Differentiation 9.41E00 1.67E-01 
GATA3,IFNGR1,BCL6,IL18,STAT4,TNF,ICOSLG/LOC102723996,IL17A,IL
4R,IL10,CD40,IL17F 
Atherosclerosis Signaling 9.4E00 1.08E-01 
NFKB1,IL1B,SELE,MMP13,CD40,VCAM1,CXCL8,CXCR4,IL18,IL1RN,TN
F,IL1A,F3,TNFRSF12A, 
   PLA2G4A       
 
 656 
b. down-regulated pathways 
Ingenuity Canonical Pathways 
-log 
(p-value) Ratio Molecules 
PXR/RXR Activation 2.28E00 2.17E-02 ABCC2, CPT1A 
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FXR/RXR Activation 2.07E00 1.82E-02 ABCC2, MTTP 
Mitochondrial L-carnitine Shuttle Pathway 1.57E00 4.55E-02 CPT1A 
Granulocyte Adhesion and Diapedesis 1.49E00 1.1E-02 CCL24, PECAM1 
Agranulocyte Adhesion and Diapedesis 1.44E00 1.04E-02 CCL24, PECAM1 
LPS/IL-1 Mediated Inhibition of RXR Function 1.31E00 8.16E-03 ABCC2, CPT1A 
Complement System 1.28E00 2.86E-02 C4BPA  
Erythropoietin Signaling 9.87E-01 1.27E-02 CBL  
Chemokine Signaling 9.75E-01 1.33E-02 CCL24  
Ephrin B Signaling 9.46E-01 1.22E-02 CBL  
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 658 
 659 
 660 
Figure 1.  Molecular structures of DON, deepoxy-DON and 3-epi-DON. 661 
 662 
 663 
 664 
 665 
 666 
Figure 2.  Effects of deepoxy-DON or 3-epi-DON on cytotoxicity of human intestinal epithelial 667 
cells. Proliferative Caco-2 cells were incubated with increasing concentrations of diluent (♦), DON 668 
(■), DEEPOXY-DON (▲) or 3-epi-DON (●) or for 48 hours. Cell viability evaluated by measurement 669 
of ATP, is expressed as % of control cells. Results are expressed as mean ± SEM of 3-4 independent 670 
experiments, ***p<0.001. 671 
  672 
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 673 
Figure 3. Effects of deepoxy-DON and 3-epi-DON on trans-epithelial electrical resistance 674 
(TEER) of human intestinal epithelial cells.  Differentiated caco-2 cells, were treated with 10µM of 675 
diluent (♦), DON (■), DEEPOXY-DON (▲) or 3-epi-DON (●) and TEER was measured. Results are 676 
expressed as mean ± SEM of 3-4 independent experiments, ***p<0.001. 677 
 678 
 679 
Figure 4. The acute effect of toxins on oxygen consumption rate (OCR) of cultured Caco-2 cells. 680 
After establishment of baseline oxygen consumption rate in proliferated Caco-2 cells seeded to 681 
1.5x10
4
 cells/well, diluent (♦), DON (■), deepoxy-DON (▲) or 3-epi-DON (●), was injected at final 682 
concentration of 10µM as indicated by the arrow. The rate of oxygen consumption was then measured 683 
for the indicated time. For visual clarity, statistical indicators were omitted from the graph. The OCR 684 
values are shown as the percent of baseline for each group. DON treatment is significantly different 685 
from others treatments, ***p<0.001, n=5. 686 
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 687 
 688 
Figure 5. Comparative effect of deepoxy-DON and 3-epi-DON and DON on morphology of 689 
intestinal explants. 690 
Jejunal explants from 4 different animals were exposed for 4 hours, to diluent or 10µM toxins and 691 
stained with HE for histological analysis. Normal villi lined with columnar enterocytes were observed 692 
on control explants (A), multifocal villi atrophy (arrow) and cell debris (arrowhead), apical necrosis 693 
(insert) on DON explants (B), histological aspects similar to control group on deepoxy-DON (C) or 3-694 
epi-DON (D) explants. Bar 100 µm; insert bar 20 µm. 695 
  696 
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 697 
 698 
Figure 6. Gene expression profile of intestinal explants exposed to deepoxy-DON, 3-epi-DON or 699 
DON 700 
Jejunal explants from 4 different animals were exposed for 4 hours, to diluent or 10µM toxins and 701 
gene expression was analyzed with a 60K microarray. Groups are represented by different colors: 702 
DON in grey, Control in cyan, deepoxy-DON (or DOM-1) in pink and 3-epi-DON in dark blue. 703 
Panel A: Venn diagram illustrating the overlaps between the probes significantly up- or down-704 
regulated in response to DON, deepoxy-DON and 3-epi-DON treatment. 705 
Panel B: Principal Component Analysis of differentially expressed probes between DON/D3G and 706 
control (747 with BH adjusted p-value < 0.05). 707 
Panel C: Heat map representing differentially expressed probes between DON, deepoxy-DON, 3-epi-708 
DON and control explant. Red and green colors indicate values above and below the mean (average Z-709 
score) respectively. Black color indicates values close to the mean. 710 
 711 
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 712 
Figure 7. Effects of deepoxy-DON or 3-epi-DON on activation of MAPK on human intestinal 713 
epithelial cells. 714 
Panel A: Caco-2 cells, differentiated on inserts. Panel B: Jejunal explants. 715 
Samples were treated for 1h with 10µM toxins and analyzed by western blot for expression of 716 
phosphorylated P38, phosphorylated JNK and GAPDH, used as a protein loading control. 717 
Representative immunoblots and normalized expression graph. 718 
Results are expressed as mean ± SEM of 3-4 independent experiments, *p<0.05, **p<0.01, 719 
***p<0.001. 720 
  721 
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 722 
 723 
Figure 8. Interaction between the ribosome 60S subunit binding site and DON, deepoxy-DON 724 
and 3-epi-DON. 725 
Both sides of the A site of the yeast ribosome 60S subunit are colored in red and yellow respectively. 726 
Hydrogen and oxygen atoms are represented in white and red respectively. 727 
Panels A: detailed views of the co-crystal (4U53) of DON inside the A-site. 728 
Panels B: detailed views of deepoxy-DON modeling inside the A-site. 729 
Panels C: detailed views of 3-epi-DON modeling inside the A-site. 730 
The magnesium atom inside the A-site pocket has been highlighted in green. 731 
DON forms 3 hydrogen bonds with the A-site: between the oxygen of the DON epoxy group on C12 732 
and one hydrogen of the sugar of the uracil U2873; between the oxygen of the C15 group CH2OH and 733 
one hydrogen of the guanine basis G2403; between the hydrogen of the C3 group and one oxygen of 734 
the uracil U2869. 735 
 736 
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Supplementary materials 738 
Supplementary Table1: Complete list of differentially expressed genes in DON treated intestinal explants 739 
Gene symbol Gene name -log  
(p-value) 
Ratio 
Up- regulated genes 
IL1B interleukin 1. beta 4.428 1.29E-11 
CCL20 chemokine (C-C motif) ligand 20 3.481 1.79E-06 
IL1A interleukin 1. alpha 3.207 6.46E-09 
CXCL2 chemokine (C-X-C motif) ligand 2 3.129 1.87E-04 
IL22 interleukin 22 2.955 1.13E-07 
PRDM1 PR domain containing 1. with ZNF domain 2.793 4.76E-06 
AREG/AREGB amphiregulin 2.662 1.94E-11 
CSF2 colony stimulating factor 2 (granulocyte-macrophage) 2.593 1.86E-05 
IL8 interleukin 8 2.585 1.25E-06 
FOSL1 FOS-like antigen 1 2.447 4.22E-04 
IER3 immediate early response 3 2.446 1.95E-04 
CCR7 chemokine (C-C motif) receptor 7 2.325 1.79E-08 
CALCB calcitonin-related polypeptide beta 2.313 9.03E-11 
GADD45A growth arrest and DNA-damage-inducible. alpha 2.270 5.61E-08 
TNFAIP3 tumor necrosis factor. alpha-induced protein 3 2.260 1.36E-08 
RND1 Rho family GTPase 1 2.255 3.24E-06 
IER2 immediate early response 2 2.227 3.44E-06 
CD83 CD83 molecule 2.207 1.10E-05 
PLAUR plasminogen activator. urokinase receptor 2.085 9.86E-04 
BTG2 BTG family. member 2 2.073 1.25E-06 
IFRD1 interferon-related developmental regulator 1 2.025 1.14E-08 
RGS1 regulator of G-protein signaling 1 2.020 3.24E-06 
GEM GTP binding protein overexpressed in skeletal muscle 2.013 4.52E-05 
CCL4 chemokine (C-C motif) ligand 4 2.004 6.44E-04 
STX11 syntaxin 11 1.989 4.27E-05 
GADD45G growth arrest and DNA-damage-inducible. gamma 1.881 2.26E-06 
GADD45B growth arrest and DNA-damage-inducible. beta 1.873 9.01E-04 
NEDD9 
neural precursor cell expressed. developmentally down-
regulated 9 1.870 1.15E-10 
LAMA3 laminin. alpha 3 1.858 2.07E-05 
CD274 CD274 molecule 1.846 8.75E-11 
IL17A interleukin 17A 1.844 2.11E-11 
NFKBIA nuclear factor of kappa light polypeptide gene enhancer in 1.779 3.53E-05 
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B-cells inhibitor. alpha 
SOCS3 suppressor of cytokine signaling 3 1.771 2.54E-06 
F3 coagulation factor III (thromboplastin. tissue factor) 1.754 4.29E-05 
IDO1 indoleamine 2.3-dioxygenase 1 1.748 2.92E-07 
HAMP hepcidin antimicrobial peptide 1.724 7.77E-07 
SPRY2 sprouty homolog 2 (Drosophila) 1.723 1.83E-07 
PHLDA1 pleckstrin homology-like domain. family A. member 1 1.708 1.57E-06 
NABP1 nucleic acid binding protein 1 1.681 3.78E-07 
BCL2A1 BCL2-related protein A1 1.681 5.18E-08 
GPR65 G protein-coupled receptor 65 1.677 5.79E-10 
TBC1D4 TBC1 domain family. member 4 1.652 2.82E-08 
NFKBIZ 
nuclear factor of kappa light polypeptide gene enhancer in 
B-cells inhibitor. zeta 1.652 6.58E-06 
ADAMTS1 
ADAM metallopeptidase with thrombospondin type 1 motif. 
1 1.652 5.54E-06 
TNF tumor necrosis factor 1.647 4.65E-06 
GPR183 G protein-coupled receptor 183 1.609 6.59E-07 
ENC1 ectodermal-neural cortex 1 (with BTB domain) 1.602 3.23E-05 
BIRC3 baculoviral IAP repeat containing 3 1.596 2.03E-07 
IL17F interleukin 17F 1.527 5.39E-09 
RCAN1 regulator of calcineurin 1 1.524 2.18E-04 
SELE selectin E 1.521 2.09E-04  
ZFAND5 zinc finger. AN1-type domain 5 1.517 8.21E-09 
EPHA2 EPH receptor A2 1.512 1.39E-06 
ABTB2 ankyrin repeat and BTB (POZ) domain containing 2 1.504 3.43E-08 
ADM adrenomedullin 1.481 7.47E-08 
TXNIP thioredoxin interacting protein 1.465 1.04E-05 
PMAIP1 phorbol-12-myristate-13-acetate-induced protein 1 1.426 1.10E-06 
NDEL1 nudE neurodevelopment protein 1-like 1 1.422 4.95E-07 
TRIB1 tribbles homolog 1 (Drosophila) 1.394 7.51E-04 
CREM cAMP responsive element modulator 1.390 1.16E-07 
TXNIP thioredoxin interacting protein 1.374 1.31E-05 
PDE4B phosphodiesterase 4B. cAMP-specific 1.373 8.64E-08 
MT1M metallothionein 1M 1.370 1.61E-06 
NR1D1 nuclear receptor subfamily 1. group D. member 1 1.364 1.72E-05 
BTG1 B-cell translocation gene 1. anti-proliferative 1.361 1.69E-07 
BIRC3 baculoviral IAP repeat containing 3 1.349 8.81E-06 
PLK2 polo-like kinase 2 1.343 1.23E-08 
FEM1C fem-1 homolog c (C. elegans) 1.334 9.72E-05 
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FADD Fas (TNFRSF6)-associated via death domain 1.331 4.02E-07 
MCL1 myeloid cell leukemia sequence 1 (BCL2-related) 1.330 1.77E-07 
LIF leukemia inhibitory factor 1.326 3.63E-04 
NFIL3 nuclear factor. interleukin 3 regulated 1.322 6.64E-05 
LPAR6 lysophosphatidic acid receptor 6 1.319 3.49E-08 
IL10 interleukin 10 1.313 3.29E-06 
CLDN4 claudin 4 1.309 4.82E-05  
MMP12 matrix metallopeptidase 12 (macrophage elastase) 1.308 1.42E-06 
TNFRSF12A tumor necrosis factor receptor superfamily. member 12A 1.299 1.01E-04 
STK17B serine/threonine kinase 17b 1.295 1.57E-05 
SOX11 SRY (sex determining region Y)-box 11 1.293 3.16E-06 
OTUD1 OTU domain containing 1 1.281 1.02E-04 
CDKN1A cyclin-dependent kinase inhibitor 1A (p21. Cip1) 1.277 6.13E-04 
IL1RN interleukin 1 receptor antagonist 1.270 8.55E-08 
BTG2 BTG family. member 2 1.267 7.49E-05 
ZBTB10 zinc finger and BTB domain containing 10 1.264 1.54E-06 
NR4A3 nuclear receptor subfamily 4. group A. member 3 1.245 2.90E-05 
ETV3 ets variant 3 1.239 8.30E-05  
NR0B2 nuclear receptor subfamily 0. group B. member 2 1.229 4.76E-05 
C1orf116 chromosome 1 open reading frame 116 1.229 2.75E-05  
TSC22D2 TSC22 domain family. member 2 1.228 1.90E-05 
PLAU plasminogen activator. urokinase 1.203 1.49E-04 
EDN1 endothelin 1 1.203 4.72E-04  
NFKBIE 
nuclear factor of kappa light polypeptide gene enhancer in 
B-cells inhibitor. epsilon 1.198 2.47E-07 
CD40 CD40 molecule. TNF receptor superfamily member 5 1.173 3.59E-04 
THBD thrombomodulin 1.171 3.11E-06 
NR4A2 nuclear receptor subfamily 4. group A. member 2 1.165 8.92E-06 
FOS FBJ murine osteosarcoma viral oncogene homolog 1.165 6.78E-05 
TBX3 T-box 3 1.156 9.31E-05  
MMP13 matrix metallopeptidase 13 (collagenase 3) 1.151 2.66E-04  
HIVEP2 
human immunodeficiency virus type I enhancer binding 
protein 2 1.150 1.81E-04  
VCAM1 vascular cell adhesion molecule 1 1.147 7.92E-06  
BCL10 B-cell CLL/lymphoma 10 1.142 1.33E-05  
EEPD1 
endonuclease/exonuclease/phosphatase family domain 
containing 1 1.133 1.66E-05  
PHLDA2 pleckstrin homology-like domain. family A. member 2 1.128 1.79E-04  
RHPN2 rhophilin. Rho GTPase binding protein 2 1.127 1.51E-05  
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DUSP6 dual specificity phosphatase 6 1.127 5.53E-04  
JMJD1C jumonji domain containing 1C 1.121 1.36E-05  
BCL6 B-cell CLL/lymphoma 6 1.119 5.51E-05  
EVI2A ecotropic viral integration site 2A 1.116 4.09E-07  
XCL1 chemokine (C motif) ligand 1 1.113 1.07E-04  
EFNB2 ephrin-B2 1.109 1.86E-05  
RASGEF1A RasGEF domain family. member 1A 1.103 1.04E-04  
COQ10B coenzyme Q10 homolog B (S. cerevisiae) 1.083 7.05E-05  
SPRY1 
sprouty homolog 1. antagonist of FGF signaling 
(Drosophila) 1.082 9.08E-04  
TIMP1 TIMP metallopeptidase inhibitor 1 1.076 1.68E-04  
TRAFD1 TRAF-type zinc finger domain containing 1 1.070 6.59E-06  
CXCR4 chemokine (C-X-C motif) receptor 4 1.065 3.32E-05  
BTG3 BTG family. member 3 1.063 9.92E-04  
KCNK5 potassium channel. subfamily K. member 5 1.048 1.05E-04  
CEBPD CCAAT/enhancer binding protein (C/EBP). delta 1.046 8.18E-05  
RHOH ras homolog family member H 1.033 6.14E-04 
REL v-rel avian reticuloendotheliosis viral oncogene homolog 1.031 2.86E-06 
TIPARP TCDD-inducible poly(ADP-ribose) polymerase 1.027 3.48E-04 
SKIL SKI-like oncogene 1.021 2.04E-04 
TNFAIP2 tumor necrosis factor. alpha-induced protein 2 1.014 4.77E-04 
EGR2 early growth response 2 1.013 5.02E-05 
ZFP36L1 ZFP36 ring finger protein-like 1 1.012 4.75E-06 
Down-regulated genes  
CHAC1 ChaC. cation transport regulator homolog 1 (E. coli) -1.696 9.18E-04 
ABCC2 
ATP-binding cassette. sub-family C (CFTR/MRP). member 
2 -1.015 2.45E-06 
SLC15A1 
solute carrier family 15 (oligopeptide transporter). member 
1 -0.851 3.56E-05 
SLC9A2 
solute carrier family 9. subfamily A (NHE2. cation proton 
antiporter 2). member 2 -0.804 9.09E-06 
CCL24 chemokine (C-C motif) ligand 24 -0.784 8.75E-04 
MTTP microsomal triglyceride transfer protein -0.755 3.26E-05 
DMBT1 deleted in malignant brain tumors 1 -0.666 2.67E-04 
MLEC malectin -0.654 9.50E-04 
SSH1 slingshot protein phosphatase 1 -0.628 1.06E-03 
VPS26B vacuolar protein sorting 26 homolog B (S. pombe) -0.610 1.04E-03 
ACE2 angiotensin I converting enzyme 2 -0.607 7.35E-04 
SCGB2A1 secretoglobin. family 2A. member 1 -0.594 2.74E-04 
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MYEOV myeloma overexpressed -0.592 1.58E-04 
NPR3 natriuretic peptide receptor 3 -0.582 8.74E-04 
CBL Cbl proto-oncogene. E3 ubiquitin protein ligase -0.574 3.70E-04 
PLOD2 procollagen-lysine. 2-oxoglutarate 5-dioxygenase 2 -0.547 3.98E-05 
C4BPA complement component 4 binding protein. alpha -0.525 1.04E-03 
ARHGEF37 Rho guanine nucleotide exchange factor (GEF) 37 -0.521 9.19E-04 
DESI2 desumoylating isopeptidase 2 -0.501 3.04E-04 
STOML3 stomatin (EPB72)-like 3 -0.487 8.33E-04 
UNC119B unc-119 homolog B (C. elegans) -0.467 2.42E-04 
ZER1 zyg-11 related. cell cycle regulator -0.455 4.92E-04 
EGLN1 egl-9 family hypoxia-inducible factor 1 -0.443 2.26E-04 
TCAP titin-cap -0.441 8.90E-04 
PECAM1 platelet/endothelial cell adhesion molecule 1 -0.431 1.43E-04 
ZCCHC14 zinc finger. CCHC domain containing 14 -0.430 5.16E-04 
GALNT4 polypeptide N-acetylgalactosaminyltransferase 4 -0.395 6.91E-04 
ANKRD13A ankyrin repeat domain 13A -0.388 8.85E-04 
UNC45A unc-45 homolog A (C. elegans) -0.377 7.64E-04 
TPP1 tripeptidyl peptidase I -0.375 5.37E-04 
OSBPL7 oxysterol binding protein-like 7 -0.349 1.05E-03 
CPT1A carnitine palmitoyltransferase 1A (liver) -0.339 6.12E-04 
FOXK2 forkhead box K2 -0.339 9.82E-04 
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Supplementary Table 2: Complete list of canonical pathways affected by DON in intestinal explants pathway  740 
 
Part a: Pathways up-regulated  
Canonical Pathways  -log 
(p-value) 
Ratio Molecules 
Granulocyte Adhesion and Diapedesis 1.18E01 1.1E-01 CCL3,IL1B,MMP12,EZR,CCL20,CLDN4,CCL3L1/CCL3L3,SELE,MMP13,CXCL2,VCAM1,CXCL8, 
   CXCR4,IL18,IL1RN,TNF,CXCR2,IL1A,CCL4,XCL1    
Agranulocyte Adhesion and Diapedesis 1.13E01 1.04E-01 CCL3,IL1B,MMP12,EZR,CCL20,CLDN4,CCL3L1/CCL3L3,SELE,MMP13,CXCL2,VCAM1,CXCL8, 
   CXCR4,IL18,IL1RN,TNF,CXCR2,IL1A,CCL4,XCL1    
Glucocorticoid Receptor Signaling 1.11E01 7.69E-02 HSPA2,NFKB1,CCL3,CSF2,JAK2,IL1B,PLAU,SELE,NFKBIE,NFATC1,NFKBIA,VCAM1,CXCL8, 
   FOS,IL1RN,DUSP1,SGK1,NR3C1,TNF,SMAD3,CDKN1A,IL10,FOXO3  
Differential Regulation of Cytokine Production in 
Intestinal Epithelial Cells by IL-17A and IL-17F 1.07E01 3.91E-01 CCL3,CSF2,IL1B,TNF,IL1A,IL17A,IL10,CCL4,IL17F    
Communication between Innate and Adaptive 
Immune Cells 1.01E01 1.25E-01 CCR7,CCL3,CSF2,IL1B,CCL3L1/CCL3L3,CD40,CXCL8,CD83,IL18,IL1RN,TNF,IL1A,IL10,CCL4 
Differential Regulation of Cytokine Production in 
Macrophages and T Helper Cells by IL-17A and 
IL-17F 1.01E01 4.44E-01 CCL3,CSF2,IL1B,TNF,IL17A,IL10,CCL4,IL17F    
Hepatic Fibrosis / Hepatic Stellate Cell Activation 9.55E00 1.03E-01 CCR7,NFKB1,IL1B,EDNRB,MMP13,CD40,VCAM1,CXCL8,IFNGR1,TNF,SMAD3,IL1A,EDN1,IL4R, 
   IL10,TIMP1       
IL-10 Signaling 9.48E00 1.54E-01 FOS,IL18,NFKB1,IL1RN,IL1B,SOCS3,TNF,IL1A,IL4R,IL10,NFKBIE,NFKBIA  
T Helper Cell Differentiation 9.41E00 1.67E-01 GATA3,IFNGR1,BCL6,IL18,STAT4,TNF,ICOSLG/LOC102723996,IL17A,IL4R,IL10,CD40,IL17F 
          
Atherosclerosis Signaling 9.4E00 1.08E-01 NFKB1,IL1B,SELE,MMP13,CD40,VCAM1,CXCL8,CXCR4,IL18,IL1RN,TNF,IL1A,F3,TNFRSF12A, 
   PLA2G4A       
Role of Cytokines in Mediating Communication 
between Immune Cells 9.36E00 2E-01 IL18,IL1RN,CSF2,IL1B,TNF,IL22,IL1A,IL17A,IL10,IL17F,CXCL8   
TREM1 Signaling 9.01E00 1.47E-01 CD83,IL18,NFKB1,CCL3,CSF2,IL1B,JAK2,TNF,IL10,CD40,CXCL8   
Role of Macrophages, Fibroblasts and Endothelial 
Cells in Rheumatoid Arthritis 8.92E00 6.43E-02 NFKB1,CEBPD,CSF2,JAK2,IL1B,SOCS3,SELE,NFKBIE,MMP13,NFATC1,NFKBIA,VCAM1, 
   CXCL8,FOS,IL18,IL1RN,CREB5,TNF,IL1A,IL17A,IL10,IRAK2   
TNFR1 Signaling 8.83E00 1.85E-01 FOS,BIRC2,NFKB1,CYCS,TNFAIP3,TNF,FADD,NFKBIE,NFKBIA,BIRC3  
TNFR2 Signaling 8.28E00 2.35E-01 FOS,BIRC2,NFKB1,TNFAIP3,TNF,NFKBIE,NFKBIA,BIRC3   
Dendritic Cell Maturation 7.97E00 7.58E-02 CCR7,NFKB1,STAT4,CSF2,JAK2,IL1B,NFKBIE,CD40,NFKBIA,CD83,IL18,IL1RN,CREB5,TNF, 
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   IL1A,IL10       
HMGB1 Signaling 7.87E00 1.1E-01 FOS,IFNGR1,RHOH,NFKB1,TNF,RHOB,IL1A,PLAT,SELE,RND3,VCAM1,CXCL8  
Role of Hypercytokinemia/hyperchemokinemia in 
the Pathogenesis of Influenza 7.84E00 1.96E-01 IL18,CCL3,IL1RN,IL1B,TNF,IL1A,IL17A,CCL4,CXCL8    
PPAR Signaling 7.82E00 1.12E-01 FOS,IL18,NFKB1,IL1RN,IL1B,TNF,IL1A,NFKBIE,PPARG,NFKBIA,CITED2,NR0B2  
IL-6 Signaling 7.72E00 1.05E-01 NFKB1,JAK2,IL1B,MCL1,SOCS3,NFKBIE,NFKBIA,CXCL8,FOS,IL18,IL1RN,TNF,IL1A 
TWEAK Signaling 7.66E00 2.05E-01 BIRC2,NFKB1,CYCS,TNFRSF12A,FADD,NFKBIE,NFKBIA,BIRC3   
Role of Osteoblasts, Osteoclasts and Chondrocytes 
in Rheumatoid Arthritis 7.45E00 6.8E-02 BIRC2,NFKB1,CSF2,IL1B,NFKBIE,BMP2,MMP13,NFATC1,NFKBIA,BIRC3,FOS,IL18,IL1RN, 
   TNF,IL1A,IL17A,IL10      
IL-17A Signaling in Fibroblasts 7.44E00 2E-01 FOS,NFKB1,CEBPD,IL17A,NFKBIE,NFKBIZ,NFKBIA,NFKBID   
Altered T Cell and B Cell Signaling in Rheumatoid 
Arthritis 7.22E00 1.1E-01 IL18,NFKB1,IL1RN,CSF2,IL1B,TNF,IL22,IL1A,IL17A,IL10,CD40   
p38 MAPK Signaling 6.7E00 1E-01 DUSP10,IL18,IL1RN,DUSP1,IL1B,CREB5,TNF,IL1A,H3F3A/H3F3B,FADD,IRAK2,PLA2G4A 
Induction of Apoptosis by HIV1 6.68E00 1.34E-01 BIRC2,CXCR4,NFKB1,CYCS,TNF,FADD,NFKBIE,NFKBIA,BIRC3   
iNOS Signaling 6.61E00 1.51E-01 FOS,IRF1,IFNGR1,NFKB1,JAK2,NFKBIE,IRAK2,NFKBIA   
Role of IL-17F in Allergic Inflammatory Airway 
Diseases 6.53E00 1.67E-01 NFKB1,CSF2,IL1B,CREB5,CCL4,MMP13,IL17F,CXCL8   
NF-κB Signaling 6.48E00 7.73E-02 NFKB1,IL1B,BMP2,NFKBIE,FADD,CD40,NFKBIA,PELI1,IL18,IL1RN,TNFAIP3,BCL10,TNF,IL1A 
Type I Diabetes Mellitus Signaling 6.2E00 9.09E-02 IRF1,IFNGR1,NFKB1,CYCS,IL1B,JAK2,SOCS3,TNF,FADD,NFKBIE,NFKBIA  
IL-17A Signaling in Gastric Cells 5.84E00 2.14E-01 FOS,NFKB1,TNF,CCL20,IL17A,CXCL8     
Acute Phase Response Signaling 5.81E00 7.18E-02 NFKB1,JAK2,IL1B,SOCS3,NFKBIE,NFKBIA,FOS,IL18,IL1RN,NR3C1,TNF,IL1A,HAMP 
Role of PKR in Interferon Induction and Antiviral 
Response 5.73E00 1.43E-01 IRF1,NFKB1,CYCS,TNF,FADD,NFKBIE,NFKBIA    
Death Receptor Signaling 5.66E00 1.18E-01 BIRC2,NFKB1,CYCS,TNF,FADD,NFKBIE,NFKBIA,BIRC3   
Cholecystokinin/Gastrin-mediated Signaling 5.57E00 9.43E-02 FOS,RHOH,IL18,CREM,IL1RN,IL1B,TNF,RHOB,IL1A,RND3   
Activation of IRF by Cytosolic Pattern Recognition 
Receptors 5.38E00 1.08E-01 NFKB1,TNF,IFIH1,IL10,FADD,CD40,NFKBIE,NFKBIA    
IL-12 Signaling and Production in Macrophages 5.27E00 7.01E-02 FOS,REL,IRF1,IFNGR1,IL18,NFKB1,STAT4,TNF,IL10,CD40,PPARG  
Apoptosis Signaling 5.19E00 9E-02 BIRC2,NFKB1,CYCS,MCL1,BCL2A1,TNF,NFKBIE,NFKBIA,BIRC3   
Hepatic Cholestasis 5.12E00 6.01E-02 IL18,NFKB1,IL1RN,IL1B,TNF,IL1A,NFKBIE,IRAK2,NFKBIA,CXCL8,NR0B2  
Role of IL-17A in Arthritis 4.83E00 1.09E-01 NFKB1,CCL20,IL17A,NFKBIE,MMP13,NFKBIA,CXCL8   
PI3K Signaling in B Lymphocytes 4.65E00 6.99E-02 FOS,NFKB1,BCL10,IL4R,CD40,NFKBIE,NFKBIA,NFATC1,FOXO3,ATF3  
Glioma Invasiveness Signaling 4.62E00 1.06E-01 RHOH,ITGAV,PLAU,RHOB,PLAUR,TIMP1,RND3    
IL-8 Signaling 4.6E00 5.33E-02 FOS,HBEGF,RHOH,NFKB1,ANGPT2,ITGAV,RHOB,CXCR2,IRAK2,RND3,VCAM1,CXCL8 
Role of Tissue Factor in Cancer 4.37E00 6.92E-02 HBEGF,CSF2,ITGAV,IL1B,JAK2,PLAUR,F3,MMP13,CXCL8   
 
172 
ERK5 Signaling 4.34E00 1.03E-01 FOS,CREB5,SGK1,LIF,FOXO3,FOSL1,SH2D2A    
Molecular Mechanisms of Cancer 4.23E00 4.12E-02 BIRC2,RHOH,NFKB1,JAK2,BMP2,NFKBIE,FADD,NFKBIA,BIRC3,FOS,CYCS,SMAD3,RHOB, 
   CDKN1A,RND3,PMAIP1      
Crosstalk between Dendritic Cells and Natural 
Killer Cells 4.23E00 7.55E-02 CCR7,CD83,IL18,NFKB1,CSF2,TNF,CD40,CD69    
Production of Nitric Oxide and Reactive Oxygen 
Species in Macrophages 4.1E00 5.19E-02 FOS,IRF1,IFNGR1,RHOH,NFKB1,JAK2,TNF,RHOB,NFKBIE,NFKBIA,RND3  
MIF-mediated Glucocorticoid Regulation 3.92E00 1.19E-01 NFKB1,NR3C1,NFKBIE,NFKBIA,PLA2G4A    
ERK/MAPK Signaling 3.91E00 5.21E-02 FOS,DUSP1,CREB5,H3F3A/H3F3B,DUSP6,ETS1,PPARG,ELF3,NFATC1,PLA2G4A,ETS2 
Lymphotoxin β Receptor Signaling 3.83E00 9.68E-02 BIRC2,NFKB1,CYCS,NFKBIA,NFKBID,VCAM1    
Coagulation System 3.8E00 1.32E-01 PLAU,THBD,PLAUR,F3,PLAT     
Regulation of IL-2 Expression in Activated and 
Anergic T Lymphocytes 3.76E00 7.87E-02 FOS,NFKB1,BCL10,SMAD3,NFKBIE,NFKBIA,NFATC1   
GADD45 Signaling 3.71E00 1.67E-01 CDKN1A,GADD45B,GADD45A,GADD45G    
April Mediated Signaling 3.62E00 1.14E-01 FOS,NFKB1,NFKBIE,NFKBIA,NFATC1     
ATM Signaling 3.58E00 9.09E-02 CREB5,CDKN1A,GADD45B,GADD45A,NFKBIA,GADD45G   
FXR/RXR Activation 3.53E00 6.36E-02 IL18,IL1RN,IL1B,TNF,IL1A,PPARG,NR0B2    
B Cell Activating Factor Signaling 3.52E00 1.09E-01 FOS,NFKB1,NFKBIE,NFKBIA,NFATC1     
RANK Signaling in Osteoclasts 3.49E00 7.22E-02 FOS,BIRC2,NFKB1,NFKBIE,NFKBIA,NFATC1,BIRC3    
MIF Regulation of Innate Immunity 3.47E00 9.62E-02 FOS,NFKB1,NFKBIE,NFKBIA,PLA2G4A    
CD40 Signaling 3.46E00 8.45E-02 FOS,NFKB1,TNFAIP3,CD40,NFKBIE,NFKBIA    
IL-17A Signaling in Airway Cells 3.42E00 7.89E-02 NFKB1,JAK2,CCL20,IL17A,NFKBIE,NFKBIA    
Role of RIG1-like Receptors in Antiviral Innate 
Immunity 3.32E00 1.02E-01 NFKB1,IFIH1,FADD,NFKBIE,NFKBIA     
Erythropoietin Signaling 3.32E00 7.59E-02 FOS,NFKB1,JAK2,SOCS3,NFKBIE,NFKBIA    
PI3K/AKT Signaling 3.29E00 5.26E-02 NFKB1,JAK2,MCL1,CDKN1A,NOS3,NFKBIE,NFKBIA,FOXO3   
Tec Kinase Signaling 3.25E00 4.89E-02 FOS,RHOH,NFKB1,STAT4,JAK2,TNF,RHOB,FADD,RND3   
Graft-versus-Host Disease Signaling 3.23E00 9.8E-02 IL18,IL1RN,IL1B,TNF,IL1A      
Antioxidant Action of Vitamin C 3.21E00 6.31E-02 NFKB1,CSF2,JAK2,TNF,NFKBIE,NFKBIA,PLA2G4A    
B Cell Receptor Signaling 3.19E00 5.14E-02 BCL6,NFKB1,BCL10,CREB5,BCL2A1,ETS1,NFKBIE,NFKBIA,NFATC1  
IL-17 Signaling 3.15E00 8E-02 NFKB1,JAK2,IL17A,TIMP1,IL17F,CXCL8     
Role of IL-17A in Psoriasis 3.08E00 2.14E-01 CCL20,IL17A,CXCL8      
CD27 Signaling in Lymphocytes 3.02E00 8.47E-02 FOS,NFKB1,CYCS,NFKBIE,NFKBIA     
Hematopoiesis from Pluripotent Stem Cells 3.02E00 7.94E-02 CSF2,IL1A,LIF,IL10,CXCL8     
Colorectal Cancer Metastasis Signaling 2.98E00 4.1E-02 FOS,IFNGR1,RHOH,NFKB1,JAK2,TNF,RHOB,SMAD3,MMP12,MMP13,RND3  
VDR/RXR Activation 2.96E00 6.82E-02 CSF2,THBD,CDKN1A,MXD1,GADD45A,KLF4    
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4-1BB Signaling in T Lymphocytes 2.96E00 1.11E-01 NFKB1,TNFRSF9,NFKBIE,NFKBIA     
Toll-like Receptor Signaling 2.84E00 7.81E-02 FOS,NFKB1,TNFAIP3,IRAK2,NFKBIA     
Gαq Signaling 2.76E00 4.68E-02 RHOH,NFKB1,RHOB,RGS2,NFKBIE,NFKBIA,NFATC1,RND3   
Type II Diabetes Mellitus Signaling 2.75E00 4.09E-02 ACSL4,NFKB1,SOCS3,TNF,NFKBIE,PPARG,NFKBIA    
Protein Kinase A Signaling 2.73E00 3.42E-02 DUSP10,NFKB1,H3F3A/H3F3B,NFKBIE,PDE4B,H1F0,NFATC1,NFKBIA,CREM,CREB5,DUSP1, 
   SMAD3,DUSP6,NOS3      
Systemic Lupus Erythematosus Signaling 2.71E00 3.91E-02 FOS,IL18,CREM,IL1RN,IL1B,TNF,IL1A,IL10,CD40,NFATC1   
ILK Signaling 2.7E00 4.39E-02 FOS,RHOH,NFKB1,CREB5,SNAI2,TNF,RHOB,BMP2,RND3   
IL-1 Signaling 2.57E00 5.5E-02 FOS,NFKB1,IL1A,NFKBIE,IRAK2,NFKBIA    
Angiopoietin Signaling 2.55E00 6.67E-02 NFKB1,ANGPT2,NOS3,NFKBIE,NFKBIA    
Hypoxia Signaling in the Cardiovascular System 2.52E00 7.35E-02 CREB5,EDN1,NOS3,NFKBIE,NFKBIA     
JAK/Stat Signaling 2.49E00 7.04E-02 FOS,STAT4,JAK2,SOCS3,CDKN1A     
Neurotrophin/TRK Signaling 2.46E00 6.58E-02 FOS,CREB5,SPRY2,SPRY1,BDNF     
p53 Signaling 2.46E00 5.31E-02 SNAI2,CDKN1A,GADD45B,GADD45A,PMAIP1,GADD45G   
Small Cell Lung Cancer Signaling 2.38E00 5.32E-02 BIRC2,NFKB1,CYCS,NFKBIE,NFKBIA     
PEDF Signaling 2.38E00 6.33E-02 NFKB1,NFKBIE,PPARG,NFKBIA,BDNF     
Prolactin Signaling 2.33E00 5.95E-02 FOS,IRF1,JAK2,SOCS3,NR3C1     
Aryl Hydrocarbon Receptor Signaling 2.3E00 4.09E-02 FOS,NFKB1,IL1B,TNF,IL1A,CDKN1A,NR0B2    
RAR Activation 2.29E00 4.1E-02 FOS,REL,NFKB1,DUSP1,JAK2,SMAD3,BMP2,CITED2   
Role of JAK1, JAK2 and TYK2 in Interferon 
Signaling 2.28E00 1.07E-01 IFNGR1,NFKB1,JAK2      
iCOS-iCOSL Signaling in T Helper Cells 2.27E00 4.76E-02 NFKB1,ICOSLG/LOC102723996,CD40,NFKBIE,NFKBIA,NFATC1   
G-Protein Coupled Receptor Signaling 2.26E00 3.62E-02 NFKB1,DUSP1,CREB5,CXCR2,RGS2,ADORA3,DUSP6,NFKBIE,PDE4B,NFKBIA  
Airway Pathology in Chronic Obstructive 
Pulmonary Disease 2.23E00 1.82E-01 TNF,CXCL8       
IL-15 Production 2.13E00 9.68E-02 IRF1,NFKB1,JAK2      
Pathogenesis of Multiple Sclerosis 2.13E00 2E-01 CCL3,CCL4       
Semaphorin Signaling in Neurons 2.13E00 7.41E-02 RHOH,RHOB,RND3,RND1      
CD28 Signaling in T Helper Cells 2.1E00 4.41E-02 FOS,NFKB1,BCL10,NFKBIE,NFKBIA,NFATC1    
PKCθ Signaling in T Lymphocytes 2.1E00 4.17E-02 FOS,NFKB1,BCL10,NFKBIE,NFKBIA,NFATC1    
Prostate Cancer Signaling 2.1E00 4.85E-02 NFKB1,CREB5,CDKN1A,NFKBIE,NFKBIA    
LXR/RXR Activation 2.02E00 4.32E-02 IL18,NFKB1,IL1RN,IL1B,TNF,IL1A     
TGF-β Signaling 2.01E00 5.32E-02 FOS,INHBA,SMAD3,PMEPA1,BMP2     
Leukocyte Extravasation Signaling 2.01E00 3.81E-02 RHOH,CXCR4,MMP12,EZR,CLDN4,TIMP1,MMP13,VCAM1   
IL-15 Signaling 1.89E00 5.56E-02 NFKB1,CSF2,JAK2,IL17A      
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SAPK/JNK Signaling 1.86E00 4.76E-02 DUSP10,GADD45A,FADD,NFATC1,SH2D2A    
Circadian Rhythm Signaling 1.86E00 7.89E-02 BHLHE40,CREB5,NR1D1      
IL-9 Signaling 1.86E00 7.5E-02 NFKB1,SOCS3,TNF      
Oncostatin M Signaling 1.86E00 8.57E-02 JAK2,PLAU,MMP13      
Interferon Signaling 1.86E00 8.33E-02 IRF1,IFNGR1,JAK2      
Role of Pattern Recognition Receptors in 
Recognition of Bacteria and Viruses 1.84E00 4.59E-02 NFKB1,IL1B,TNF,IFIH1,IL10     
GM-CSF Signaling 1.84E00 5.88E-02 CSF2,JAK2,BCL2A1,ETS1     
T Cell Receptor Signaling 1.82E00 4.59E-02 FOS,NFKB1,BCL10,NFKBIA,NFATC1     
Relaxin Signaling 1.77E00 3.66E-02 FOS,NFKB1,NOS3,NFKBIE,PDE4B,NFKBIA    
HGF Signaling 1.77E00 4.5E-02 FOS,CDKN1A,ETS1,ELF3,ETS2     
PPARα/RXRα Activation 1.77E00 3.5E-02 NFKB1,IL1B,JAK2,SMAD3,NFKBIE,NFKBIA,NR0B2    
cAMP-mediated signaling 1.75E00 3.54E-02 CREM,DUSP1,CREB5,CXCR2,RGS2,ADORA3,DUSP6,PDE4B   
PXR/RXR Activation 1.75E00 4.35E-02 NR3C1,TNF,FOXO3,NR0B2     
Retinoic acid Mediated Apoptosis Signaling 1.75E00 5.48E-02 TIPARP,IRF1,CYCS,FADD     
LPS/IL-1 Mediated Inhibition of RXR Function 1.74E00 3.27E-02 ACSL4,IL18,IL1RN,IL1B,TNF,IL1A,SMOX,NR0B2    
Docosahexaenoic Acid (DHA) Signaling 1.7E00 6E-02 CYCS,IL1B,BCL2A1      
Inhibition of Matrix Metalloproteases 1.7E00 7.5E-02 MMP12,TIMP1,MMP13      
Pancreatic Adenocarcinoma Signaling 1.66E00 3.91E-02 HBEGF,NFKB1,JAK2,SMAD3,CDKN1A     
Extrinsic Prothrombin Activation Pathway 1.64E00 9.09E-02 THBD,F3       
LPS-stimulated MAPK Signaling 1.63E00 4.82E-02 FOS,NFKB1,NFKBIE,NFKBIA     
NF-κB Activation by Viruses 1.61E00 4.82E-02 NFKB1,ITGAV,NFKBIE,NFKBIA     
IL-4 Signaling 1.61E00 5E-02 JAK2,NR3C1,IL4R,NFATC1     
Corticotropin Releasing Hormone Signaling 1.57E00 3.45E-02 FOS,JUND,CREB5,NOS3,BDNF     
Integrin Signaling 1.54E00 3.37E-02 RHOH,ITGAV,RHOB,NEDD9,BCAR3,ARF6,RND3    
Thiosulfate Disproportionation III (Rhodanese) 1.53E00 1.67E-01 MOCS3       
Ceramide Signaling 1.5E00 4.4E-02 FOS,NFKB1,CYCS,TNF      
Polyamine Regulation in Colon Cancer 1.38E00 6.67E-02 MXD1,PPARG      
Role of NFAT in Regulation of the Immune 
Response 1.36E00 3E-02 FOS,NFKB1,RCAN1,NFKBIE,NFKBIA,NFATC1    
Bladder Cancer Signaling 1.36E00 4.12E-02 MMP12,CDKN1A,MMP13,CXCL8     
IL-22 Signaling 1.31E00 8E-02 SOCS3,IL22       
Tumoricidal Function of Hepatic Natural Killer 
Cells 1.31E00 7.41E-02 CYCS,FADD       
Actin Nucleation by ARP-WASP Complex 1.29E00 4.48E-02 RHOH,RHOB,RND3      
Role of JAK family kinases in IL-6-type Cytokine 1.28E00 7.14E-02 JAK2,SOCS3      
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Signaling 
Regulation of the Epithelial-Mesenchymal 
Transition Pathway 1.27E00 3.06E-02 NFKB1,JAK2,ID2,SNAI2,SMAD3,ETS1     
IGF-1 Signaling 1.24E00 3.74E-02 FOS,JAK2,SOCS3,FOXO3     
Airway Inflammation in Asthma 1.23E00 1.67E-01 TNF       
Spermine and Spermidine Degradation I 1.23E00 7.14E-02 SMOX       
Melatonin Degradation II 1.23E00 8.33E-02 SMOX       
Molybdenum Cofactor Biosynthesis 1.23E00 6.25E-02 MOCS3       
Phospholipase C Signaling 1.21E00 2.64E-02 RHOH,NFKB1,CREB5,RHOB,NFATC1,PLA2G4A,RND3   
Telomerase Signaling 1.19E00 3.77E-02 CDKN1A,ETS1,ELF3,ETS2     
Role of JAK1 and JAK3 in γc Cytokine Signaling 1.19E00 4.41E-02 JAK2,SOCS3,IL4R      
Estrogen-Dependent Breast Cancer Signaling 1.17E00 4.11E-02 FOS,NFKB1,CREB5      
HIF1α Signaling 1.17E00 3.57E-02 MMP12,EDN1,NOS3,MMP13     
Tetrahydrofolate Salvage from 5,10-
methenyltetrahydrofolate 1.14E00 1E-01 MTHFD1L       
Citrulline-Nitric Oxide Cycle 1.14E00 6.25E-02 NOS3       
Role of PI3K/AKT Signaling in the Pathogenesis of 
Influenza 1.14E00 3.95E-02 NFKB1,NFKBIE,NFKBIA      
Tight Junction Signaling 1.1E00 2.99E-02 FOS,NFKB1,MPP5,TNF,CLDN4     
CXCR4 Signaling 1.1E00 2.87E-02 FOS,RHOH,CXCR4,RHOB,RND3     
fMLP Signaling in Neutrophils 1.1E00 3.03E-02 NFKB1,NFKBIE,NFKBIA,NFATC1     
Renin-Angiotensin Signaling 1.1E00 3.17E-02 FOS,NFKB1,JAK2,TNF      
Growth Hormone Signaling 1.08E00 3.85E-02 FOS,JAK2,SOCS3      
Chemokine Signaling 1.08E00 4E-02 FOS,CXCR4,CCL4      
CCR5 Signaling in Macrophages 1.06E00 3.09E-02 FOS,CCL3,CCL4      
Role of JAK2 in Hormone-like Cytokine Signaling 1.04E00 5.41E-02 JAK2,SOCS3      
STAT3 Pathway 1.02E00 3.75E-02 JAK2,SOCS3,CDKN1A      
Hereditary Breast Cancer Signaling 1.02E00 2.99E-02 CDKN1A,GADD45B,GADD45A,GADD45G    
Cell Cycle Regulation by BTG Family Proteins 1.02E00 5.13E-02 BTG1,BTG2       
Folate Polyglutamylation 1E00 5E-02 MTHFD1L       
Gα12/13 Signaling 1E00 3.15E-02 LPAR6,NFKB1,NFKBIE,NFKBIA     
RhoA Signaling 1E00 3.25E-02 LPAR6,EZR,RHPN2,RND3      
VEGF Family Ligand-Receptor Interactions 9.81E-01 3.41E-02 FOS,NOS3,PLA2G4A      
BMP signaling pathway 9.81E-01 3.49E-02 NFKB1,FST,BMP2      
Histidine Degradation III 9.46E-01 5.56E-02 MTHFD1L       
Tryptophan Degradation to 2-amino-3- 9.46E-01 5.56E-02 IDO1       
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carboxymuconate Semialdehyde 
Endothelin-1 Signaling 9.39E-01 2.6E-02 FOS,EDN1,EDNRB,NOS3,PLA2G4A     
Thyroid Cancer Signaling 9.23E-01 4.55E-02 PPARG,BDNF      
Ephrin Receptor Signaling 9.16E-01 2.38E-02 EFNB2,CXCR4,JAK2,CREB5,EPHA2     
Regulation of Actin-based Motility by Rho 8.96E-01 3.26E-02 RHOH,RHOB,RND3      
Allograft Rejection Signaling 8.96E-01 3.09E-02 TNF,IL10,CD40      
Signaling by Rho Family GTPases 8.79E-01 2.28E-02 FOS,RHOH,NFKB1,RHOB,EZR,RND3     
ErbB Signaling 8.74E-01 3.33E-02 FOS,HBEGF,AREG      
Insulin Receptor Signaling 8.7E-01 2.68E-02 JAK2,SOCS3,SGK1,FOXO3     
OX40 Signaling Pathway 8.63E-01 3.09E-02 NFKB1,NFKBIE,NFKBIA      
Folate Transformations I 8.55E-01 3.03E-02 MTHFD1L       
Cell Cycle: G2/M DNA Damage Checkpoint 
Regulation 8.55E-01 4.08E-02 CDKN1A,GADD45A      
Human Embryonic Stem Cell Pluripotency 8.44E-01 2.47E-02 INHBA,SMAD3,BMP2,BDNF     
MSP-RON Signaling Pathway 8.39E-01 3.92E-02 JAK2,TNF       
UVA-Induced MAPK Signaling 8.11E-01 3.06E-02 FOS,TIPARP,CYCS      
Autoimmune Thyroid Disease Signaling 8.09E-01 3.23E-02 IL10,CD40       
Thrombin Signaling 8.03E-01 2.37E-02 GATA3,RHOH,NFKB1,RHOB,RND3     
VEGF Signaling 8.01E-01 2.75E-02 NOS3,FOXO3,SH2D2A      
Fcγ Receptor-mediated Phagocytosis in 
Macrophages and Monocytes 7.91E-01 2.83E-02 CSF2,EZR,ARF6      
Hematopoiesis from Multipotent Stem Cells 7.83E-01 8.33E-02 CSF2       
Chronic Myeloid Leukemia Signaling 7.82E-01 2.83E-02 NFKB1,SMAD3,CDKN1A      
Mouse Embryonic Stem Cell Pluripotency 7.72E-01 3.03E-02 JAK2,ID2,LIF      
Glioblastoma Multiforme Signaling 7.52E-01 2.38E-02 RHOH,RHOB,CDKN1A,RND3     
Fatty Acid Activation 7.51E-01 5.26E-02 ACSL4       
Amyotrophic Lateral Sclerosis Signaling 7.36E-01 2.38E-02 BIRC2,CYCS,BIRC3      
UVB-Induced MAPK Signaling 7.28E-01 3.45E-02 FOS,H3F3A/H3F3B      
Superpathway of Citrulline Metabolism 7.22E-01 2.63E-02 NOS3       
Phenylalanine Degradation IV (Mammalian, via 
Side Chain) 7.22E-01 2.56E-02 SMOX       
Thrombopoietin Signaling 7.04E-01 3.12E-02 FOS,JAK2       
Nur77 Signaling in T Lymphocytes 7.04E-01 3.12E-02 CYCS,NFATC1      
Axonal Guidance Signaling 7E-01 1.85E-02 EFNB2,CXCR4,BMP2,MMP13,EPHA2,NFATC1,BDNF,RND1,ADAMTS1  
NAD biosynthesis II (from tryptophan) 6.95E-01 2.86E-02 IDO1       
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Germ Cell-Sertoli Cell Junction Signaling 6.9E-01 2.37E-02 RHOH,TNF,RHOB,RND3      
Granzyme B Signaling 6.7E-01 5.56E-02 CYCS       
Parkinson's Signaling 6.7E-01 5.26E-02 CYCS       
Myc Mediated Apoptosis Signaling 6.69E-01 3.17E-02 CYCS,FADD       
Xenobiotic Metabolism Signaling 6.6E-01 2.08E-02 NFKB1,IL1B,TNF,IL1A,SMOX,CITED2     
Fc Epsilon RI Signaling 6.54E-01 2.56E-02 CSF2,TNF,PLA2G4A      
Role of BRCA1 in DNA Damage Response 6.48E-01 2.82E-02 CDKN1A,GADD45A      
γ-linolenate Biosynthesis II (Animals) 6.47E-01 4.17E-02 ACSL4       
Mitochondrial L-carnitine Shuttle Pathway 6.47E-01 4.55E-02 ACSL4       
Putrescine Degradation III 6.47E-01 3.33E-02 SMOX       
Sphingosine-1-phosphate Signaling 6.46E-01 2.44E-02 RHOH,RHOB,RND3      
Role of NANOG in Mammalian Embryonic Stem 
Cell Pluripotency 6.31E-01 2.52E-02 JAK2,LIF,BMP2      
Tryptophan Degradation X (Mammalian, via 
Tryptamine) 6.25E-01 3.45E-02 SMOX       
Huntington's Disease Signaling 6.2E-01 1.98E-02 HSPA2,CYCS,CREB5,SGK1,BDNF     
Cardiomyocyte Differentiation via BMP Receptors 6.05E-01 4.55E-02 BMP2       
Granzyme A Signaling 6.05E-01 5E-02 H1F0       
1D-myo-inositol Hexakisphosphate Biosynthesis II 
(Mammalian) 6.05E-01 3.57E-02 ITPKC       
D-myo-inositol (1,3,4)-trisphosphate Biosynthesis 6.05E-01 4E-02 ITPKC       
PTEN Signaling 5.96E-01 2.17E-02 NFKB1,CDKN1A,FOXO3      
Cell Cycle: G1/S Checkpoint Regulation 5.88E-01 2.78E-02 SMAD3,CDKN1A      
DNA Methylation and Transcriptional Repression 
Signaling 5.86E-01 4.35E-02 ARID4B       
RhoGDI Signaling 5.82E-01 1.98E-02 RHOH,RHOB,EZR,RND3      
Role of MAPK Signaling in the Pathogenesis of 
Influenza 5.7E-01 2.78E-02 TNF,PLA2G4A      
Tryptophan Degradation III (Eukaryotic) 5.68E-01 2.08E-02 IDO1       
P2Y Purigenic Receptor Signaling Pathway 5.63E-01 2.08E-02 FOS,NFKB1,CREB5      
D-myo-inositol (1,4,5,6)-Tetrakisphosphate 
Biosynthesis 5.56E-01 2.08E-02 DUSP10,DUSP1,SOCS3      
D-myo-inositol (3,4,5,6)-tetrakisphosphate 
Biosynthesis 5.56E-01 2.08E-02 DUSP10,DUSP1,SOCS3      
Renal Cell Carcinoma Signaling 5.52E-01 2.53E-02 FOS,ETS1       
NRF2-mediated Oxidative Stress Response 5.51E-01 2.05E-02 FOS,JUND,FOSL1,ENC1      
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IL-3 Signaling 5.44E-01 2.67E-02 FOS,JAK2       
Estrogen Receptor Signaling 5.32E-01 2.21E-02 NR3C1,H3F3A/H3F3B,NR0B2     
Ephrin B Signaling 5.19E-01 2.44E-02 EFNB2,CXCR4      
Estrogen-mediated S-phase Entry 5.19E-01 3.57E-02 CDKN1A       
Dopamine Degradation 5.19E-01 2.63E-02 SMOX       
Superpathway of D-myo-inositol (1,4,5)-
trisphosphate Metabolism 5.19E-01 3.03E-02 ITPKC       
GNRH Signaling 5.14E-01 1.96E-02 FOS,NFKB1,CREB5      
FLT3 Signaling in Hematopoietic Progenitor Cells 5.12E-01 2.53E-02 STAT4,CREB5      
Leptin Signaling in Obesity 5.12E-01 2.35E-02 JAK2,SOCS3      
eNOS Signaling 5.08E-01 1.94E-02 HSPA2,LPAR6,NOS3      
HER-2 Signaling in Breast Cancer 5.04E-01 2.44E-02 AREG,CDKN1A      
Superpathway of Inositol Phosphate Compounds 5.02E-01 1.71E-02 DUSP10,DUSP1,SOCS3,ITPKC     
PDGF Signaling 4.96E-01 2.33E-02 FOS,JAK2       
Lipid Antigen Presentation by CD1 4.9E-01 3.33E-02 ARF6       
Antiproliferative Role of TOB in T Cell Signaling 4.9E-01 3.85E-02 SMAD3       
Cytotoxic T Lymphocyte-mediated Apoptosis of 
Target Cells 4.68E-01 2.27E-02 CYCS,FADD       
Intrinsic Prothrombin Activation Pathway 4.64E-01 2.7E-02 THBD       
Pyrimidine Ribonucleotides Interconversion 4.64E-01 2.5E-02 ENTPD7       
D-myo-inositol-5-phosphate Metabolism 4.6E-01 1.85E-02 DUSP10,DUSP1,SOCS3      
3-phosphoinositide Degradation 4.6E-01 1.85E-02 DUSP10,DUSP1,SOCS3      
Pyrimidine Ribonucleotides De Novo Biosynthesis 4.4E-01 1.85E-02 ENTPD7       
Fatty Acid β-oxidation I 4.4E-01 2.22E-02 ACSL4       
Neuregulin Signaling 4.22E-01 1.92E-02 HBEGF,AREG      
B Cell Development 4.18E-01 2.78E-02 CD40       
Retinoate Biosynthesis I 4.18E-01 2.7E-02 BMP2       
Serotonin Receptor Signaling 4.08E-01 2.04E-02 SMOX       
3-phosphoinositide Biosynthesis 4.03E-01 1.66E-02 DUSP10,DUSP1,SOCS3      
Aldosterone Signaling in Epithelial Cells 3.98E-01 1.78E-02 HSPA2,DUSP1,SGK1      
G Protein Signaling Mediated by Tubby 3.98E-01 2.27E-02 JAK2       
Inhibition of Angiogenesis by TSP1 3.98E-01 2.38E-02 NOS3       
tRNA Splicing 3.88E-01 2.17E-02 PDE4B       
Stearate Biosynthesis I (Animals) 3.88E-01 2.04E-02 ACSL4       
Noradrenaline and Adrenaline Degradation 3.79E-01 1.89E-02 SMOX       
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Neuropathic Pain Signaling In Dorsal Horn 
Neurons 3.56E-01 1.83E-02 FOS,BDNF       
Netrin Signaling 3.53E-01 1.72E-02 NFATC1       
Paxillin Signaling 3.51E-01 1.71E-02 ITGAV,ARF6       
Transcriptional Regulatory Network in Embryonic 
Stem Cells 3.45E-01 2.33E-02 SKIL       
Melanoma Signaling 3.3E-01 2E-02 CDKN1A       
UVC-Induced MAPK Signaling 3.3E-01 2.27E-02 FOS       
NGF Signaling 3.23E-01 1.64E-02 NFKB1,CREB5      
Role of Oct4 in Mammalian Embryonic Stem Cell 
Pluripotency 3.08E-01 1.92E-02 JARID2       
Sertoli Cell-Sertoli Cell Junction Signaling 3.07E-01 1.52E-02 TNF,CLDN4,NOS3      
Androgen Signaling 3.02E-01 1.38E-02 NFKB1,SMAD3      
Gαs Signaling 3.02E-01 1.6E-02 CREB5,RGS2      
Calcium Signaling 2.97E-01 1.38E-02 CREB5,RCAN1,NFATC1      
Ephrin A Signaling 2.89E-01 1.85E-02 EPHA2       
14-3-3-mediated Signaling 2.82E-01 1.65E-02 FOS,TNF       
Protein Ubiquitination Pathway 2.76E-01 1.48E-02 HSPA2,BIRC2,NEDD4L,BIRC3     
Sperm Motility 2.74E-01 1.39E-02 PDE4B,PLA2G4A      
CNTF Signaling 2.66E-01 1.75E-02 JAK2       
Endometrial Cancer Signaling 2.66E-01 1.67E-02 FOXO3       
Primary Immunodeficiency Signaling 2.66E-01 1.56E-02 CD40       
mTOR Signaling 2.64E-01 1.41E-02 RHOH,RHOB,RND3      
Gαi Signaling 2.63E-01 1.48E-02 CXCR2,ADORA3      
IL-2 Signaling 2.6E-01 1.64E-02 FOS       
Role of CHK Proteins in Cell Cycle Checkpoint 
Control 2.5E-01 1.69E-02 CDKN1A       
EGF Signaling 2.45E-01 1.56E-02 FOS       
Cellular Effects of Sildenafil (Viagra) 2.4E-01 1.29E-02 NOS3, PDE4B      
Regulation of Cellular Mechanics by Calpain 
Protease 2.4E-01 1.37E-02 EZR       
Phospholipases 2.35E-01 1.47E-02 PLA2G4A       
Superpathway of Melatonin Degradation 2.26E-01 1.23E-02 SMOX       
Serotonin Degradation 2.21E-01 1.28E-02 SMOX       
Eicosanoid Signaling 2.13E-01 1.16E-02 PLA2G4A       
Antiproliferative Role of Somatostatin Receptor 2 2.09E-01 1.39E-02 CDKN1A       
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Non-Small Cell Lung Cancer Signaling 2.05E-01 1.2E-02 FOXO3       
Pyridoxal 5'-phosphate Salvage Pathway 2.01E-01 1.32E-02 SGK1       
Mitotic Roles of Polo-Like Kinase 1.97E-01 1.35E-02 PLK2       
 
 741 
 742 
Part b: Pathways down-regulated  
 
Ingenuity Canonical Pathways 
-log 
(p-value) Ratio Molecules 
PXR/RXR Activation 2.28E00 2.17E-02 ABCC2,CPT1A 
FXR/RXR Activation 2.07E00 1.82E-02 ABCC2,MTTP 
Mitochondrial L-carnitine Shuttle Pathway 1.57E00 4.55E-02 CPT1A  
Granulocyte Adhesion and Diapedesis 1.49E00 1.1E-02 CCL24,PECAM1 
Agranulocyte Adhesion and Diapedesis 1.44E00 1.04E-02 CCL24,PECAM1 
LPS/IL-1 Mediated Inhibition of RXR Function 1.31E00 8.16E-03 ABCC2,CPT1A 
Complement System 1.28E00 2.86E-02 C4BPA  
Erythropoietin Signaling 9.87E-01 1.27E-02 CBL  
Chemokine Signaling 9.75E-01 1.33E-02 CCL24  
Ephrin B Signaling 9.46E-01 1.22E-02 CBL  
FLT3 Signaling in Hematopoietic Progenitor Cells 9.41E-01 1.27E-02 CBL  
RANK Signaling in Osteoclasts 8.81E-01 1.03E-02 CBL  
Fcγ Receptor-mediated Phagocytosis in Macrophages and Monocytes 8.54E-01 9.43E-03 CBL  
T Cell Receptor Signaling 8.37E-01 9.17E-03 CBL  
Telomerase Signaling 8.2E-01 9.43E-03 TPP1  
HIF1α Signaling 8.13E-01 8.93E-03 EGLN1  
CCR3 Signaling in Eosinophils 7.69E-01 7.46E-03 CCL24  
14-3-3-mediated Signaling 7.62E-01 8.26E-03 CBL  
PTEN Signaling 7.58E-01 7.19E-03 CBL  
Gαi Signaling 7.45E-01 7.41E-03 NPR3  
PI3K Signaling in B Lymphocytes 7.26E-01 6.99E-03 CBL  
Insulin Receptor Signaling 7.14E-01 6.71E-03 CBL  
AMPK Signaling 7.06E-01 5.52E-03 CPT1A  
Hepatic Cholestasis 6.94E-01 5.46E-03 ABCC2  
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Mitochondrial Dysfunction 6.26E-01 4.65E-03 CPT1A  
Acute Phase Response Signaling 6.19E-01 5.52E-03 C4BPA  
NRF2-mediated Oxidative Stress Response 5.95E-01 5.13E-03 ABCC2  
Clathrin-mediated Endocytosis Signaling 5.85E-01 5.05E-03 CBL  
Leukocyte Extravasation Signaling 5.6E-01 4.76E-03 PECAM1  
Actin Cytoskeleton Signaling 5.31E-01 4.13E-03 SSH1  
Role of Osteoblasts, Osteoclasts and Chondrocytes in Rheumatoid Arthritis 5.21E-01 4E-03 CBL  
cAMP-mediated signaling 5.21E-01 4.42E-03 NPR3  
Systemic Lupus Erythematosus Signaling 5.18E-01 3.92E-03 CBL  
Protein Ubiquitination Pathway 4.68E-01 3.7E-03 CBL  
G-Protein Coupled Receptor Signaling 4.64E-01 3.62E-03 NPR3  
Xenobiotic Metabolism Signaling 4.47E-01 3.47E-03 ABCC2  
Molecular Mechanisms of Cancer 3.68E-01 2.58E-03 CBL  
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Chapter II 
 
In vivo toxicity of purified deepoxy-
deoxynivalenol (DOM-1) in piglets 
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I. Context of the study 
 
In the previous chapter, it was shown that DOM-1, in comparison to DON, has a 
reduced toxicity on intestinal cells and intestinal explants. The aim of this study was to assess 
the toxicity of purified DOM-1 on animal model. Actually, the toxicity of purified DOM-1 
has never been assessed. Previous experiments were conducted on pigs receiving DON and 
the bacteria (bacillus sp. Ls100 or contents of the large intestine of chickens (CLIC)), able to 
deepoxidize DON into DOM-1 into the gut of the animal. In addition, in these experiments 
that are more focused on the zootechnical parameters such as feed intake and weight gain, 
they described no effect on treated animals. This prove that microbial detoxification of DON 
in contaminated feed can eliminate the negative effects of the mycotoxin, and the pre-feeding 
detoxification approach may be applied in the livestock industry (He et al. 1993; Li et al. 
2011).  
The aim of the present study was to evaluate the toxic effect of purified DOM-1 based on 
several parameters, including zootechnical parameters but also on the intestinal and immune 
responses. In fact, the effects of DON on the intestine and immunity are well characterized 
and represent a serious risk for animal health. Among animal species, pig constituted a 
relevant model to evaluate the toxicity of DOM-1, due to its high sensibility to mycotoxin, 
especially DON and its cereals rich diet.   
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II. Material and Methods 
 
A. Experimental design 
1. Animals 
All animal experimentation procedures were carried out in accordance with the 
European Directive on the protection of animals used for scientific purposes (Directive 
2010/63/EU). All the experimental design is summary in the Figure 1. 
 For the experiment, twenty-two 4-wk-old weaned castrated male pigs (PIC 410) were 
obtained locally (GAEC Calvignac, St Vincent d’Autejac, France). As previously described a 
greater effect of DON occurs on male pigs compared to female pigs (Cote et al. 1985; Marin 
et al. 2006). Animals were acclimatized for 2 weeks in the animal facility of the Toxalim 
Laboratory (INRA, Toulouse, France), prior to being used in experimental protocols. Eight 
pigs were allocated per box to each treatment on the basis of body weight for (1) control 
group and (2) DON group, and six pigs for (3) DOM-1 group. At the start of the experiment, 
there were no differences in body weights among all treatment groups including the control; 
piglets weighted 10.9±0.08Kg, p>0.05. Then they were weighed and observed daily, and the 
animal behaviour was noted. During the three weeks of experimental period, each group was 
given free access to water and feed. They were fed with a commercial feed adapted to their 
age, complete food for the first piglet age Belecla (Annex 1) and complete food for the second 
piglet age Stimiouti (Annex 2). A period of transition of 3 days was respected between the 
two foods. After the experimental period the animals were submitted to electrical stunning, 
and euthanized by exsanguination. 
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2. Toxins 
Purified DON was purchased from Sigma-Aldrich (St Louis, MO, USA). DOM-1 was 
obtained by transforming the crystalline DON (Romer Labs, Tulln, Austria), dissolved in 
medium 10 (Caldwell and Bryant, 1966) at a concentration of 2 mg/ml, and then by 
inoculating with BBSH 797, Gen. nov. sp. nov. of family Coriobacteriaceae in sterile 
medium, at 37°C for six days. Biotransformation of DON to deepoxy-DON was confirmed by 
LC-MS/MS, and deepoxy-DON was purified by solid phase extraction and preparative HPLC 
(Schwartz-Zimmermann et al., 2014). The purity of the deepoxy-DON preparation was 99%, 
based on chromatograms recorded at 220nm. 
 
3. Gavage 
During the experiment, animals were exposed to DON and DOM-1 as powder at 100% 
and 63% of purity respectively (provides by Austria BIOMIN GmgH, Tulln). The two 
molecules were administered by gavage for 21 days, at the same molar concentration (0.15 
mg/kg BW /day for DON and 0.14 mg/Kg BW/day for DOM-1). Toxins were diluted in water 
and black current syrup, to increase the palatability. 
 
 
 
4. Sample collection 
The experimental design used in this study was randomized with eight or six 
repetitions (each animal represented one repetition). To evaluate the vaccine response, all 
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piglets were immunized by subcutaneous inoculation with 1 mg of ovalbumin (OVA) for the 
primary injection and 2 mg for the booster vaccine, respectively (Sigma, St Quentin Fallavier, 
France), dissolved in sterile PBS and mixed with incomplete Freund’s adjuvant (Sigma). At 
weekly time intervals, blood samples were aseptically collected from the left jugular vein. 
Blood was collected in tubes containing sodium heparin or EDTA (Vacutainer®, becton-
Dickinson, USA) for blood culture or blood formula, respectively. Serum samples were 
obtained after centrifugation of blood and stored at -20°C for later analysis. After 21 days of 
exposure pigs were killed by electrical stunning and exsanguination. 
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Figure 1 - Experimental design of the in vivo experiment
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B. Samples analysis 
1. Plasma analysis 
Total concentration of the immunoglobulin subsets (IgG) was measured by ELISA as 
already described (Taranu et al. 2005). Briefly, plasma samples diluted 1:15.000 to detect 
IgG, in Tris–buffered saline and added to plates coated with immunoglobulin class specific 
pig antibody (Bethyl, Interchim, Montluçon, France). The different subsets were detected with 
the appropriate peroxidase anti-pig IgG (Bethyl) and were quantified by reference to standard 
curves constructed with known amounts of pig immunoglobulin subsets. Antibody titles 
against ovalbumin were also measured by ELISA (Meissonnier et al. 2008). Briefly, ELISA 
plates were coated with 2µg/mL ovalbumin diluted in 0.05 M NaHCO3 (pH 9.6). Diluted 
plasma, were then added to the plates and the anti-ovalbumin antibodies were detected with 
peroxidase-labeled anti-pig IgG (Bethyl). Absorbance was read at 450 nm using an ELISA 
plate reader (Spectra thermo scan, Tecan, NC, USA). 
 
2. Histology 
Fragments of liver, spleen, lymph node and intestine (jejunum with and without Peyer 
patches, ileum with and without Peyer patches) were fixed in 10% buffered formalin for 24 h, 
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fixed in ethanol 70%, embedded in paraffin and cut into sections of 3µm. Paraffin sections of 
all the fragments were stained with the hematoxylin-eosin method.  
Histological findings were graduated in scores. The score is based in histological 
changes and severity of lesions as previously reported (Bracarense et al. 2012; Grenier et al. 
2011).  Morphometry of intestinal villous and crypt was performed using a MOTIC Image 
Plus 2.0 ML® image analysis system. Thirty measurements from each fragment of intestine 
(duodenum, jejunum, ileum and colon) were done to determine villous height and crypts 
length.  
 
3. mRNA expression for cytokines by real-time PCR 
RNA on tissue was extracted with lysing matrix D tubes (MP Biomedicals, Illkirch, 
France) containing guanidine thiocyanate-acid phenol (Extract-All ; Eurobio, les Ulis, France) 
for use with the FastPrep-24 (MP Biomedicals, Illkirch, France). Concentration and quality of 
samples were analysed using Nanodrop ND1000 (Labtech International, Paris France) and 
using Bioanalyser (Agilent RNA 6000 Nano Kit Quick Start Guide). Then, reverse 
transcription and real-time qPCR steps were performed as previously described (Meissonnier, 
2008). Specificity of qPCR products was assessed at the end of the reactions by analyzing 
dissociation curves. Primers were purchased from Invitrogen (Invitrogen, Life Technologies 
Corporation, Paisley, UK). Specific sequences were specified in Table 1. Amplification 
efficiency and initial fluorescence were determined by the ΔCt method, then obtained values 
were normalized using a reference gene, the cyclophillin A (Bruel et al. 2010). Stability of 
these genes was demonstrated previously in intestinal tissues (Delgado-Ortega et al. 2011). 
mRNA expression levels were expressed relative to the mean of the control group. 
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Table 1- Primer sequences used for RT-qPCR analysis (F: Forward; R: Reverse)  
 
 
4. Statistical analysis 
 For statistical analysis, a One-way or Two-way ANOVA were realized with a 
Bonferroni test as Post-hoc, p<0.05. 
 
  
Gene symbol Gene name Primer sequence References
CycloA Cyclophilin A F: CCCACCGTCTTCTTCGACAT NM_214353
R: TCTGCTGTCTTTGGAACTTTGTCT Curtis MM 2009
IL1beta Interleukin 1 beta F: ATGCTGAAGGCTCTCCACCTC NM_214055
R: TTGTTGCTATCATCTCCTTGCAC Von der Hardt et al.2004
IL6 Interleukin 6 F:   TTCACCTCTCCGGACAAAACTG NM_214399
R:   TCTGCCAGTACCTCCTTGCTGT Grenier et al. 2011
IL8 Interleukin 8 F: GCTCTCTGTGAGGCTGCAGTTC NM_213867
R: AAGGTGTGGAATGCGTATTTATGC Grenier et al. 2011
IL1alpha Interleukin 1 alpha F: TCAGCCGCCCATCCA NM_214029,1
R: AGCCCCCGGTGCCATGT Cano et al. 2013
IL10 Interleukin 10 F:   GGCCCAGTGAAGAGTTTCTTTC NM_214041
R:  CAACAAGTCGCCCATCTGGT Bracarense 2012
IL17alpha Interleukin 17 alpha F: CCAGACGGCCCTCAGATTAC AB102693
R: CACTTGGCCTCCCAGATCAC Cano et al. 2013
IFNgamma Interferon gamma F:  TGGTAGCTCTGGGAAACTGAATG NM_213948
R:  GGCTTTGCGCTGGATCTG Royaee et al. 2004
TNFalpha Tumor necrosis factor alpha F: ACTGCACTTCGAGGTTATCGG NM_214022
R: GGCGACGGGCTTATCTGA Meissonnier et al. 2008
TGFbeta Transforming growth factor beta F:  GAAGCGCATCGAGGCCATTC NM_214015
R:  GGCTCCGGTTCGACACTTTC Meurens et al. 2009
CCL20 Chemokine (C-C motif) ligand 20 F:  GCTCCTGGCTGCTTTGATGTC NM_001024589
R:  CATTGGCGAGCTGCTGTGTG Meurens et al. 2009
TLR2 Toll like receptor 2 F: TCACTTGTCTAACTTATCATCCTCTTG AB085935
R:  TCAGCGAAGGTGTCATTATTGC Arce et al. 2010
TLR4 Toll like receptor 4 F:  GCCATCGCTGCTAACATCATC AB188301
R:  CTCATACTCAAAGATACACCATCGG Arce et al. 2010
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III. Results 
A. Comparative effect of DOM-1 and DON on animal 
performance 
 During the experiment, the mean body weight gained per animal was no significantly 
different between groups (Fig. 2), excepted on week 2, where DOM-1 group had a weight 
gain higher in comparison to other groups (Fig. 2). 
 In another study with similar design but higher dose of toxins (0.3 mg DON or DOM-
1 /Kg BW for 2 weeks) we obtained similar results. Animals in the DOM-1 group had a 
significant higher weight gain on the second week compared to than animals in the control 
and DON groups, while animals in the DON group had a significant lower weight gain on the 
first week (Fig. 3). Morover 4 of 6 pigs receiving DON vomitted during the experiment. 
 
Figure 2 - Mean weight gain per piglets measured on animals submitted to the gavage to control 
treatment (blue), DON (0.15mg/Kg BW, red) or DOM-1 (0.14mg/Kg BW, green) during 21 days. 
Two-way ANOVA, Bonferroni test as Post-hoc, p<0.05, n=6 to 8. 
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Figure 3 - Mean weight gain per piglets measured on animals submitted by gavages to control  
treatment (blue), DON (0.3 mg/Kg BW, red) and DOM-1 (0.28 mg/Kg BW, green), during 14 days at 
0.3mg/Kg BW. Two-way ANOVA, Bonferroni test as Post-hoc, p<0.05, n=6. 
 
B. Comparative intestinal toxicity of DOM-1 and DON  
Ingestion of DOM-1 induced no significant change on intestinal morphology when 
compared to control. By contrast, animal fed with DON showed a significant increase in the 
lesional score of the jejunum (4.5 fold higher than control) and the ileum (3 fold higher than 
control). Villi atrophy and fusion with flattening of enterocytes and denuded villi were the 
main histological changes observed on the intestine (Figure 4) in animals receiving DON.  
The effects of DON and DOM-1 on the expression of cytokines were assessed, on the 
jejunum without (Fig. 5, A.) and with Peyer patches (Fig. 5, B.). Whatever the intestinal part 
and the cytokine considered, no significant increase in mRNA level were observed in DOM-1 
treated animals when compared to control ones. In DON treated animals, IL-8, IL-10 and IL-
17A mRNA levels were significantly increased in the jejunum when compared to control and 
DOM-1- treated animals. In jejunum with Peyer’s patches, IL1 beta and IL17A significantly 
increased in animals from the DON group when compared to control and DOM-1 groups (Fig. 
5, B.). In this organ, a slight but non significant increase of IL-6, IL8, IL1alpha, IL10 and 
IFNgamma mRNA levels was also observed in DON treated animals. 
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Figure 4 - Histological intestinal samples from piglets submitted by gavage to control treatment 
(blue), DON (0.15 mg/Kg BW, red) or DOM-1 (0.14 mg/Kg BW, green) during 21 days. Two-way 
ANOVA, Bonferroni test as Post-hoc, p<0.05, n=6 to 8. 
A- Jejunum, control group. Villi with normal morphology. B- Jejunum, DON group. Villi fusion and 
lymphatic vessel expansion. C- Jejunum with Peyer patches, DOM-1 group. Villi with normal 
morpholy. D- Ileum, DON group. Villi atrophy, villi fusion and edema of lamina propria. 
Hematoxilin-eosin. Bar 100 µm. 
A.
B.
C.
D.
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Figure 5 - The mRNA expression levels of markers of inflammation are affected by gavage to control 
treatment (blue), DON (0.15 mg/Kg BW, red) or DOM-1 (0.14 mg/Kg BW, green) during 21 days. At 
the end of the experiment, samples from different organs (A.jejunum, B.jejunal Peyer patches) were 
collected, and mRNA levels of inflammatory markers (IL1beta, IL6, IL8, IL1alpha, IL10, IL17A, 
IFNgamma, TNFalpha, TGFbeta, CCL20) were measured by RT-PCR. Results are expressed as the 
relative mRNA expression as means ± SEM; n=6 to 8 animals/group.*p<0.05, **p<0.01 and 
***p<0.001, Two Away ANOVA with Bonferroni Post-hoc test. 
 
C. Comparative effects of DOM-1 and DON on liver 
Animals receiving DOM-1 were similar to the control ones. By contrasts, a significant 
increase on liver lesional score was observed in the DON-treated group (3 fold higher than 
control). In these animals the liver, showed a disorganization of hepatocytes, a vacuolization 
and a megalocytosis of these cells (Figure 6). 
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Figure 6 - Histological liver samples from piglets submitted by gavage to control treatment (blue), 
DON (0.15 mg/Kg BW, red) or DOM-1 (0.14 mg/Kg BW, green) during 21 days. One-way ANOVA, 
Bonferroni test as Post-hoc, p<0.05, n=6 to 8. 
A- Control group. Hepatocytes’ trabeculae with normal arrangement. B- DON group. Hepatocyte 
apoptosis (arrows) and mild vacuolation of hepatocytes cytoplasm. C- DOM-1 group. Disorganization 
of hepatocytes’ trabeculae and mild vacuolation of cytoplasm. D-  DON group. Nuclear vacuolation of 
hepatocyte (arrow) and megalocytosis. Hematoxilin-eosin. Bar 30 µm (A), 20 µm (C), 10 µm (B,D). 
 
D. Comparative effect of DOM-1 and DON on immune parameters 
The last part of the experiment was to evaluate the effect of DOM-1 and DON on immunity 
related parameters such as the histology of the spleen and lymph node, total and specific antibody 
response.  
A significant increase in histological changes was observed in animals treated with DOM-1 in 
spleen (2.4 fold), and a non-significant increase in mesenteric lymph nodes in comparison to control 
group was also seen (1.4 fold). A similar increase in histological changes was also observed in animals 
treated with DON (1.5 fold and 2.5 fold for lymph node and spleen, respectively). In these organs, 
lymphoid depletion and apoptosis of lymphocytes were the most frequent changes observed in DOM-1 
or DON treated animals. Reactive germinal center with macrophages containing tangible bodies was 
also observed in spleen of DON treated group (Figure 7). 
The effect of DON and DOM-1 were also measured on the total and specific IgG. The 
plasmatic concentration of IgG was not significantly modified by the presence of toxins (Fig. 8). The 
immunization protocol allowed investigating the effects of mycotoxins on antigen-specific immunity. 
Ingestion of either DOM-1 or DON significantly increased the production of OVA-specific IgG at day 
A.
B.
C.
D.
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21 when compared to control (15.2 ± 2.9; 86.3 ± 25.9 and 82.3 ± 37.4 Arbitrary Units in 
DOM-1, DON and control animals respectively) (Fig. 9). 
 
Figure 7 - Histological spleen from piglets submitted by gavage to control treatment (blue), DON 
(0.15 mg/Kg BW, red) or DOM-1 (0.14 mg/Kg BW, green) during 21 days. Two-way ANOVA, 
Bonferroni test as Post-hoc, p<0.05, n=6 to 8. 
A- Spleen, control group. Lymphoid follicle with normal arrangement. B- Spleen, DON group. 
Reactive germinal center with macrophages containing tangible bodies (arrow). Hematoxilin-eosin. 
Bar 40 µm (A), 50 µm (B). 
 
Figure 8 - Total Immune response for each treatment control (blue), DON (0.15 mg/Kg BW, red) or 
DOM-1 (0.14 mg/Kg BW, green) during the experiment. 
Ratio of Total IgG/Total IgG at DO of piglets for each treatment at D7, D14 and D21. N=8 for control 
and DON groups and 6 for DOM-1 group, Two-way ANOVA, p<0.05 
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Figure 9 - IgG-antiOVA during the experiment per treatment control (blue), DON (0.15 mg/Kg BW, 
red) or DOM-1 (0.14 mg/Kg BW, green) during the experiment, following one vaccine injection 
against OVA at day 3 and one booster at day 8. Two-way ANOVA, Bonferroni test as Post-hoc, 
p<0.05, n=6 to 8. 
 
IV. Discussion 
In this present 3-week study, piglets were exposed to low doses of one major 
mycotoxin, the DON, and one of its derivatives, the DOM-1. Previous studies on the toxicity 
of DOM-1 toxicity were done with feed contaminated with DON in presence of the bacteria 
that is able to deepoxydise the DON and focused on zootechnical parameters (He et al. 1993; 
Li et al. 2011). By contrast, this study assessed the effect of purified DOM-1 on animals, and 
assessed major markers of toxicity, zootechnical parameters, intestine, systemic and 
immunologic parameters. 
The use of purified toxin by gavages allowed to precisely control the dose used and to 
make sure that each animal received the same amount. Purified DOM-1 were given to pig at a 
dose of 0.14mg/Kg BW, molecular equivalent of 0.15mg/Kg BW of DON corresponding 
approximately to 3-4 ppm (Sergent et al. 2006), at levels commonly found in crops (SCOOP 
2003). 
From an agronomic point of view, pigs are exposed to mycotoxins due to the proportion 
of cereals in their diet. In addition, pigs are very sensitive to mycotoxins, due to the absence 
of ruminal tank, known to contain microorganisms capable of degrading toxins before their 
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intestinal absorption (Rotter et al. 2006). Finally, considering the similarity in the immune and 
digestive systems of pigs and humans, the use of pig model allow to extrapolate data to man 
(Heinritz et al. 2013; Nedjfors et al. 2000; Helm et al. 2003; Kimber et al. 2003; Rothkotter et 
al. 2002). For the choice of doses and time of exposure, this work fits in the current dynamic 
of a toxicological study, for chronic exposure going from low doses to moderate ones, not 
inducing major clinical manifestations (Forsyth 1977). 
In summary, results showed that DOM-1 does not have toxic effects on zootechnical 
parameters, intestinal histology, intestinal and inflammatory response and liver histology. For 
these parameters we found toxic effects of DON as already described by others (Grenier et al. 
2011; Pestka 2010; Rotter et al. 1996).  The zootechnical parameters were not impacted by 
DOM-1 ingestion, with no decrease of weight gain and no emesis observed. Concerning the 
impact of DOM-1 on the intestine, which is the first organ targeted by feed contaminant 
(Prelusky et al. 1996; Oswald 2006), no tissue damage were induced. Moreover, DOM-1 
didn’t induce a pro-inflammatory response on intestinal tissue like it was observed with DON. 
One organ of the systemic response was analyzed, the liver, to complete the information about 
the action of DOM-1 once absorbed in the intestine. Histomorphological analysis on liver 
showed no damage induced by DOM-1 in contrary to DON. Finally, concerning the global 
immune response, DOM-1 didn’t elicit total immune response. 
On secondary lymphoid organs and on total and specific immune response, DOM-1 
elicited the same increased immune response as DON. Indeed, concerning the specific 
immune response, and after a vaccine injection DOM-1 seems to act like an adjuvant, in 
increasing the immune response against the vaccine. Moreover, lymphoid depletion and 
apoptosis of lymphocytes were observed on lymph node and spleen like in DON group, may 
be correlated to the important specific immune response. In a previous study (see results of 
paper Chapter I, Part 2), we found that DOM-1 didn’t induce MAPKs activation and a pro-
inflammatory response like DON. The results obtained in the present study indicate that 
DOM-1, not activating MAPKinase have the same effect on the immune response than DON 
that activates the MAPKinase. This suggests that all effects induced by DON, especially the 
ones on the immune response are not mediated by the way MAPKs works. This was already 
proposed by Wu et al. (2014) when investigating the effect on the immune response induced 
by D3G, another DON derivative that do not activate MAPKinase. 
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In conclusion these results are in accordance with previous results found in others in vivo 
study. DOM-1, deepoxidated from DON by a strain BBSH 797, Gen. nov. sp. nov. of family 
Coriobacteriaceae, sold as a food additive, is globally not toxic for animals as DON. Taking 
into account that degrading product of DON (DOM-1) formed by this bacteria is much less 
toxic than DON, associated to the information given by previous in vivo studies (He et al. 
1993; Li et al. 2011); the use of these detoxifying products seems to be a relevant strategy to 
protect animals, against the toxic effects of DON found in pig feed. However, this study has 
also shown that DOM-1 is able to act on the immune response. The underlying mechanism 
still need to be investigated. 
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I. Discussion 
Once present in cereals or feed materials, the high stability of mycotoxins make them very 
difficult to eliminate. Several strategies have been developed to manage mycotoxins contamination, 
such as physical (cleaning, sieving), chemical (ammoniation) and biological (binding agents, feed 
additives, resistant crops) treatments. In this context, my thesis project deals with problematic of 
mycotoxin detoxification and was in particular focused on DON.  
Indeed, among mycotoxins, DON is the most common in the world and can be present in various 
cereals and raw materials. As other mycotoxins, it is really hard to manage and eliminate. New 
strategies of biological detoxification led to the formation of metabolites, such as the deepoxy-
deoxynivalenol (DOM-1) and the 3-epi-deoxynivalenol (3-epi-DON). The “masked” mycotoxin, 
deoxynivalenol-3-glucoside (D3G) is produced in plant resistant to Fusarium and is very often present 
simultaneously with DON. Thereby it becomes important to assess the toxicity of these biological 
degradation products of detoxification of DON. Limited toxicological information on DON-
transformation products are available, this may be due to the lack of suitable methods to purify 
sufficient amounts of the chemicals for structure identification and toxicological studies. 
The main purpose of this work was to assess the toxicity of “modified” and “masked” forms of 
DON, to evaluate the efficacy of the detoxification. This thesis investigates the toxicity of these DON 
derivatives on human and animal models, mostly on immune and intestinal parameters, using several 
approaches. These new molecules issued from a natural way of transformation can be a promising 
approach to detoxify mycotoxins and protect human and animals from their hazard effects. 
Problematic of modified and masked mycotoxin in context of risk assessment, effects of DON on 
health pig and comparative toxicological effects of DON, DOM-1, 3-epi-DON and D3G have been 
summarized and discussed in the previous papers and will not be repeated here. This general 
discussion will focus on the studied models used, the specific results obtained with in silico and IPA 
analysis, and to finish the perspectives on experiments that could be realized to further investigate or 
complete information of toxicity and mechanisms of toxicity on DON and its derivatives. 
 
A. Discussion on the analysis performed in the thesis 
In silico, in vitro, and ex vivo models, were used to compare the intestinal and immune toxicity 
of D3G, DOM-1 and 3-epi-DON to those of DON. 
 In silico analysis allowed to draw three dimensions molecules and to visualize their interaction 
with the ribosome, especially with the petptidyl transferase center (PTC) of the ribosome. In silico 
approach is widely used in medical chemistry to decipher the mechanism of binding between protein 
and ligands, to predict interactions between molecules or to study structure activity relationship. This 
approach is not so commonly used in food safety, however some studies show that this approach allow 
in food safety studies to discover and study, quickly and economically, new putative endocrine 
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disruptors (Amadasi et al., 2009), like ZEN and its masked derivative (Cozzini and Dellafiora 2012). 
In this thesis, modeling allow the better understanding of the molecular mechanism of DON toxicity. 
 In vitro model using cell lines is a powerful tool for the exploration of fundamental questions 
regarding drug delivery dynamics and kinetics (Artursson et al. 2001; Boveri et al. 2004). To study the 
toxicity of DON and its derivatives on intestinal epithelial cells, we chose a human intestinal cell line. 
Caco-2 has the advantage to express characteristics markers of adults’ intestinal cells,  to be a 
reference line in toxicology studies, and to be largely used to study intestinal absorption (Sambruy et 
al. 2001). 
 Explant model allows a direct testing of the toxicity of molecules on intestinal living tissue 
keeping its polarity and extracellular integrity (Gonzalez-Vallina et al. 1996).  Moreover, in the 
context of 3R, explants limit the use of animals, as well as the variability. Indeed many conditions are 
tested on the same animal, thus an animal is its own control. This model also allows to investigate in 
detail the impact of each derivatives on the expression of many genes on the intestinal tissue of pigs. 
Using a microarray encompassing the genome, associated with a functional analysis allows to go 
deeper on the investigation on the pathways targeted by these derivatives. 
 Finally the use of in vivo model, allow assessing the toxicity on the entire organism, looking at 
several organs and parameters that can be targeted by mycotoxins.  
 
 
1. In silico analysis of the interaction between DON, DON 
derivatives and the ribosome 
The in silico analysis lets us go deeper in the understanding of the mechanism of toxicity. The 
molecules binding of DON, DOM-1 and 3epi-DON into the peptidyl transferase center of the 
ribosome were modeled. The in silico analysis demonstrates that DON interacts with the two chains of 
the A-site of the ribosome through three hydrogen bonds (with G2403, U2873 and U2869). The 
deepoxydation of the epoxy group (into one hydrogen double bound) leads to a loose of the hydrogen 
bond U2873 and to the absence of toxicity. We can thus imagine that the three hydrogen bounds are 
required to maintain the molecule in the peptidyl transferase center; when only two bounds forming 
the stability is too weak to maintain the molecule in the peptidyl transferase center and to induce a 
subsequent cellular response. A similar analysis was performed with the 3-epi-DON; due to the 
isomeric change, the hydrogen bond with the uracile U2869 is lost. The molecule is only maintained in 
the ribosome pocket by two hydrogen bonds, this reduces the stability of the interaction and prevent 
cellular activation. 
 As both DOM-1 and 3-epi DON do not activate MAPKinase, the three hydrogen bonds seem 
required to maintain stably the molecule of DON into the A-site of the ribosome, to activate the 
MAPKinase and to induce the toxicity of this mycotoxin. This finding is in line with the hypothesis 
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that the toxicity of DON is linked to the epoxy group and the C3 group (Karlovsky 2011; Sundstol 
Eriksen et al. 2004) (Rotter et al. 1996). The loss of one hydrogen bound decreases the toxicity of 
DON. Most of the A-site inhibitors molecules, such as DON, impair peptide bond formation during 
translation elongation. They all block protein synthesis by competing with the amino acid side chains 
of incoming aminoacyl-tRNAs for binding in the A-site cleft in the PTC, which is universally 
conserved (Garreau de Loubresse et al. 2014). In addition, these structures support the hypothesis that 
the species specificity exhibited by the A-site cleft inhibitors is determined by the interactions they 
make, or fail to make, with a single nucleotide, U2504 (Escherichia coli) (Gurel et al. 2009). In our 
case, it confirms that just one change of interaction can change the toxicity of the molecule. However, 
we did not determine the role of the third hydrogen bond (between the oxygen of C15 group CH2OH 
and the hydrogen of the guanine basis G2403) on the binding of DON to the PTC of the ribosome and 
the subsequent toxicity of DON. Indeed, we couldn't identify a DON metabolite or another 
fusariotoxin metabolite to confirm the involvement of this H-bound in the structure-toxicity 
relationship. It would be interesting to test a molecule having both the epoxy and the C3 group but not 
the G2403 hydrogen bound. A second possibility would be to make a double mutations on the A-site 
of the ribosome, replacing the uracile basis U2869 by a guanine and the guanine G2403 by an 
adenosine, and to test the interaction of this mutated ribosome with DON. 
 
The molecular basis to explain the lack of toxicity of D3G is easier. Due to its size, D3G can't 
interact with the A-site. Indeed, glucose molecule, added during the phase II of metabolization to 
easily eliminate the molecule, importantly increase its size. 
 
2. Pan genomic analysis of the effect of DON and its 
derivatives 
After the microarray analysis of explant treated with DON, or its derivative, a functional 
analysis using Ingenuity Pathways Analysis (IPA), was performed. IPA is a database gathering 
information on molecules (genes, proteins, metabolites, xenobiotics) and their interactions between 
each other or with pathologies, phenotypes, cells or cellular processes. The sources of information of 
IPA consist in existing databases (GenBank, Ensembl Entrez Gene, Gene Ontology, GEO ...), and 
knowledge extracted from the literature. This software allows to rapidly obtain information on genes 
expressed in the tissue and find genes who interferes (in different ways) with these genes and that are 
differentially expressed in our analysis. The Ingenuity Pathways Analysis demonstrates the absence of 
toxicity of DOM-1, 3-epi-DON and D3G, with no genes differentially expressed and thus no functions 
impacted. It also allows identifying key biological functions regulated by DON. This is a powerful 
tool to assess, on one tissue, all the functions that could be regulated by one molecule. It both confirms 
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the implication of function and genes that have been already described but also demonstrates the 
implication of new functions/genes.  
IPA highlighted several genes and pathways already known to be impaired by DON in the 
intestine. For example we observed that in the intestine, DON modulates cytokines involved in the 
inflammatory pathway, tight junction signaling, p38MAPK Signaling, Protein Ubiquitination 
pathways, oxidative stress, protein degradation pathway as already described (Katika et al. 2012; 
Mishra et al. 2014; Osman et al. 2010; Shen et al. 2007; van Kol et al. 2011). Functional analysis 
pathway also brings new information on DON effects in the intestine. It’s the case on metallothionein, 
shown to be a marker of oxidative stress and mycotoxins contamination in rats (Vasatkova et al. 
2009). Results also underline the effect of DON on genes of intestinal transporters (Bookstein et al. 
1997; Smith et al. 2013; Videmann et al. 2007) and on the decrease of the unfolded protein response 
pro-apoptotic gene CHAC1 that seems to play a role in glutathione degradation (Kumar et al. 2012). 
This study also shows the impact of DON on mitochondrial dysfunction. 
 
3. The in vivo experimental protocol 
During the experiments, purified mycotoxins were used. In cereals naturally contaminated, 
there are always co-contamination that doesn't allow to discriminate the effect of each mycotoxin 
(Schatzmayr and Streit 2013). Moreover, fungi contamination on cereals affects nutritional quality and 
change the final quality of pig feed. So the use of purified mycotoxins  allows to keep the nutritional 
quality of feed and to attribute observed effect to the tested mycotoxins. In addition, gavage allowed to 
adjust precisely the dose given and to be sure that all animals received the calculated dose per Kg/BW. 
A moderate dose was used in the perspective to assess the toxicity of probable quantity of 
DON in animals. Many studies performed with DON contaminated feed using moderate amounts 
corresponding to contamination doses that can be found in natural conditions (Poolman et a., 1985; 
Harvey et al., 1996; Trenholm et al., 1984; Friend et al., 1992; Rotter et al. 1994). 
 
B. Toxicity assessment of biological strategies to reduce toxic 
effects of DON 
Despite all preventive efforts and improvement of agricultural practices, important 
concentrations of mycotoxins still occur in agricultural products. Due to the difficulty to eliminate and 
detoxify DON, alternative effective strategies of detoxification are needed. the use of plants resistant 
to fungi infection or biological biotransformation to detoxify are new promising strategies (He et al. 
2010). Indeed, biological methods are a good way to eliminate toxicity without acting on the grain 
quality or on the processed feed. There have been several transformation products of DON reported 
(Table 1), such as DON-sulfonate, DON lactone, norDON A, norDON B and norDON C, 3-acetyl-
deoxynivalenol (3-ADON), 15-acetyl-deoxynivalenol (15-ADON), diacetyl-DON, triacetyl-DON, iso-
DON, 3-keto-deoxynivalenol (3-keto-DON), deepoxy-deoxynivalenol (DOM-1), DON-3-glucuronide, 
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DON-3-glucoside, and 3-epi-deoxynivalenol (3-epi-DON) (He et al. 2010; Ikunaga et al. 2011; Sato et 
al. 2012; Zhou and He 2009). 
 
Table 1. Biological transformation of DON by microorganisms (He Jian We thesis) 
 
 
1. Efficiency of detoxifying strategies 
a) Bacterial transformation 
The use of feed additives is a well-established practice in the animal feed industry. Successful 
mycotoxin-binding agents act by preventing its intestinal absorption by the animal from the 
contaminated feed (Bryden 2012). However, adsorption approaches for DON are relatively ineffective 
and so the use of microorganisms is recommended for trichothecene (Awad et al. 2010). Moreover, 
due to the chemical diversity of mycotoxins, often present in food in the same time, additional 
approaches to detoxifying feedstuffs are required, even if adsorbing, binding or trapping agents can be 
very effective. 
Concerning the use of detoxifying agents, the major part of my work was to assess the global in 
vivo toxicity of DOM-1. Indeed, one strategy to protect animal from mycotoxin, is the use of 
microorganisms/enzymes detoxifying mycotoxins to limit the absorption in the organism (Schatzmayr 
et al. 2006). These microorganisms realize some transformation not feasible by the plant or by the 
animal. These transformations on the basic structure will play on the original toxicity of the molecule. 
The toxicity of trichothecene mycotoxins varies and is determined by their molecular structures, 
particularly functional groups such as epoxy, ester, and hydroxyl groups (Betina 1989; Nagy et al. 
 
214 DISCUSSION & PERSPECTIVES 
2005; Zhou et al. 2008). The number and the position of hydroxyl groups influence trichothecene 
toxicity. Currently, information on the toxicity of these transformation products (or DON derivatives) 
are limited. 
BIOMIN group isolated and stabilized bacterium, now called BBSH 797, Gen. nov. sp. nov. of 
family Coriobacteriaceae able to remove the epoxide group of trichothecenes in vivo, and to transform 
DON into DOM-1 (Binder et al. 2001; Fuchs et al. 2002). Since its discovery in 1997, Eubacterium 
specific of trichothecenes, named BBSH797 in honour of the research team who discovered it (BBSH, 
Binder Binder Schatzmayr Heidler), was the first additive detoxifying mycotoxins formulated from a 
life microorganism. This derivative is recognized to be less toxic than DON, based on in vitro and in 
vivo experiment with animal ingesting the bacteria in presence of DON (He et al. 1993; Li et al. 2011; 
Schatzmayr et al. 2006; Sundstol Eriksen et al. 2004; Swanson et al. 1987). However, actual DOM-1 
cytotoxic assays are not sufficient to correctly evaluate the overall toxicological relevance (Rychlik et 
al. 2014). And these in vivo studies didn’t evaluate the global toxicity of purified DOM-1 on the 
animal. 
 The 3-epi-DON is also issued from a bacterial transformation. A bacteria, issued from the an 
alfalfa soil enriched with F. graminearum-infested corn, bacterium Devosia mutans 17-2-E-8 that is 
capable of completely transforming DON into a major product 3-epi-DON and a minor product 3-
keto-DON in aerobic conditions (He et al. 2015b; Zhou and He 2009, 2010). 3-epi-DON, is an epimer 
of DON, the only difference between these two chemicals is the stereochemistry at the 3-OH Group 
(He et al. 2015b). 3-epi-DON, has received very little attention. Nevertheless, it is known that epimers 
can have different physicochemical properties, biological activities and toxicities. A study shows that 
a epimeric form of catechin was less active than the initial form (Mendoza-Wilson and Glossman-
Mitnik 2006). A second study showed a five-fold difference in in vitro toxicity that has been 
demonstrated for the marine biotoxins azaspiracid-1 (AZA1) and 37-epi- AZA1 (Kilcoyne et al. 
2014). Moreover, it seems that, once it is formed, the molecule is stable and the transformation is 
irreversible (Karlovsky 2011). This is a very interesting point in the context of the problem of the 
metabolization into the animal. 3-epi-DON could be a promising new commercial product if is not 
toxic and if it stay stable into the organism. Today, only one study assesses its toxicity on in vitro and 
in vivo models (He et al. 2015a) and there are no information on its metabolization. The above 
mentioned study demonstrated that 3-epi-DON is far less toxic than DON on Caco-2 cells and mouse 
models.  
Different analysis realized in this thesis complete the information known about DOM-1 and 3-epi-
DON toxicity. In conclusion, our results confirm the lack of in vitro toxicity of DOM-1 and 3-epi-
DON as seen in previous studies performed on Caco-2 cells, a relevant model in toxicology studies on 
the intestine (He et al. 1993; Li et al. 2011; Sambruy et al. 2001; Schatzmayr et al. 2006; Sundstol 
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Eriksen et al. 2004; Swanson et al. 1987). Our results also show that these DON metabolites did not 
impair the integrity of intestinal tissue and the barrier function. They also demonstrate that DOM-1 
and 3-epi-DON do not alter gene expression, do not induce a pro-inflammatory response and do not 
induce the activation of MAPKs. Moreover, results obtained in vivo show that DOM-1 did not alter 
most of the parameters investigated. Finally, our results bring a mechanistic hypothesis on the lack of 
toxicity of DOM-1 and 3-epi-DON. 
 
b) Plant transformation 
In natural conditions, some plants are able with efficacy to manage xenobiotics and mycotoxin, as 
DON. Plants could accumulate toxic levels of these molecules without efficient detoxification 
strategy. The natural way of defence includes biosynthesis pathways, phase I transformation 
(hydrolysis, reduction or oxidation), phase II solubilisation (conjugaison) and phase III 
compartmentalisation. These different phases (I and II) aim at increasing the polarity of the molecule 
making it more water soluble and facilitating by that its transport mediation by ATP-dependent 
glutathione-conjugate transporters to the vacuole or apoplastic space outside cell (phase III) (Coleman 
et al. 1997). 
Mycotoxins issued from this biosynthesis pathway, are “modified” mycotoxins and more 
specifically called “masked” mycotoxins by ILSI as they are issued from a conjugation transformation 
into the plant (Berthiller et al. 2013). Thereby, masked derivatives of DON can be found in co-
contamination in raw cereals and processed food, such as deoxynivalenol-3-β-D-glucoside (D3G). A 
study showed that D3G was present in all tested wheat and maize samples (Berthiller et al. 2009). 
One strategy of fight against mycotoxin is the use of plant, for instance wheat cultivars, that carry 
a major QTL for increased Fusarium resistance and increased ability to conjugate DON into D3G. 
Indeed DON enhances the virulence on wheat (Jansen et al. 2005; Lemmens et al. 2005). These plants 
resistant to fungi over express UDP-glycosyl-transferase, an enzyme able to glycosylate DON in 
higher proportion (Berthiller et al. 2013; Karlovsky 2011; Poppenberger et al. 2003). So, this increased 
use of wheat cultivars may lead to a higher D3G/DON ratio in the future. In this case, the contribution 
of D3G to overall DON toxicity has to be taken into account. 
 Different analyses realized in this thesis bring new information about D3G toxicity, and show 
that it is non toxic. These results imply that the increasing use of resistant plant to Fusarium could be a 
promising strategy to reduce mycotoxin production and their occurrence in cereals and food process 
products. However, studies show that D3G can be  hydrolyzed into DON by acid lactic of some 
bacteria inside the gut (Berthiller et al. 2011). A study realized on pig shows that the major part of 
D3G ingested, was excreted by urine in DON form and in minority in DON-glucuronidate forms (Nagl 
et al. 2014). So, even if D3G is not toxic by itself, if hydrolyzed into DON by the animal, it could be 
reabsorbed and thus the total amount of DON to which pig is exposed would be increased. 
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II. Perspectives 
Results obtained in the present thesis demonstrate the non toxicity of several derivatives of DON 
on numerous parameters. To completely evaluate the toxicity of each molecule, an in vivo experiment 
on D3G and 3-epi-DON would be necessary. Actually, as we have seen for DOM-1, an in vivo 
experiment can make reveal unexpected properties of the molecule. No studies evaluating the toxicity 
of D3G and 3-epi-DON on farm animal were done yet. In order to assess in a significant way all the 
parameters impacted by D3G and 3-epi-DON, a longer exposure could be interesting to asses chronic 
effect of the toxin. The use of more animals, even if it is difficult to handle, should reduce the 
important individual variability that we observed in our in vivo experiment. 
Our results associated with previous studies assessing the effectiveness and toxicity of bacteria 
transforming DON into DOM-1, as well as the safety for pig with tolerance studies (He et al. 1993; Li 
et al. 2011; EFSA 2013), seems to show that the use of bacteria to transform DON into a less toxic 
compound is be an efficient approach. It will be thus interesting to extend this approach to other 
mycotoxins. Indeed, as described in the introduction, the detoxification methods have not the same 
efficacy according to the mycotoxin. The use of bacteria efficient to transform other mycotoxins in 
less toxic compounds is already tested (Grenier et al. 2011); the toxicity of all the transformed 
products obtained on many different parameters has not been completely investigated.  
In this context, the explants model, was shown to be efficient to evaluate the intestinal toxicity. 
Combined with others tools, such as microarray and functional analysis, it allows to deeply investigate 
the impact of a molecule on the tissue and to determine all the genes impacted by the exposure in the 
tested tissue. This model also allows to perform functional tests. For example, the evaluation of the 
barrier function can be measured by the TEER of jejunal explants placed in Ussing Chamber. 
Nevertheless, to completely assess the impact of a mycotoxin on the organism, in vivo experiments are 
required. These type of experiment especially allow to assess zootechnical effects, systemic or specific 
immune responses as well as the metabolism of the ingested molecule. Indeed, as we saw for DOM-1, 
its effect on the immune response was not observed in vitro or ex vivo. Concerning the metabolization, 
as described for D3G, modified mycotoxins could be retransformed into its native form by the host or 
the microbiota. Thus, in vivo experiment cannot be completely substituted by the use of in vitro and ex 
vivo models.  Livestock feeding studies (e.g. swine, goat and chicken) are recommended to confirm 
the detoxification of the transformed product and to determine the metabolism/toxicokinetic of this 
modified mycotoxin. The toxicological results are critical for future industrial application, but they 
also provide fundamental scientific information for toxicological research. 
In order to assess, the metabolization of modified and masked mycotoxin into the organism, the 
pig constitutes a relevant model. The bacterial profil of pig matches quite well with human, which is 
important to investigate the metabolization of “modified” DON in pig. Herein, pig is a good model; 
beside is similar intestinal tract to those of man (Heinritz et al, 2013), it also possess a similar bacterial 
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profile to human (Maresca 2013). Plus, since it’s a monogastric just like human its similar tract is 
organized in the same way. 
Concerning the use of resistant plants to mycotoxins, the toxicity analysis and the metabolization 
of products transformed by these plants is important. This step is required to correctly estimate the risk 
of exposure to native mycotoxin. It’s essential to determine if D3G or other masked mycotoxin, 
present in high quantity in selected or genetically modified plants, won’t be all re-transformed to DON 
in the animal. Even if D3G is not toxic by itself (because issued from a detoxification pathway into 
plant), it could be transformed back to its aglycone into the organism and thus increase the amount of 
DON present in the organism. So, in this case to correctly assess the risk, it is necessary to take into 
account both “native” and “masked” mycotoxins in the calculation of exposure and the calculation of 
NOEL and LOAEL by regulator organism like European Food Safety Authorities (EFSA). 
An alternate application of bacteria is to only use for detoxification the enzymes and/or the genes 
implicated in the detoxification process. The genes may be cloned and expressed in crops to develop 
varieties that are resistant to the production of mycotoxins or which detoxify mycotoxin and, thus 
prevent this mycotoxin from entering the human and animal food chains. The detoxification genes 
may also be cloned and expressed in microorganisms to produce recombinant microorganisms that are 
suitable in an industrial scale enzyme production and purification (Altalhi and El-Deeb 2009). These 
detoxification enzymes should have great potential to eliminate DON and other mycotoxins present in 
the human and animal food chains. 
 
In conclusion, this work fits in context of animal production, where expenses linked to 
prophylaxis, cares and productivity loss are important points in the agricultural sector. Mycotoxins 
present a problem all over the world for both human and animals. Therefore, the necessity to continue 
developing strategies of prevention and detoxification, is encouraged by the global warming, which 
will have an impact on the development of fungi (Bryden 2009; Paterson and Lima 2009; Tirado et al. 
2010). In the long run, these new ways of detoxification, using plants and bacteria, have great 
potentials and could help the food safety sector, the livestock production and the crop disease 
management face these mycotoxins. 
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CONCLUSION
 
  
Conclusion 
 
The thesis brings new data on modified forms issued from strategies to detoxify mycotoxins. 
The general objective of this research was to evaluate the toxicity of three DON derivatives issued 
from biological transformation, DOM-1, 3-epi-DON and D3G. This thesis allowed to examine 
numerous parameters, through in silico, in vitro and ex vivo experiments. Results increased the 
knowledge on the toxicity and the mechanism of toxicity of DON, using pangenomic array on a 
jejunal tissue and in silico analysis. Finally, in vivo experiments allowed assessing the intestinal and 
immune toxicity of purified DOM-1 in comparison to DON, on piglets. 
In silico, in vitro and ex vitro results showed that the tested DON derivatives were less toxic 
than DON; they were not able to induce a ribotoxic stress, a “keystone” of DON toxicity. Another 
important aspect that was not studied during this thesis is the metabolism of these derivatives in the 
organism. Certainly, each derivative and mycotoxin has its own behavior into organism, and in vitro 
and ex vivo assessment are not enough to give use a complete information on the molecule. In vivo 
studies allow investigating the organ toxicity of the tested molecules. In the present work we did not 
investigate the transformation of the derivatives, to the “native” mycotoxin into the intestine. Such a 
transformation, especially with "masked" mycotoxin, could lead to an underestimation of the risk.  
In perspectives, assessing the in vivo toxicity of 3-epi-DON, D3G and the metabolisation of all 
the molecules on farm animals, will bring us all the information needed regarding the management of 
risk assessment for these molecules. 
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cereals or feed materials, becomes difficult. Thereby, it is present in many cereals and final feed 
products, inducing several toxic effects on human and animals, and causing big economic losses. 
New strategies of to fight against mycotoxins were developed, as biological transformation, either by 
the use of bacteria or plants. Indeed, some microorganisms are able to transform DON in new 
products, by enzymatic reaction, forming the deepoxy-deoxynivalenol (DOM-1) and the 3-epi-
deoxynivalenol (3-epi-DON). Moreover, some plants naturally own the capacity to glycosylate DON 
in the aim to detoxify it, forming the deoxynivalenol-3-β-D-glucoside (D3G). 
The aim of this thesis was to assess the toxicity of these DON derivatives, on the intestine and immune 
response, using several approaches such as in silico, in vitro, ex vivo and in vivo models. 
On the human intestinal Caco-2 cell line, DOM-1, 3-epi-DON and D3G were not cytotoxic; they did 
not alter its viability and barrier function, as measured by the trans epithelial electrical resistance. 
The expression profile of DOM-1, 3-epi-DON and D3G-treated jejunal explants was similar to that of 
controls and these explants did not show any histomorphology alteration.  On the other hand, the 
treatment of intestinal explants with DON, induced morphological lesions and upregulated the 
expression of proinflammatory cytokines. The impact of these three derivatives was also studied on 
intestinal explants with a pan-genomic transcriptomic analysis. Results show that the derivatives of 
DON did not induce any change on the gene expression in comparison to the control-treated explants. 
In contrary, DON-treated explants differentially expressed 747 probes, representing 323 genes 
involved in immune and inflammatory responses, oxidative stress, cell death, molecular transport and 
mitochondrial function. 
In silico analysis revealed that D3G, opposing to DON, was unable to bind to the A site of the 
ribosome, which is the main target for DON toxicity. Both DOM-1 and 3-epi-DON were able to fit 
into the pockets of the A site of the ribosome but only by forming two hydrogen bonds, while in this 
position, DON forms three hydrogen bonds. Moreover, the three derivatives do not elicit a ribotoxic 
stress, MAPKinase activation, and inflammatory response.  
Then, an in vivo study was carried out to assess the toxicity of DOM-1 on pig (feed forced during 21 
days at 0.14 mg/Kg BW). The results showed that DOM-1 does not have as much toxic effects as 
DON on zootechnical parameters (no emesis induced, no decrease of food consumption or weight loss 
observed), on intestine and liver (no tissues damages), or on the immune response (no inflammatory 
response induced). 
Our data demonstrate that bacterial de-epoxidation or epimerization of deepoxy-DON modified its 
interaction with the ribosome, leading to an absence of MAPKinase activation and toxicity; and that 
the glycosylation of DON suppresses its ability to bind to the ribosome and decreases its intestinal 
toxicity. The mycotoxin deoxynivalenol (DON) remains an important challenge in many regions in the 
world. Thus, these biological detoxifications of DON seem to represent a new promising approach 
helping manage the problem of its contamination. 
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RESUME : 
Les mycotoxines sont des métabolites secondaires de moisissures contaminant de façon naturelle de nombreuses 
denrées alimentaires, notamment les céréales. Le déoxynivalénol (DON), produit par Fusarium sp., est la 
mycotoxine la plus répandue dans le monde. Du fait de sa grande stabilité chimique, le DON est difficile à 
éliminer, et se retrouve dans les céréales et les produits finis ou il induit des effets toxiques pour l’homme et 
l’animal. De nouvelles stratégies de lutte sont mises en places, telle la transformation biologique utilisant des 
bactéries ou des plantes. En effet certaines bactéries possèdent des enzymes capables de transformer le DON en 
de nouveaux composés, le déepoxy-déoxynivalénol (DOM-1) et le 3-épi-déoxynivalénol (3-epi-DON). De plus, 
certaines plantes sont naturellement capables de transformer le DON dans le but de l’éliminer et de le détoxifier, 
formant ainsi le deoxynivalénol-3-β-D-glucoside (D3G). 
L'objectif de cette thèse était d'évaluer la toxicité de ces dérivés du DON au niveau de l’intestin et du système 
immunitaire par le biais d’analyses in silico, in vitro, ex vivo et in vivo.  
Les tests de toxicité in vitro sur la lignée humaine intestinale cellulaire Caco-2 montrent que le DOM-1, le 3-epi-
DON et le D3G n’étaient pas cytotoxiques, ils ne modifiaient ni la viabilité, ni la fonction de barrière des 
cellules, mesurée par la résistance électrique transépithéliale. Les tests de toxicité ex vivo sur des explants 
jéjunum porcin ont montré que le DOM-1, le 3-epi-DON ou le D3G n’induisaient pas de  modifications 
histomorphologiques. En revanche, les explants exposés au DON montraient des lésions morphologiques et une 
régulation positive de l'expression des cytokines pro-inflammatoires. L’impact de ces trois dérivés a été 
également analysé sur l’expression de l’ensemble des gènes du tissu, avec une analyse microarray. Ceci a montré 
que ces dérivés du DON n’induisaient aucun changement dans l’expression des gènes par rapport au groupe 
contrôle. Le DON quand a lui exprimait différentiellement 747 sondes, correspondantes à 333 gènes impliqués 
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fonction mitochondriale. 
L’analyse in silico a montré que le D3G, contrairement au DON était incapable de se lier au site-A du ribosome, 
principale cible de la toxicité pour le DON. Les deux dérivés microbiens eux, étaient capables de se fixer au site-
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trois. De plus, ces trois dérivés n’induisaient pas de stress ribotoxique, d’activation des MAPKs (mitogen-
activated protein kinases), et de réponse pro-inflammatoire. 
Une étude complémentaire a été menée in vivo pour évaluer la toxicité du DOM-1 chez le porc (gavage pendant 
21 jours avec .0.14mg / kg de poids vif). Les résultats ont montré que le DOM-1, contrairement au DON 
n’induisait pas les effets toxiques du DON au niveau des paramètres zootechniques (pas de vomissements, 
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dommages tissulaires), ou sur la réponse immunitaire (pas de réponse inflammatoire induite). 
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toxicité du DON, passant par une absence de toxicité sur le ribosome avec une absence d’activation des MAPKs 
et de réponses inflammatoires. Dans ce contexte de contamination par les mycotoxines, ces méthodes de luttes 
alternatives semblent être des approches prometteuses. 
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